{NP_1}PMID{/NP_1} - {CP_2}12237455{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}The <p>SPOT</p> technique{/NP_5} as {NP_6}a tool{/NP_6} for {VP_act_7}studying{/VP_act_7} {NP_8}<Bppf>protein tyrosine phosphatase substrate</Bppf> specificities{/NP_8} .

{NP_9}The activity{/NP_9} of {NP_P_10}<p>protein tyrosine phosphatases ( PTPs )</p>{/NP_P_10} {VP_pass_11}is restricted{/VP_pass_11} by {NP_12}their <Bppf>substrate</Bppf> specificities{/NP_12} .

{NP_13}The analysis{/NP_13} of {NP_14}<p>PTP</p> specificity{/NP_14} {VP_pass_15}was greatly helped{/VP_pass_15} by {NP_16}the discovery{/NP_16} that {NP_P_17}<Bppf>"substrate -trapping" <p>PTP</p> mutants</Bppf>{/NP_P_17} , {JP_18}such{/JP_18} as {NP_P_19}<p>PTP-1B D181A</p>{/NP_P_19} , {VP_act_20}stably and specifically bind{/VP_act_20} {NP_P_21}their <Bppf>substrates</Bppf>{/NP_P_21} .

{NP_22}We{/NP_22} {VP_act_23}have set{/VP_act_23} up {NP_24}a <p>PTP</p> substrate specificity assay{/NP_24} {VP_pass_25}based{/VP_pass_25} on {NP_26}the <p>SPOT</p> technique{/NP_26} , {NP_27}which{/NP_27} {VP_act_28}involves{/VP_act_28} {NP_29}the microsynthesis{/NP_29} of {NP_PP_30}<pp>( phospho ) peptides</pp>{/NP_PP_30} on {NP_31}membranes{/NP_31} .

OUTPUT 0
PTM = ({NP_P_39};autophosphorylated)
Kinase = ({NP_P_39}<p>insulin receptor ( IR )</p>{/NP_P_39};-)
Substrate = ({NP_P_39}<p>insulin receptor ( IR )</p>{/NP_P_39};-)
Site = (-;-;UNK)

{VP_act_32}To validate{/VP_act_32} {NP_33}this approach{/NP_33} , {NP_P_34}<Bppf>substrate</Bppf>{/NP_P_34} {VP_act_35}trapping{/VP_act_35} {NP_P_36}<p>PTP-1B</p>{/NP_P_36} {VP_pass_37}was tested{/VP_pass_37} on {NP_38}its cognate <Bpf>ligand</Bpf>{/NP_38} , {NP_P_39}the autophosphorylated <p>insulin receptor ( IR )</p>{/NP_P_39} .

On {NP_40}<p>SPOT</p> membranes{/NP_40} , {NP_PP_41}<pp>IR peptides</pp>{/NP_PP_41} with {NP_PP_42}<pp>phosphotyrosine 1163</pp>{/NP_PP_42} {VP_pass_43}were efficiently bound{/VP_pass_43} by {NP_P_44}<p>PTP1B D181A</p>{/NP_P_44} , and {VP_pass_45}dephosphorylated{/VP_pass_45} by {NP_P_46}<p>PTP-1B</p>{/NP_P_46} .

{NP_PP_47}<pp>Phosphotyrosine 1163</pp>{/NP_PP_47} {VP_pass_48}was preferred{/VP_pass_48} over {NP_PP_49}the neighboring 1158 and 1162 <pp>phosphotyrosines</pp>{/NP_PP_49} .

OUTPUT 4
PTM = ({NP_PP_53};autophosphorylation)
Kinase = ({NP_PP_53}<p>Trk</p>{/NP_PP_53};-)
Substrate = ({NP_PP_53}<p>Trk</p>{/NP_PP_53};-)
Site = (-;-;{NP_PP_53}<pp><p>Trk</p> autophosphorylation domains</pp>{/NP_PP_53})
(-;-;{NP_PP_53}<pp>phosphopeptides</pp>{/NP_PP_53})

{NP_P_50}<p>PTP-1B</p>{/NP_P_50} {VP_act_51}also recognized{/VP_act_51} {NP_PP_52}<pp>IR-like motifs</pp>{/NP_PP_52} in {NP_PP_53}<pp><p>Trk</p> autophosphorylation domains</pp> , and <p>STAT 5</p> <pp>phosphopeptides</pp>{/NP_PP_53} .

{VP_act_54}Using{/VP_act_54} {NP_55}a gridded <p>20-by-20 SPOT</p> library{/NP_55} , {NP_56}we{/NP_56} {VP_act_57}show{/VP_act_57} that {NP_PP_58}<Bppp>peptides</Bppp>{/NP_PP_58} with {NP_PP_59}the <pp>YZM motif</pp>{/NP_PP_59} ( {NP_60}Z{/NP_60} : {NP_PP_61}<pp>phosphotyrosine</pp>{/NP_PP_61} ) {VP_pass_62}are{/VP_pass_62} {NP_63}the strongest <Bpf>ligands</Bpf>{/NP_63} for {NP_P_64}<p>PTP-1B D181A</p>{/NP_P_64} , but {AV_65}not{/AV_65} {NP_P_66}the optimal <Bppf>substrates</Bppf>{/NP_P_66} for {NP_67}dephosphorylation{/NP_67} by {NP_P_68}<Bppf>wild-type</Bppf> <p>PTP1B</p>{/NP_P_68} .

In {NP_69}addition{/NP_69} {NP_70}we{/NP_70} {VP_act_71}show{/VP_act_71} that {NP_72}<p>PTP-1B</p> and PTP-beta dephosphorylation efficiency{/NP_72} {VP_pass_73}is strongly modulated{/VP_pass_73} by {NP_74}the introduction{/NP_74} of {NP_PP_75}phospho-<pp>serine</pp> or phospho-<pp>threonine</pp>{/NP_PP_75} in {NP_P_76}their cognate phospho-<Bppf>tyrosine substrates</Bppf>{/NP_P_76} .

{AV_77}Altogether{/AV_77} {NP_78}our data{/NP_78} {VP_act_79}illustrate{/VP_act_79} that {NP_80}the <p>SPOT</p> technique{/NP_80} {VP_act_81}is{/VP_act_81} {NP_82}a highly efficient tool{/NP_82} for {NP_83}the study{/NP_83} of {NP_84}<Bppf><p>PTP</p> substrate</Bppf> specificity{/NP_84} .


{NP_1}PMID{/NP_1} - {CP_2}24225996{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_6};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6})

{NP_4}AB{/NP_4} - {NP_5}Selective detection{/NP_5} of {NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6} in {NP_7}<Bpf>complex</Bpf> mixtures{/NP_7} by {NP_8}electrospray liquid chromatography/mass spectrometry{/NP_8} .

OUTPUT 1
PTM = ({NP_PP_16};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_16}<pp>phosphopeptides</pp>{/NP_PP_16})

{NP_9}A mass spectrometry-based method{/NP_9} {NP_10}that{/NP_10} {VP_act_neg_11}does not involve{/VP_act_neg_11} {NP_12}the use{/NP_12} of {VP_act_13}radiolabeling{/VP_act_13} {VP_pass_14}was developed{/VP_pass_14} for {NP_15}selective detection{/NP_15} of {NP_PP_16}<pp>phosphopeptides</pp>{/NP_PP_16} in {NP_17}<Bpf>complex</Bpf> mixtures{/NP_17} .

{NP_18}Mixtures{/NP_18} of {JP_19}phosphorylated{/JP_19} and {VP_act_20}nonphosphorylated{/VP_act_20} {NP_PP_21}<Bppp>peptides</Bppp>{/NP_PP_21} at {NP_22}the low picomole level{/NP_22} {VP_pass_23}are analyzed{/VP_pass_23} by {NP_24}negative ion electrospray liquid chromatography/mass spectrometry{/NP_24} {VP_act_25}using{/VP_act_25} {NP_P_26}<p>C-18</p>{/NP_P_26} {VP_act_27}packed{/VP_act_27} {NP_28}fused-silica columns{/NP_28} ( {NP_29}&lt;{/NP_29} = {NP_30}<B>320-mm</B> i.d.{/NP_30} ) .

OUTPUT 2
PTM = ({NP_PP_31};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_31}<pp>Peptides</pp>{/NP_PP_31})
(-;-;{NP_PP_31}<pp>phosphopeptides</pp>{/NP_PP_31})

{NP_PP_31}<pp>Peptides</pp> and <pp>phosphopeptides</pp>{/NP_PP_31} in the {VP_act_32}chromatographic eluant undergo{/VP_act_32} {NP_33}collision-induced dissociation{/NP_33} in {NP_PP_34}the free-jet <Bppp>expansion region</Bppp>{/NP_PP_34} {AV_35}prior{/AV_35} to {NP_36}the mass{/NP_36} {VP_act_37}analyzing{/VP_act_37} {NP_38}quadrupole{/NP_38} .

{VP_act_39}Using{/VP_act_39} {NP_40}relatively high collisional excitation potentials{/NP_40} , {NP_PP_41}<pp>phospho|peptides</pp>{/NP_PP_41} {VP_act_42}containing{/VP_act_42} {NP_PP_43}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp>phosphotyrosine fragment</pp>{/NP_PP_43} {VP_act_44}to yield{/VP_act_44} {NP_45}diagnostic ions{/NP_45} at {NP_46}m/z{/NP_46} {JP_47}63 and 79 corresponding{/JP_47} to {NP_B_48}<B>PO2</B> (-){/NP_B_48} ; and {NP_B_49}<B>PO3</B> (-){/NP_B_49} , {AV_50}respectively{/AV_50} .

OUTPUT 4
PTM = ({NP_PP_53};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_53}<pp>phosphopeptides</pp>{/NP_PP_53})

{NP_51}Chromatographic peaks{/NP_51} {VP_act_52}containing{/VP_act_52} {NP_PP_53}<pp>phosphopeptides</pp>{/NP_PP_53} {VP_pass_54}are indicated{/VP_pass_54} where {NP_55}these diagnostic ions{/NP_55} {VP_act_56}maximize{/VP_act_56} .

{NP_57}The highest sensitivity{/NP_57} for {NP_58}<pp>phosphopeptide</pp> detection{/NP_58} {VP_pass_59}is obtained{/VP_pass_59} {VP_act_60}using{/VP_act_60} {NP_61}selected-ion monitoring{/NP_61} for {NP_62}m/z 63 and 79{/NP_62} .

{NP_63}Full-scan mass spectra{/NP_63} {NP_64}that{/NP_64} {VP_act_65}exhibit{/VP_act_65} {NP_66}the diagnostic <pp>phosphopeptide fragment</pp> ions{/NP_66} , {AV_67}together{/AV_67} with {NP_68}pseudomolecular ions{/NP_68} , {VP_pass_69}may be obtained{/VP_pass_69} by {VP_act_70}stepping{/VP_act_70} {NP_71}the collisional excitation{/NP_71} {JP_72}potential{/JP_72} from {NP_73}a high value{/NP_73} during {NP_74}the portion{/NP_74} of {NP_75}each scan{/NP_75} in {NP_76}which{/NP_76} {NP_77}the low-mass-to-charge ratio diagnostic marker ions{/NP_77} {VP_act_78}are being{/VP_act_78} {VP_act_79}detected{/VP_act_79} to {NP_80}a lower value{/NP_80} while {NP_81}the upper mass-to-charge ratio range{/NP_81} {VP_act_82}is being{/VP_act_82} {VP_act_83}scanned{/VP_act_83} .

{NP_84}Good sensitivity{/NP_84} for {NP_85}<pp>phosphopeptide</pp> detection{/NP_85} {VP_pass_86}was achieved{/VP_pass_86} {VP_act_87}using{/VP_act_87} {NP_P_88}standard <p>trifluoroacetic acid</p>{/NP_P_88} {VP_act_89}containing{/VP_act_89} {NP_90}mobile phases{/NP_90} for {NP_91}reversed-phase high-performance liquid chromatography{/NP_91} .

OUTPUT 5
PTM = ({NP_PP_98};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_98}<pp>peptides</pp>{/NP_PP_98})
(-;-;{NP_PP_98}<pp>phosphopeptides</pp>{/NP_PP_98})

OUTPUT 6
PTM = ({NP_PP_100};phosphorylated)
Kinase = (-;-)
Substrate = ({NP_P_88}<p>trifluoroacetic acid</p>{/NP_P_88};-)
Site = (-;-;{NP_PP_100}<Bppp>amino acids</Bppp>{/NP_PP_100})
(-;-;{NP_PP_41}<pp>phospho|peptides</pp>{/NP_PP_41})
(-;{NP_PP_43}Ser{/NP_PP_43};UNK)
(-;{NP_PP_43}Thr{/NP_PP_43};UNK)
(-;{NP_PP_43}Tyr{/NP_PP_43};UNK)

{NP_92}Data{/NP_92} {VP_act_93}illustrating{/VP_act_93} {NP_94}the selectivity and sensitivity{/NP_94} of {NP_95}the approach{/NP_95} {VP_pass_96}are presented{/VP_pass_96} for {NP_97}mixtures{/NP_97} of {NP_PP_98}<pp>peptides</pp> and <pp>phosphopeptides</pp>{/NP_PP_98} {VP_act_99}containing{/VP_act_99} {NP_PP_100}the three commonly phosphorylated <Bppp>amino acids</Bppp>{/NP_PP_100} .


{NP_1}PMID{/NP_1} - {CP_2}18463617{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Large-scale phosphorylation mapping{/NP_5} {VP_act_6}reveals{/VP_act_6} {NP_7}the extent{/NP_7} of {NP_8}<pp>tyrosine</pp> phosphorylation{/NP_8} in {NP_9}Arabidopsis{/NP_9} .

{NP_10}<Bppf>Protein</Bppf> phosphorylation{/NP_10} {VP_act_11}regulates{/VP_act_11} {NP_12}a wide range{/NP_12} of {NP_13}cellular processes{/NP_13} .

OUTPUT 3
PTM = ({NP_PP_18};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_18}<Bppp>phosphorylation sites</Bppp>{/NP_PP_18})

{AV_14}Here{/AV_14} , {NP_15}we{/NP_15} {VP_act_16}report{/VP_act_16} {NP_17}the proteome-wide mapping{/NP_17} of {NP_PP_18}in vivo <Bppp>phosphorylation sites</Bppp>{/NP_PP_18} in {NP_19}Arabidopsis{/NP_19} by {VP_act_20}using{/VP_act_20} {NP_21}complementary <pp>phosphopeptide</pp> enrichment techniques{/NP_21} {VP_act_22}coupled{/VP_act_22} with {NP_23}high-accuracy mass spectrometry{/NP_23} .

OUTPUT 4
PTM = ({NP_PP_29};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_29}<pp>phosphopeptides</pp>{/NP_PP_29})

OUTPUT 5
PTM = ({NP_PP_31};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_31}<Bppp>phosphorylation sites</Bppp>{/NP_PP_31})

{VP_act_24}Using{/VP_act_24} {NP_25}unfractionated whole <Bpcl>cell</Bpcl> lysates{/NP_25} of {NP_26}Arabidopsis{/NP_26} , {NP_27}we{/NP_27} {VP_act_28}identified{/VP_act_28} {NP_PP_29}2597 <pp>phosphopeptides</pp>{/NP_PP_29} with {JP_30}2172 high-confidence{/JP_30} , {NP_PP_31}unique <Bppp>phosphorylation sites</Bppp>{/NP_PP_31} from {NP_P_32}1346 <Bppf>proteins</Bppf>{/NP_P_32} .

{NP_33}The distribution{/NP_33} of {NP_PP_34}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp><B>phosphotyrosine</B> sites</pp>{/NP_PP_34} {VP_pass_35}was{/VP_pass_35} {NP_36}85.0{/NP_36} , {NP_37}10.7{/NP_37} , and {NP_38}4.3%{/NP_38} .

Although {NP_P_39}typical tyrosine-specific <Bppf>protein kinases</Bppf>{/NP_P_39} {VP_pass_40}are absent{/VP_pass_40} in {NP_41}Arabidopsis{/NP_41} , {NP_42}the proportion{/NP_42} of {NP_PP_43}<pp>phosphotyrosines</pp>{/NP_PP_43} among {NP_C_44}the phospho-<c>residues</c>{/NP_C_44} in {NP_45}Arabidopsis{/NP_45} {VP_pass_46}is similar{/VP_pass_46} to that in {NP_47}<s>humans</s>{/NP_47} , where over {NP_P_48}90 tyrosine-specific <Bppf>protein kinases</Bppf>{/NP_P_48} {VP_pass_49}have been identified{/VP_pass_49} .

In {NP_50}addition{/NP_50} , {NP_C_51}the <c>tyrosine phosphoproteome</c>{/NP_C_51} {VP_act_52}shows{/VP_act_52} {NP_53}features{/NP_53} {JP_54}distinct{/JP_54} from those of {NP_C_55}the <pp>serine</pp> and <c>threonine phosphoproteomes</c>{/NP_C_55} .

{AV_56}Taken together{/AV_56} , {NP_57}we{/NP_57} {VP_act_58}highlight{/VP_act_58} {NP_59}the extent and contribution{/NP_59} of {NP_60}<pp>tyrosine</pp> phosphorylation{/NP_60} in {NP_61}plants{/NP_61} .


{NP_1}PMID{/NP_1} - {CP_2}21134632{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}FHA domain pThr binding specificity{/NP_5} :

{VP_act_6}it's{/VP_act_6} all about {NP_7}me{/NP_7} .

OUTPUT 0
PTM = ({NP_10};phospho-<pp>peptide</pp>)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_10}<pp>peptide</pp>{/NP_10})

{NP_PP_8}The <pp>FHA domain</pp>{/NP_PP_8} {VP_act_9}is{/VP_act_9} {NP_10}a phospho-<pp>peptide</pp> binding module{/NP_10} {VP_pass_11}involved{/VP_pass_11} in {NP_12}a wide range{/NP_12} of {NP_13}cellular pathways{/NP_13} , with {NP_14}a striking specificity{/NP_14} for {NP_PP_15}phospho-<pp>threonine</pp>{/NP_PP_15} over {NP_16}phospho-<pp>serine</pp> binding partners{/NP_16} .

{NP_17}<Bpcf>Biochemical</Bpcf>{/NP_17} , {JP_18}structural{/JP_18} , and {NP_19}dynamic simulations analysis{/NP_19} {VP_act_20}allowed{/VP_act_20} {NP_B_21}<B>Pennell</B>{/NP_B_21} and {NP_22}colleagues{/NP_22} {VP_act_23}to unravel{/VP_act_23} {NP_24}the molecular basis{/NP_24} of {NP_25}FHA domain phospho-<pp>threonine</pp> specificity{/NP_25} .


{NP_1}PMID{/NP_1} - {CP_2}17184134{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}<pp>Phosphopeptide</pp> modification and enrichment{/NP_5} by {NP_6}oxidation-reduction condensation{/NP_6} .

{NP_7}Many cellular processes{/NP_7} {VP_pass_8}are regulated{/VP_pass_8} by {NP_9}the reversible phosphorylation{/NP_9} of {NP_P_10}<Bppf>proteins</Bppf>{/NP_P_10} .

OUTPUT 2
PTM = ({NP_PP_15};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_15}<pp>phosphopeptides</pp>{/NP_PP_15})

Despite {NP_11}the importance{/NP_11} of {NP_12}<Bppf>monitoring protein</Bppf> phosphorylation{/NP_12} , {NP_13}available methods{/NP_13} {VP_act_14}to modify and enrich{/VP_act_14} {NP_PP_15}<pp>phosphopeptides</pp>{/NP_PP_15} from {NP_16}<Bpf>complex</Bpf> mixtures{/NP_16} for {NP_17}subsequent mass spectrometric analysis{/NP_17} {VP_act_18}are challenging{/VP_act_18} .

OUTPUT 3
PTM = ({NP_G_24};phosphate)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_P_25}<pp>phosphopeptides</pp>{/NP_P_25})

OUTPUT 4
PTM = ({NP_P_25};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_P_25}<pp>phosphopeptides</pp>{/NP_P_25})

{AV_19}Here{/AV_19} {NP_20}the oxidation-reduction condensation{/NP_20} {VP_pass_21}was shown{/VP_pass_21} for {NP_22}the first time{/NP_22} {VP_act_23}to directly modify{/VP_act_23} {NP_G_24}the <c>phosphate</c>{/NP_G_24} of {NP_P_25}<pp>phosphopeptides</pp> and <p>phosphoproteins</p>{/NP_P_25} .

By {VP_act_26}coupling{/VP_act_26} with {NP_27}a solid-phase resin{/NP_27} , {NP_28}the oxidation-reduction condensation{/NP_28} {VP_pass_29}was validated{/VP_pass_29} for {NP_30}capture{/NP_30} and {NP_31}recovery{/NP_31} of {NP_PP_32}<c>phosphoserine-</c> , <c>phosphothreonine-</c> , and <pp>phosphotyrosine-containing peptides</pp>{/NP_PP_32} from {NP_33}a <Bppp>peptide</Bppp> mixture{/NP_33} .

OUTPUT 6
PTM = ({NP_PP_35};phosphoproteins)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_35}<pp>phosphopeptides</pp>{/NP_PP_35})

In {NP_34}addition{/NP_34} , {NP_PP_35}<p>full-length phosphoproteins</p> or <pp>phosphopeptides</pp>{/NP_PP_35} from {NP_36}a <Bppf>protein</Bppf> digestion{/NP_36} {VP_pass_37}were captured and recovered{/VP_pass_37} {VP_act_38}using{/VP_act_38} {NP_39}the oxidation-reduction condensation{/NP_39} , {VP_act_40}demonstrating{/VP_act_40} {NP_41}its compatibility{/NP_41} with {NP_42}<Bppf>protein</Bppf> mixtures{/NP_42} .

OUTPUT 7
PTM = ({NP_PP_45};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_45}<pp>phosphopeptides</pp>{/NP_PP_45})

{NP_43}The strategy{/NP_43} {VP_act_44}modifies{/VP_act_44} {NP_PP_45}all <pp>phosphopeptides</pp>{/NP_PP_45} , {VP_act_46}maintains{/VP_act_46} {NP_47}high <Bpcf>chemical</Bpcf> selectivity{/NP_47} , {VP_act_48}requires{/VP_act_48} {NP_49}only two steps{/NP_49} , and {VP_act_50}relies{/VP_act_50} on {NP_51}commercially available reagents{/NP_51} , {VP_act_52}suggesting{/VP_act_52} that {NP_53}the oxidation-reduction condensation{/NP_53} {VP_act_54}has{/VP_act_54} the {JP_55}potential{/JP_55} {VP_act_56}to enhance{/VP_act_56} {NP_57}<pp>phosphopeptide</pp> enrichment methods{/NP_57} and {VP_act_58}encourage{/VP_act_58} {NP_59}development{/NP_59} of {NP_60}efficient <Bpcf>biochemical</Bpcf>{/NP_60} and {NP_61}proteomics tools{/NP_61} {VP_act_62}targeting{/VP_act_62} {NP_63}phosphorylation{/NP_63} .


{NP_1}PMID{/NP_1} - {CP_2}11857762{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}<pp>Phosphopeptide</pp> detection{/NP_5} and {VP_act_6}sequencing{/VP_act_6} by {NP_7}matrix-assisted laser desorption/ionization quadrupole time-of-flight tandem mass spectrometry{/NP_7} .

{NP_8}A <B>prototype LONGTOKEN</B> tandem mass spectrometer{/NP_8} {VP_pass_9}was used{/VP_pass_9} to {NP_PP_10}<Bppp>sequence</Bppp>{/NP_PP_10} {NP_11}a series{/NP_11} of {NP_C_12}<c>phosphotyrosine-</c>{/NP_C_12} , {NP_PP_13}<pp>phosphothreonine</pp>{/NP_PP_13} - and {NP_PP_14}<Bppp>phosphoserine-containing peptides</Bppp>{/NP_PP_14} .

OUTPUT 3
PTM = ({NP_PP_20};phosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_20}<Bppp>amino acid residues</Bppp>{/NP_PP_20})

OUTPUT 4
PTM = ({NP_PP_21};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_21}<pp>phosphopeptides</pp>{/NP_PP_21})

{NP_15}The high mass resolution and mass accuracy{/NP_15} of {NP_16}the instrument{/NP_16} {VP_act_17}allowed{/VP_act_17} {NP_18}the localization{/NP_18} of {CP_19}one{/CP_19} , {NP_PP_20}three or four phosphorylated <Bppp>amino acid residues</Bppp>{/NP_PP_20} in {NP_PP_21}<pp>phosphopeptides</pp>{/NP_PP_21} up to {NP_B_22}3.1 <B>kDa</B>{/NP_B_22} .

OUTPUT 6
PTM = ({NP_PP_27};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_27}<Bppp>phosphorylation sites</Bppp>{/NP_PP_27})

{NP_23}Tandem mass spectra{/NP_23} of {NP_PP_24}two different <pp>phosphotyrosine peptides</pp>{/NP_PP_24} {VP_act_25}permitted{/VP_act_25} {NP_26}<Bppp>amino acid sequence</Bppp> determination and localization{/NP_26} of {NP_PP_27}one and three <Bppp>phosphorylation sites</Bppp>{/NP_PP_27} , {AV_28}respectively{/AV_28} .

{NP_29}The <pp>phosphotyrosine</pp> immonium ion{/NP_29} at {NP_30}m/z 216.04{/NP_30} {VP_pass_31}was observed{/VP_pass_31} in {NP_32}these <B>MALDI low-energy CID</B> tandem mass spectra{/NP_32} .

OUTPUT 8
PTM = ({NP_PP_36};triphosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_36}<Bppp>peptide</Bppp>{/NP_PP_36})

{NP_33}Elimination{/NP_33} of {NP_G_34}<c>phosphate groups</c>{/NP_G_34} {VP_pass_35}was evident{/VP_pass_35} from {NP_PP_36}the triphosphorylated <Bppp>peptide</Bppp>{/NP_PP_36} but {AV_37}not{/AV_37} from {NP_38}the monophosphorylated species{/NP_38} .

{NP_39}The main fragmentation pathway{/NP_39} for {NP_PP_40}the synthetic <Bppp>phosphothreonine-containing peptide</Bppp>{/NP_PP_40} and for {NP_PP_41}<Bppp>phosphoserine-containing peptides</Bppp>{/NP_PP_41} {VP_act_42}derived{/VP_act_42} from {NP_43}beta-casein{/NP_43} and {NP_P_44}<p>ovalbumin</p>{/NP_P_44} {VP_pass_45}was{/VP_pass_45} {NP_46}the beta-elimination{/NP_46} of {NP_P_47}<p>phosphoric acid</p>{/NP_P_47} with {NP_48}concomitant conversion{/NP_48} of {NP_PP_49}<pp>phosphoserine</pp>{/NP_PP_49} to {NP_PP_50}<pp>dehydroalanine</pp> and <pp>phosphothreonine</pp>{/NP_PP_50} to {NP_P_51}<p>2-aminodehydrobutyric acid</p>{/NP_P_51} .

OUTPUT 13
PTM = ({NP_PP_57};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_57}<Bppp>phosphorylation sites</Bppp>{/NP_PP_57})

{NP_52}<Bppp>Peptide fragment</Bppp> ions{/NP_52} of {NP_53}the b{/NP_53} - and {VP_act_54}y-type allowed{/VP_act_54} , in {NP_55}all cases{/NP_55} , {NP_56}the localization{/NP_56} of {NP_PP_57}<Bppp>phosphorylation sites</Bppp>{/NP_PP_57} .

{NP_58}Ion signals{/NP_58} {JP_59}corresponding{/JP_59} to ( {NP_60}b-17 ) , ( b-18 ) and ( y-17 ) <Bppp>fragment</Bppp> ions{/NP_60} {VP_pass_61}were also observed{/VP_pass_61} .

{NP_62}The abundant neutral loss{/NP_62} of {NP_P_63}<p>phosphoric acid</p> ( -98 Da ){/NP_P_63} {VP_pass_64}is useful{/VP_pass_64} for {NP_65}femtomole level detection{/NP_65} of {NP_PP_66}<pp>phosphoserine-peptides</pp>{/NP_PP_66} in {NP_67}crude <Bppp>peptide</Bppp> mixtures{/NP_67} {VP_pass_68}generated{/VP_pass_68} by {NP_69}gel in situ digestion{/NP_69} of {NP_P_70}<p>phosphoproteins</p>{/NP_P_70} .


{NP_1}PMID{/NP_1} - {CP_2}11908807{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_6};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6})

{NP_4}AB{/NP_4} - {NP_5}Fragmentation{/NP_5} of {NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6} by {NP_7}atmospheric pressure MALDI and <p>ESI/Ion</p> trap mass spectrometry{/NP_7} .

{NP_8}An investigation{/NP_8} of {NP_9}<c>phosphate</c> loss{/NP_9} from {NP_10}<pp>phosphopeptide</pp> ions{/NP_10} {VP_pass_11}was conducted{/VP_pass_11} , {VP_act_12}using{/VP_act_12} {NP_B_13}both <B>atmospheric pressure matrix-assisted laser desorption/ionization ( AP MALDI )</B> and <B>electrospray ionization ( ESI )</B>{/NP_B_13} {VP_act_14}coupled{/VP_act_14} to {NP_B_15}an <B>ion trap mass spectrometer ( ITMS )</B>{/NP_B_15} .

OUTPUT 1
PTM = ({NP_PP_19};phosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_19}<Bppp>peptides</Bppp>{/NP_PP_19})

{NP_16}These experiments{/NP_16} {VP_pass_17}were carried{/VP_pass_17} out on {NP_18}a number{/NP_18} of {NP_PP_19}phosphorylated <Bppp>peptides</Bppp>{/NP_PP_19} in {NP_20}order{/NP_20} {VP_act_21}to investigate{/VP_act_21} {NP_22}gas phase dephosphorylation patterns{/NP_22} {VP_act_23}associated{/VP_act_23} with {NP_PP_24}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp>phosphotyrosine residues</pp>{/NP_PP_24} .

In {JP_25}particular{/JP_25} , {NP_26}we{/NP_26} {VP_act_27}explored{/VP_act_27} {NP_28}the fragmentation patterns{/NP_28} of {NP_PP_29}<pp>phosphotyrosine</pp>{/NP_PP_29} {VP_act_30}containing{/VP_act_30} {NP_PP_31}<Bppp>peptides</Bppp>{/NP_PP_31} , {NP_32}which{/NP_32} {VP_act_33}experience{/VP_act_33} {NP_34}a loss{/NP_34} of {NP_B_35}98 <B>Da</B>{/NP_B_35} under {NP_36}<B>collision induced dissociation ( CID )</B> conditions{/NP_36} in {NP_B_37}the <B>ITMS</B>{/NP_B_37} .

{NP_38}The loss{/NP_38} of {NP_B_39}98 <B>Da</B>{/NP_B_39} {VP_pass_40}is unexpected{/VP_pass_40} for {NP_PP_41}<pp>phosphotyrosine</pp>{/NP_PP_41} , {VP_act_42}given{/VP_act_42} {NP_43}the <Bpf>structure</Bpf>{/NP_43} of {NP_PP_44}its side <Bppp>chain</Bppp>{/NP_PP_44} .

{NP_45}The fragmentation{/NP_45} of {NP_PP_46}<pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_46} {VP_act_47}containing{/VP_act_47} {NP_PP_48}<Bppp>peptides</Bppp>{/NP_PP_48} {VP_pass_49}was also investigated{/VP_pass_49} .

While {NP_PP_50}<pp>phosphoserine</pp> and <pp>phosphothreonine residues</pp>{/NP_PP_50} {VP_act_51}undergo{/VP_act_51} {NP_52}a loss{/NP_52} of {NP_B_53}98 <B>Da</B>{/NP_B_53} under {NP_54}<B>CID</B> conditions{/NP_54} {AV_55}regardless{/AV_55} of {NP_56}<Bppp>peptide amino acid</Bppp> composition{/NP_56} , {NP_57}<c>phosphate</c> loss{/NP_57} from {NP_PP_58}<pp>phosphotyrosine residues</pp>{/NP_PP_58} {VP_act_59}seems{/VP_act_59} {VP_pass_60}to be dependent{/VP_pass_60} on {NP_61}the presence{/NP_61} of {NP_PP_62}<pp>arginine</pp> or <pp>lysine residues</pp>{/NP_PP_62} in {NP_PP_63}the <Bppp>peptide sequence</Bppp>{/NP_PP_63} .


{NP_1}PMID{/NP_1} - {CP_2}7539777{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}A new approach{/NP_5} to {NP_6}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> and <pp>phosphotyrosine</pp> synthons{/NP_6} and to {NP_B_7}<B>thiophospho analogs</B>{/NP_B_7} .

OUTPUT 1
PTM = ({VP_act_10};multiphosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_11}<pp>phosphopeptides</pp>{/NP_PP_11})

OUTPUT 2
PTM = ({NP_PP_11};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_11}<pp>phosphopeptides</pp>{/NP_PP_11})

{NP_8}Stepwise synthesis{/NP_8} of {JP_9}mono{/JP_9} - and {VP_act_10}multiphosphorylated{/VP_act_10} {NP_PP_11}<pp>phosphopeptides</pp>{/NP_PP_11} {VP_act_12}related{/VP_act_12} to {NP_13}src{/NP_13} - {NP_P_14}<Bppf>protein kinase</Bppf>{/NP_P_14} .

OUTPUT 4
PTM = ({NP_PP_18};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_18}<pp>phosphopeptides</pp>{/NP_PP_18})

{NP_15}Several <pp>phosphoserine</pp> , <pp>phosphothreonine</pp> and <pp>phosphotyrosine</pp> synthons{/NP_15} {JP_16}suitable{/JP_16} for {NP_17}the stepwise synthesis{/NP_17} of {NP_PP_18}<pp>phosphopeptides</pp>{/NP_PP_18} {VP_pass_19}were prepared{/VP_pass_19} .

{NP_20}Treatment{/NP_20} of {NP_C_21}<c>methylthiomethyl ( MTM ) esters</c>{/NP_C_21} of {NP_PP_22}either <pp>Z-</pp> , <pp>Boc-</pp> , <pp>Allocserine</pp> and <pp>threonine</pp>{/NP_PP_22} with {NP_C_23}<c>phosphochloridate</c>{/NP_C_23} in {NP_C_24}<c>pyridine</c>{/NP_C_24} {VP_pass_25}followed{/VP_pass_25} by {NP_26}<p>MgBr2</p> cleavage{/NP_26} of {NP_B_27}<B>MTM</B>{/NP_B_27} in {NP_C_28}<c>diethyl ether</c>{/NP_C_28} {VP_act_29}afforded{/VP_act_29} {NP_30}the title <Bpcf>compounds</Bpcf>{/NP_30} in {NP_31}good yield{/NP_31} .

{NP_32}<pp>Thiophosphoserine</pp> and <pp>phosphotyrosine</pp> synthons{/NP_32} {VP_pass_33}were also obtained{/VP_pass_33} by {NP_34}the <c>phosphoramidite</c> method{/NP_34} {VP_act_35}using{/VP_act_35} {NP_B_36}di- <B>( 2, 2, 2-trichloroethyl ) -N</B> , <c>N-diisopropylphosphoramidite</c> and <B>MCPBA</B>{/NP_B_36} as {VP_act_37}oxidizing{/VP_act_37} {NP_38}reagent{/NP_38} .

{NP_C_39}<c>Trichloroethyl</c>{/NP_C_39} {VP_act_40}proved{/VP_act_40} {JP_41}valuable{/JP_41} as {NP_G_42}<c>phosphate</c>{/NP_G_42} {VP_act_43}protecting{/VP_act_43} {NP_44}<Bpcf>group</Bpcf>{/NP_44} {AV_45}especially{/AV_45} in {NP_46}<B>phosphotyrosine derivatives</B> owing{/NP_46} to {NP_47}its stability{/NP_47} in {NP_48}acidic conditions{/NP_48} .

OUTPUT 7
PTM = ({NP_PP_52};thiophosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_52}<pp><c>phospho</c> and/or thiophosphopeptides</pp>{/NP_PP_52})

{NP_49}These synthons{/NP_49} {VP_pass_50}were involved{/VP_pass_50} in {NP_51}the liquid-phase synthesis{/NP_51} of {NP_PP_52}several <pp><c>phospho</c> and/or thiophosphopeptides</pp>{/NP_PP_52} {VP_act_53}related{/VP_act_53} to {NP_54}either src{/NP_54} - {NP_P_55}<Bppf>protein kinase</Bppf> or <s>rat</s> liver <p>pyruvate kinase</p>{/NP_P_55} .


{NP_1}PMID{/NP_1} - {CP_2}19521975{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_7};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_7}<pp>phosphopeptides</pp>{/NP_PP_7})

{NP_4}AB{/NP_4} - {NP_C_5}<c>Fluorine-18</c>{/NP_C_5} {VP_act_6}labeling{/VP_act_6} of {NP_PP_7}<pp>phosphopeptides</pp>{/NP_PP_7} :

{NP_8}a potential approach{/NP_8} for {NP_9}the evaluation{/NP_9} of {NP_10}<pp>phosphopeptide</pp> metabolism{/NP_10} in {NP_11}vivo{/NP_11} .

OUTPUT 1
PTM = ({NP_PP_12};Phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_12}<pp>Phosphopeptides</pp>{/NP_PP_12})

{NP_PP_12}<pp>Phosphopeptides</pp>{/NP_PP_12} {VP_pass_13}are{/VP_pass_13} {NP_14}very useful reagents{/NP_14} {VP_act_15}to study{/VP_act_15} {NP_16}signal transduction pathways{/NP_16} {VP_act_17}related{/VP_act_17} with {NP_18}cellular <Bppf>protein</Bppf> phosphorylation/dephosphorylation{/NP_18} .

OUTPUT 3
PTM = ({NP_PP_19};Phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_19}<pp>Phosphopeptides</pp>{/NP_PP_19})

{NP_PP_19}<pp>Phosphopeptides</pp>{/NP_PP_19} {VP_pass_20}have also been identified{/VP_pass_20} as {NP_21}important <Bpcf>drug</Bpcf> candidates{/NP_21} {VP_act_22}to modulate{/VP_act_22} {NP_23}intracellular signaling mechanisms{/NP_23} through {VP_act_24}targeting{/VP_act_24} {NP_PP_25}<pp>phosphotyrosine</pp> , <pp>phosphoserine</pp> , or <pp><p><pp>phosphothreonine residue</pp> -binding protein</p> domains</pp>{/NP_PP_25} .

OUTPUT 5
PTM = ({NP_PP_32};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_32}<pp>phosphopeptides</pp>{/NP_PP_32})

In {NP_26}this report{/NP_26} , {NP_27}we{/NP_27} {VP_act_28}describe{/VP_act_28} {NP_29}the development{/NP_29} of {NP_30}a convenient method{/NP_30} for {NP_31}the mild and sufficient radiolabeling{/NP_31} of {NP_PP_32}<pp>phosphopeptides</pp>{/NP_PP_32} with {NP_C_33}the short-lived positron emitter <c>fluorine-18 ( 18F )</c>{/NP_C_33} {VP_act_34}to allow{/VP_act_34} {NP_35}radiopharmacological studies{/NP_35} on {NP_36}<pp>phosphopeptide</pp> metabolism{/NP_36} in {NP_37}vivo{/NP_37} by {NP_38}means{/NP_38} of {NP_B_39}<B>positron emission tomography ( PET )</B>{/NP_B_39} .

OUTPUT 6
PTM = ({NP_PP_44};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_44}<pp>polo-box domain ( PBD )- binding phosphopeptide H-Met-Gln-Ser-pThr-Pro-Leu-OH</pp>{/NP_PP_44})

{VP_act_40}Radiolabeling{/VP_act_40} {VP_pass_41}was accomplished{/VP_pass_41} via {NP_42}conjugation{/NP_42} of {NP_PP_43}the <pp>N-terminus</pp>{/NP_PP_43} of {NP_PP_44}<pp>polo-box domain ( PBD )- binding phosphopeptide H-Met-Gln-Ser-pThr-Pro-Leu-OH</pp>{/NP_PP_44} with {NP_C_45}the bifunctional labeling agent <c>N-succinimidyl-4-[18F]fluorobenzoate ( [18F]SFB )</c>{/NP_C_45} in {NP_46}reproducible isolated <Bpcf>radiochemical</Bpcf> yields{/NP_46} of {NP_47}25-28%{/NP_47} .

OUTPUT 7
PTM = ({NP_PP_51};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_51}<pp>phosphopeptide [18F]FB-Met-Gln-Ser-pThr-Pro-Leu-OH [18F]-3</pp>{/NP_PP_51})

{NP_48}Radiopharmacological evaluation{/NP_48} in {NP_49}vitro{/NP_49} and {NP_50}in vivo{/NP_50} of {NP_PP_51}radiolabeled <pp>phosphopeptide [18F]FB-Met-Gln-Ser-pThr-Pro-Leu-OH [18F]-3</pp>{/NP_PP_51} and {NP_PP_52}its non-phosphorylated <B>analog</B> <pp>[18F]FB-Met-Gln-Ser-Thr-Pro-Leu-OH [18F]-4</pp>{/NP_PP_52} {VP_act_53}involved{/VP_act_53} {NP_54}metabolic stability , cell uptake studies , and small animal <B>PET</B> experiments{/NP_54} .

OUTPUT 8
PTM = ({NP_PP_55};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_55}<pp>phosphopeptide [18F]-3</pp>{/NP_PP_55})

{NP_PP_55}Radiolabeled <pp>phosphopeptide [18F]-3</pp>{/NP_PP_55} {VP_act_56}showed{/VP_act_56} {NP_57}a remarkable high metabolic stability{/NP_57} in {NP_58}vivo{/NP_58} {VP_act_59}compared{/VP_act_59} to {NP_PP_60}the corresponding non-phosphorylated <pp>peptide [18F]-4</pp>{/NP_PP_60} .

OUTPUT 9
PTM = ({NP_PP_64};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_64}<pp>phosphopeptides</pp>{/NP_PP_64})

{NP_61}The presented method{/NP_61} {VP_act_62}indicates{/VP_act_62} that {VP_act_63}radiolabeling{/VP_act_63} of {NP_PP_64}<pp>phosphopeptides</pp>{/NP_PP_64} with {NP_C_65}<c>[18F]SFB</c>{/NP_C_65} {VP_act_66}is{/VP_act_66} {NP_67}a promising approach{/NP_67} for {VP_act_68}studying{/VP_act_68} {NP_69}<pp>phosphopeptide</pp> metabolism{/NP_69} in {NP_70}vivo{/NP_70} .


{NP_1}PMID{/NP_1} - {CP_2}7687226{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_8};phosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_8}<Bppp>amino acids</Bppp>{/NP_PP_8})

{NP_4}AB{/NP_4} - {NP_5}Strategies{/NP_5} for {NP_6}nonradioactive methods{/NP_6} in {NP_7}the localization{/NP_7} of {NP_PP_8}phosphorylated <Bppp>amino acids</Bppp>{/NP_PP_8} in {NP_P_9}<Bppf>proteins</Bppf>{/NP_P_9} .

OUTPUT 1
PTM = ({NP_PP_11};phosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_11}<pp>amino acids</pp>{/NP_PP_11})

{NP_10}Identification{/NP_10} of {NP_PP_11}O -phosphorylated <pp>amino acids</pp>{/NP_PP_11} within {NP_12}the primary <Bpf>structure</Bpf>{/NP_12} of {NP_P_13}regulatory <Bppf>proteins</Bppf>{/NP_P_13} {VP_pass_14}is important{/VP_pass_14} in {VP_act_15}understanding{/VP_act_15} {NP_16}the mechanisms{/NP_16} by {NP_17}which{/NP_17} {NP_18}their functions{/NP_18} {VP_pass_19}are regulated{/VP_pass_19} .

In {NP_20}many cases radioactive labeling{/NP_20} with {NP_G_21}<c>[32P]phosphate</c>{/NP_G_21} {VP_pass_22}is tedious or sometimes impossible{/VP_pass_22} .

{AV_23}Therefore{/AV_23} , {NP_24}we{/NP_24} {VP_act_25}have established{/VP_act_25} {NP_26}a series{/NP_26} of {NP_27}new non-radioactive methods{/NP_27} {NP_28}that{/NP_28} {VP_act_29}permit{/VP_act_29} {NP_30}the localization{/NP_30} of {NP_PP_31}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp>phosphotyrosine</pp>{/NP_PP_31} .

OUTPUT 3
PTM = ({NP_P_33};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_P_33}<pp>phosphopeptide</pp>{/NP_P_33})

After {NP_32}partial hydrolysis{/NP_32} of {NP_P_33}a <pp>phosphopeptide</pp> or <p>phosphoprotein</p>{/NP_P_33} , {NP_PP_34}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , or <pp>phosphotyrosine</pp>{/NP_PP_34} {VP_pass_35}are determined{/VP_pass_35} by {NP_36}capillary electrophoresis{/NP_36} as {NP_37}their <Bpf>dabsyl-derivatives</Bpf>{/NP_37} .

{NP_38}<Bpcf>Chemical</Bpcf> modification{/NP_38} {VP_act_39}transforms{/VP_act_39} {NP_PP_40}<pp>phosphoserine</pp> or <pp>phosphothreonine</pp>{/NP_PP_40} to {NP_PP_41}<pp>S-ethyl-cysteine</pp> or <pp>beta-methyl-S-ethyl-cysteine</pp>{/NP_PP_41} , {AV_42}respectively{/AV_42} , {VP_act_43}allowing{/VP_act_43} {NP_44}their localization{/NP_44} during {NP_45}<Bppp>sequence</Bppp> analysis{/NP_45} .

{NP_46}We{/NP_46} {VP_act_47}apply{/VP_act_47} {NP_48}solid-phase sequencing{/NP_48} {VP_act_49}to overcome{/VP_act_49} {NP_50}the limitations{/NP_50} of {NP_51}the gas-phase sequenator{/NP_51} in {NP_52}the case{/NP_52} of {NP_PP_53}<Bppp>phosphotyrosine-containing peptides</Bppp>{/NP_PP_53} .

{NP_54}Liquid chromatography on{/NP_54} - {NP_55}line{/NP_55} {VP_act_56}connected{/VP_act_56} to {NP_57}an electrospray mass spectrometer{/NP_57} {VP_act_58}is{/VP_act_58} {NP_59}a powerful new method{/NP_59} of {VP_act_60}increasing{/VP_act_60} {NP_61}importance{/NP_61} in {NP_62}the <Bppf>protein</Bppf> chemistry field{/NP_62} .

OUTPUT 9
PTM = ({NP_P_69};phosphoprotein)
Kinase = (-;-)
Substrate = ({NP_P_69}a <p>phosphoprotein</p>{/NP_P_69};-)
Site = (-;-;UNK)

{NP_63}It{/NP_63} {VP_pass_64}is especially well suited{/VP_pass_64} for {NP_65}identification{/NP_65} of {NP_PP_66}<pp>phosphoserine</pp>{/NP_PP_66} - or {NP_PP_67}<Bppp>phosphothreonine-containing peptides</Bppp>{/NP_PP_67} in {NP_68}a proteolytic digest{/NP_68} of {NP_P_69}a <p>phosphoprotein</p>{/NP_P_69} .

In {NP_70}this article{/NP_70} {NP_71}we{/NP_71} {VP_act_72}will describe{/VP_act_72} how {VP_act_73}to work{/VP_act_73} with {NP_74}these new methods{/NP_74} {AV_75}practically{/AV_75} .


{NP_1}PMID{/NP_1} - {CP_2}19764811{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_C_5}In vivo <c>phosphoproteome</c>{/NP_C_5} of {NP_6}<s>human</s> skeletal muscle{/NP_6} {VP_pass_7}revealed{/VP_pass_7} by {NP_B_8}<pp>phosphopeptide</pp> enrichment and <B>HPLC-ESI-MS/MS</B>{/NP_B_8} .

{NP_9}<Bppf>Protein</Bppf> phosphorylation{/NP_9} {VP_act_10}plays{/VP_act_10} {NP_11}an essential role{/NP_11} in {NP_12}signal transduction pathways{/NP_12} {NP_13}that{/NP_13} {VP_act_14}regulate{/VP_act_14} {NP_P_15}<Bppf>substrate</Bppf>{/NP_P_15} and {NP_16}energy metabolism , contractile function , and muscle mass{/NP_16} in {NP_17}<s>human</s> skeletal muscle{/NP_17} .

{NP_18}Abnormal phosphorylation{/NP_18} of {NP_P_19}signaling <Bppf>enzymes</Bppf>{/NP_P_19} {VP_pass_20}has been identified{/VP_pass_20} in {NP_21}insulin-resistant muscle{/NP_21} {VP_act_22}using{/VP_act_22} {NP_P_23}<p>phosphoepitope-specific antibodies</p>{/NP_P_23} , but {NP_24}its role{/NP_24} in {NP_25}other skeletal muscle disorders{/NP_25} {VP_act_26}remains{/VP_act_26} {JP_27}largely unknown{/JP_27} .

{NP_28}This{/NP_28} {VP_pass_29}may be{/VP_pass_29} in {NP_30}part{/NP_30} {JP_31}due{/JP_31} to {NP_32}insufficient knowledge{/NP_32} of {NP_33}relevant targets{/NP_33} .

{AV_34}Here{/AV_34} , {NP_35}we{/NP_35} {VP_act_36}therefore present{/VP_act_36} {NP_37}the first large-scale in vivo <c>phosphoproteomic</c> study{/NP_37} of {NP_38}<s>human</s> skeletal muscle{/NP_38} from {JP_39}3 lean{/JP_39} , {NP_40}healthy volunteers{/NP_40} .

{NP_41}<c>Trypsin</c> digestion{/NP_41} of {NP_P_42}3-5 mg <s>human</s> skeletal muscle <Bppf>protein</Bppf>{/NP_P_42} {VP_pass_43}was followed{/VP_pass_43} by {NP_44}<pp>phosphopeptide</pp> enrichment{/NP_44} {VP_act_45}using{/VP_act_45} {NP_P_46}<p>SCX</p> and <p>TiO(2)</p>{/NP_P_46} .

OUTPUT 2
PTM = ({NP_PP_47};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_47}<pp>phosphopeptides</pp>{/NP_PP_47})

{NP_PP_47}The resulting <pp>phosphopeptides</pp>{/NP_PP_47} {VP_pass_48}were analyzed{/VP_pass_48} by {NP_B_49}<B>HPLC-ESI-MS/MS</B>{/NP_B_49} .

OUTPUT 3
PTM = ({NP_PP_54};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_54}<Bppp>phosphorylation sites</Bppp>{/NP_PP_54})

{VP_act_50}Using{/VP_act_50} {NP_51}this unbiased approach{/NP_51} , {NP_52}we{/NP_52} {VP_act_53}identified{/VP_act_53} {NP_PP_54}306 distinct in vivo <Bppp>phosphorylation sites</Bppp>{/NP_PP_54} in {NP_P_55}127 <Bppf>proteins</Bppf>{/NP_P_55} , {VP_act_56}including{/VP_act_56} {NP_PP_57}240 <pp>phosphoserines</pp>{/NP_PP_57} , {NP_PP_58}53 <pp>phosphothreonines</pp>{/NP_PP_58} , and {NP_PP_59}13 <pp>phosphotyrosines</pp>{/NP_PP_59} in {JP_60}atleast{/JP_60} {CP_61}2{/CP_61} out of {NP_62}3 subjects{/NP_62} .

OUTPUT 7
PTM = ({NP_PP_64};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_64}<Bppp>phosphorylation sites</Bppp>{/NP_PP_64})

In {NP_63}addition{/NP_63} , {NP_PP_64}61 ambiguous <Bppp>phosphorylation sites</Bppp>{/NP_PP_64} {VP_pass_65}were identified{/VP_pass_65} in {JP_66}atleast{/JP_66} {CP_67}2{/CP_67} out of {NP_68}3 subjects{/NP_68} .

{NP_69}The majority{/NP_69} of {NP_P_70}<p>phosphoproteins</p>{/NP_P_70} {VP_act_71}detected{/VP_act_71} {VP_pass_72}are involved{/VP_pass_72} in {NP_73}sarcomeric function{/NP_73} , {NP_74}excitation-contraction coupling{/NP_74} ( {NP_75}the <B>Ca(2+)</B>- cycle{/NP_75} ) , {NP_76}glycolysis , and <c>glycogen</c> metabolism{/NP_76} .

OUTPUT 9
PTM = ({NP_PP_80};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_P_81}<p>Z-disk proteins</p>{/NP_P_81};-)
Site = (-;-;{NP_PP_80}<Bppp>phosphorylation sites</Bppp>{/NP_PP_80})

Of {NP_77}particular interest{/NP_77} , {NP_78}we{/NP_78} {VP_act_79}identified{/VP_act_79} {NP_PP_80}multiple novel <Bppp>phosphorylation sites</Bppp>{/NP_PP_80} on {NP_P_81}several sarcomeric <p>Z-disk proteins</p>{/NP_P_81} {VP_act_82}known{/VP_act_82} {VP_pass_83}to be involved{/VP_pass_83} in {VP_act_84}signaling{/VP_act_84} and {NP_85}muscle disorders{/NP_85} .

OUTPUT 10
PTM = ({NP_P_90};phosphoproteins)
Kinase = (-;-)
Substrate = ({NP_P_90}<s>human</s> skeletal muscle <p>phosphoproteins</p>{/NP_P_90};-)
Site = (-;-;UNK)

{NP_86}These results{/NP_86} {VP_act_87}provide{/VP_act_87} {NP_88}numerous new targets{/NP_88} for {NP_89}the investigation{/NP_89} of {NP_P_90}<s>human</s> skeletal muscle <p>phosphoproteins</p>{/NP_P_90} in {NP_91}health{/NP_91} and {NP_92}disease{/NP_92} and {VP_act_93}demonstrate{/VP_act_93} {NP_94}feasibility{/NP_94} of {NP_C_95}<c>phosphoproteomics</c>{/NP_C_95} {VP_act_96}research{/VP_act_96} of {NP_97}<s>human</s> skeletal muscle{/NP_97} in {NP_98}vivo{/NP_98} .


{NP_1}PMID{/NP_1} - {CP_2}7894600{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_6};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6})

{NP_4}AB{/NP_4} - {NP_5}Synthesis{/NP_5} of {NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6} {VP_act_7}containing{/VP_act_7} {NP_PP_8}<pp>O-phosphoserine</pp> and <pp>O-phosphothreonine</pp>{/NP_PP_8} .


{NP_1}PMID{/NP_1} - {CP_2}31707662{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_B_5}<B>High-Throughput Characterization</B>{/NP_B_5} of {NP_B_6}<B>Histidine Phosphorylation Sites Using UPAX</B> and <B>Tandem Mass Spectrometry</B>{/NP_B_6} .

OUTPUT 1
PTM = ({NP_PP_10};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_10}<Bppp>phosphorylation sites</Bppp>{/NP_PP_10})

{NP_B_7}<B>Liquid chromatography ( LC )- tandem mass spectrometry ( MS/MS )</B>{/NP_B_7} {VP_pass_8}is key{/VP_pass_8} for {NP_9}the characterization{/NP_9} of {NP_PP_10}<Bppp>phosphorylation sites</Bppp>{/NP_PP_10} in {NP_11}a <B>high-throughput</B> manner{/NP_11} , and {NP_12}its application{/NP_12} {VP_act_13}has proven{/VP_act_13} {JP_14}essential{/JP_14} {VP_act_15}to elucidate{/VP_act_15} {NP_C_16}the <c>phosphoproteome</c>{/NP_C_16} of {NP_17}many biological systems{/NP_17} .

OUTPUT 2
PTM = ({NP_PP_23};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_23}<pp>phosphopeptides</pp>{/NP_PP_23})

{VP_act_18}Following{/VP_act_18} {NP_19}proteolytic digestion{/NP_19} of {NP_P_20}<Bppf>proteins</Bppf>{/NP_P_20} {VP_act_21}extracted{/VP_act_21} from {NP_22}<Bpcl>tissues</Bpcl> or <Bpcl>cells</Bpcl>{/NP_22} , {NP_PP_23}<pp>phosphopeptides</pp>{/NP_PP_23} {VP_pass_24}are typically enriched{/VP_pass_24} by {NP_B_25}affinity chromatography <B>using TiO2</B>{/NP_B_25} or {NP_26}metal-ions{/NP_26} ( {NP_27}e.g.{/NP_27} , {NP_B_28}<B>Fe3+</B>{/NP_B_28} ) {VP_act_29}coupled{/VP_act_29} {VP_act_30}to solid-phase{/VP_act_30} {NP_31}materials{/NP_31} , {AV_32}prior{/AV_32} to {NP_33}<B>LC-MS/MS</B> analysis{/NP_33} .

OUTPUT 3
PTM = ({NP_PP_35};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_35}<pp>phosphopeptides</pp>{/NP_PP_35})

{NP_34}Separation{/NP_34} of {NP_PP_35}relatively low abundance <pp>phosphopeptides</pp>{/NP_PP_35} from {NP_PP_36}nonphosphorylated <Bppp>peptides</Bppp>{/NP_PP_36} in {NP_37}these types{/NP_37} of {NP_38}extremely <Bpf>complex</Bpf> mixtures{/NP_38} {VP_pass_39}is essential{/VP_pass_39} {VP_act_40}to maximize{/VP_act_40} {NP_41}coverage{/NP_41} of {NP_C_42}the <c>phosphoproteome</c>{/NP_C_42} .

{VP_act_43}Maintaining{/VP_act_43} {NP_44}acidic conditions{/NP_44} during {NP_45}these <p>IMAC</p> or <B>TiO2-based</B> enrichment{/NP_45} {VP_act_46}minimizes{/VP_act_46} {NP_47}the concurrent unwanted binding{/NP_47} of {NP_PP_48}highly acidic <Bppp>peptides</Bppp>{/NP_PP_48} .

OUTPUT 5
PTM = ({NP_PP_57};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_57}<pp>phosphopeptides</pp>{/NP_PP_57})

OUTPUT 6
PTM = ({NP_G_59};phosphate group)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_57}<pp>phosphopeptides</pp>{/NP_PP_57})

{AV_49}However{/AV_49} , while {NP_PP_50}<Bppp>peptides</Bppp>{/NP_PP_50} {VP_act_51}containing{/VP_act_51} {NP_C_52}<c>phosphomonoesters</c>{/NP_C_52} , {AV_53}namely{/AV_53} , {NP_P_54}<p>phosphoserine ( pSer )</p> , <p>phosphothreonine ( pThr )</p> , and <p>phosphotyrosine ( pTyr )</p>{/NP_P_54} , {VP_pass_55}are stable{/VP_pass_55} under {NP_56}these acidic binding conditions{/NP_56} , {NP_PP_57}<pp>phosphopeptides</pp>{/NP_PP_57} {VP_act_58}containing{/VP_act_58} {NP_G_59}acid -labile <c>phosphate group</c>{/NP_G_59} {JP_60}such{/JP_60} as {NP_C_61}<c>phosphohistidine ( pHis )</c>{/NP_C_61} , {VP_pass_neg_62}are not{/VP_pass_neg_62} .

OUTPUT 7
PTM = ({NP_PP_66};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_66}<pp>phosphopeptides</pp>{/NP_PP_66})

{AV_63}Consequently{/AV_63} , {NP_64}hydrolysis{/NP_64} of {NP_65}these types{/NP_65} of {NP_PP_66}<pp>phosphopeptides</pp>{/NP_PP_66} {VP_act_67}occurs{/VP_act_67} during {NP_68}standard <pp>phosphopeptide</pp> enrichment{/NP_68} , and {NP_69}subsequent <c>phosphosite</c> identification{/NP_69} by {NP_B_70}<B>LC-MS/MS</B>{/NP_B_70} {VP_pass_71}is severely compromised{/VP_pass_71} .

OUTPUT 8
PTM = ({NP_PP_83};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_83}<pp>phosphopeptides</pp>{/NP_PP_83})

{AV_72}Here{/AV_72} {NP_73}we{/NP_73} {VP_act_74}describe{/VP_act_74} {NP_B_75}<B>UPAX</B>{/NP_B_75} , {NP_76}unbiased <B>phosphopeptide enrichment using</B> strong anion exchange{/NP_76} , for {NP_77}the separation{/NP_77} of {NP_78}both acid{/NP_78} {JP_79}-stable{/JP_79} ( {NP_80}pSer{/NP_80} , {NP_P_81}<p>pThr</p>{/NP_P_81} , {NP_P_82}<p>pTyr</p>{/NP_P_82} ) and {NP_PP_83}acid -labile <pp>phosphopeptides</pp>{/NP_PP_83} ( {VP_act_84}including{/VP_act_84} {NP_C_85}those containing <c>pHis</c>{/NP_C_85} ) from {NP_PP_86}nonphosphorylated <Bppp>peptides</Bppp>{/NP_PP_86} .

{NP_87}We{/NP_87} {VP_act_88}outline{/VP_act_88} how {NP_89}implementation{/NP_89} of {NP_B_90}<B>UPAX</B>{/NP_B_90} {AV_91}prior{/AV_91} to {NP_92}a minimally modified standard proteomics{/NP_92} {VP_act_93}workflow{/VP_act_93} {VP_pass_94}can be used{/VP_pass_94} {VP_act_95}to identify{/VP_act_95} {NP_PP_96}<Bppp>sites</Bppp>{/NP_PP_96} of {NP_C_97}<c>pHis</c>{/NP_C_97} as well as {NP_98}other acid -labile{/NP_98} , as well as {NP_C_99}acid -stable <c>phosphosites</c>{/NP_C_99} .


{NP_1}PMID{/NP_1} - {CP_2}2193799{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_7};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_7}<p>insulin receptor</p>{/NP_7};-)
Site = (-;-;UNK)

{NP_4}AB{/NP_4} - {NP_5}The effect{/NP_5} of {NP_6}<p>protein kinase-C</p> inhibition{/NP_6} on {NP_7}<p>insulin receptor</p> phosphorylation{/NP_7} .

OUTPUT 1
PTM = ({NP_10};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_10}<p>insulin receptor</p>{/NP_10};-)
Site = (-;-;UNK)

OUTPUT 2
PTM = ({NP_PP_13};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_13}<pp>phosphopeptide</pp>{/NP_PP_13})

{NP_8}The effect{/NP_8} of {NP_9}<p>protein kinase-C ( PKC )</p> inhibition{/NP_9} on {NP_10}<p>insulin receptor</p> phosphorylation{/NP_10} in {NP_S_11}<S>HepG2 cells</S>{/NP_S_11} {VP_pass_12}was analyzed{/VP_pass_12} by {NP_PP_13}two-dimensional tryptic <pp>phosphopeptide</pp>{/NP_PP_13} {VP_act_14}maps{/VP_act_14} .

In {NP_15}basal <Bpcl>cells</Bpcl>{/NP_15} , there {VP_pass_16}was{/VP_pass_16} {NP_PP_17}one major <pp><p>insulin receptor</p> -derived tryptic phosphothreonine peptide</pp>{/NP_PP_17} and {NP_PP_18}atleast four <pp>phosphoserine peptides</pp>{/NP_PP_18} .

OUTPUT 5
PTM = ({NP_21};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_PP_17}<p>insulin receptor</p>{/NP_PP_17};-)
Site = (-;{NP_PP_22}Thr{/NP_PP_22};UNK)

{NP_C_19}<c>Phorbol 12,13-dibutyrate ( PDBU )</c>{/NP_C_19} {VP_act_20}stimulated{/VP_act_20} {NP_21}phosphorylation{/NP_21} of {NP_PP_22}the <pp>phosphothreonine peptide</pp>{/NP_PP_22} , some of {NP_PP_23}the basal <pp>phosphoserine peptides</pp>{/NP_PP_23} , and {NP_PP_24}atleast one <pp>phosphoserine peptide</pp>{/NP_PP_24} {NP_25}that{/NP_25} {VP_pass_neg_26}was not detected{/VP_pass_neg_26} in {NP_27}the basal state{/NP_27} .

{NP_C_28}<c>Staurosporine</c>{/NP_C_28} {VP_act_29}completely inhibited{/VP_act_29} {NP_30}the <c>PDBU</c> -mediated phosphorylation{/NP_30} .

OUTPUT 10
PTM = ({NP_33};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_41}<p>insulin receptor</p>{/NP_41};-)
Site = (-;{NP_PP_34}Thr{/NP_PP_34};UNK)

OUTPUT 12
PTM = ({NP_41};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_41}<p>insulin receptor</p>{/NP_41};-)
Site = (-;-;UNK)

Although {NP_C_31}<c>staurosporine</c>{/NP_C_31} {VP_act_32}also inhibited{/VP_act_32} {NP_33}basal phosphorylation{/NP_33} of {NP_PP_34}the <pp>phosphothreonine peptide</pp>{/NP_PP_34} , {NP_35}down-regulation{/NP_35} of {NP_P_36}<p>PKC</p>{/NP_P_36} {VP_act_neg_37}did not{/VP_act_neg_37} , {VP_act_38}suggesting{/VP_act_38} that {NP_P_39}<p>PKC</p>{/NP_P_39} {VP_act_neg_40}does not mediate{/VP_act_neg_40} {NP_41}basal <p>insulin receptor</p> phosphorylation{/NP_41} .

{NP_42}<p>Insulin</p> treatment{/NP_42} {VP_pass_43}resulted{/VP_pass_43} in {NP_44}the appearance{/NP_44} of {NP_PP_45}four <pp>phosphotyrosine peptides</pp>{/NP_PP_45} .

OUTPUT 14
PTM = ({NP_48};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_41}<p>insulin receptor</p>{/NP_41};-)
Site = (-;{NP_PP_49}Ser{/NP_PP_49};UNK)

{NP_46}It{/NP_46} {VP_act_47}also stimulated{/VP_act_47} {NP_48}the phosphorylation{/NP_48} of {NP_PP_49}atleast two <pp>phosphoserine peptides</pp>{/NP_PP_49} .

OUTPUT 16
PTM = ({NP_PP_56};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_56}<pp>phosphopeptides</pp>{/NP_PP_56})

{CP_50}One{/CP_50} of these {VP_pass_51}may have been{/VP_pass_51} {NP_52}a <Bpf>complex</Bpf>{/NP_52} of {CP_53}two{/CP_53} or {JP_54}more distinct{/JP_54} but {VP_act_55}poorly resolved{/VP_act_55} {NP_PP_56}<pp>phosphopeptides</pp>{/NP_PP_56} , {NP_57}which{/NP_57} {VP_pass_58}was seen{/VP_pass_58} in {NP_59}basal <Bpcl>cells</Bpcl>{/NP_59} and {NP_60}a component{/NP_60} of {NP_61}which{/NP_61} {VP_act_62}seemed{/VP_act_62} {VP_pass_63}to be stimulated{/VP_pass_63} by {NP_C_64}<c>PDBU</c>{/NP_C_64} .

{AV_65}However{/AV_65} , {NP_66}neither <c>staurosporine</c> nor down-regulation{/NP_66} of {NP_P_67}<p>PKC</p>{/NP_P_67} {VP_act_68}diminished{/VP_act_68} {NP_69}insulin-stimulated <pp>serine</pp> phosphorylation{/NP_69} of {NP_PP_70}these <Bppp>peptides</Bppp>{/NP_PP_70} , {VP_act_71}indicating{/VP_act_71} that {NP_72}insulin-stimulated <Bppf>receptor</Bppf> <pp>serine</pp> phosphorylation{/NP_72} {VP_act_neg_73}did not involve{/VP_act_neg_73} {NP_74}<p>PKC</p> activity{/NP_74} .

OUTPUT 19
PTM = ({NP_83};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_41}<p>insulin receptor</p>{/NP_41};-)
Site = (-;{NP_PP_84}Thr{/NP_PP_84};UNK)

OUTPUT 21
PTM = ({NP_87};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_41}<p>insulin receptor</p>{/NP_41};-)
Site = (-;-;{NP_PP_86}<Bppp>site</Bppp>{/NP_PP_86})
(-;{NP_PP_84}Thr{/NP_PP_84};UNK)

OUTPUT 23
PTM = ({NP_93};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_92}<Bppp>site</Bppp>{/NP_PP_92})

{NP_75}The addition{/NP_75} of {NP_C_76}<c>staurosporine</c>{/NP_C_76} to {NP_77}<Bpcl>cells</Bpcl>{/NP_77} {NP_78}that{/NP_78} {VP_pass_79}had been incubated{/VP_pass_79} with {NP_C_80}<c>PDBU</c>{/NP_C_80} {VP_pass_81}resulted{/VP_pass_81} in {NP_82}the very rapid decay{/NP_82} of {NP_83}phosphorylation{/NP_83} of {NP_PP_84}the <Bppp>phosphothreonine-containing peptide</Bppp>{/NP_PP_84} , {VP_act_85}indicating{/VP_act_85} that {NP_PP_86}this <Bppp>site</Bppp>{/NP_PP_86} of {NP_87}phosphorylation{/NP_87} {VP_act_88}turns{/VP_act_88} over {AV_89}very rapidly{/AV_89} , while some of {NP_PP_90}the other <Bppp>phosphoserine-containing peptides</Bppp>{/NP_PP_90} , {VP_act_91}including{/VP_act_91} {NP_PP_92}the major unique <Bppp>site</Bppp>{/NP_PP_92} of {NP_93}phosphorylation{/NP_93} {VP_pass_94}stimulated{/VP_pass_94} by {NP_C_95}<c>PDBU</c>{/NP_C_95} , {VP_act_96}turned{/VP_act_96} over {AV_97}more slowly{/AV_97} .

OUTPUT 24
PTM = ({NP_102};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_P_99}<p>insulin receptor</p>{/NP_P_99};-)
Site = (-;-;{NP_PP_101}<Bppp>sites</Bppp>{/NP_PP_101})
(-;{NP_102}Ser{/NP_102};UNK)
(-;{NP_102}Thr{/NP_102};UNK)

{AV_98}Thus{/AV_98} , {NP_P_99}the <p>insulin receptor</p>{/NP_P_99} {VP_act_100}contains{/VP_act_100} {NP_PP_101}several <Bppp>sites</Bppp>{/NP_PP_101} of {NP_102}<pp>serine/threonine</pp> phosphorylation{/NP_102} , {NP_103}some of which{/NP_103} {VP_pass_104}are{/VP_pass_104} {NP_P_105}<Bppf>substrates</Bppf>{/NP_P_105} for {JP_106}more{/JP_106} than {NP_P_107}one <Bppf>protein kinase</Bppf>{/NP_P_107} .

{NP_108}This{/NP_108} {VP_act_109}may permit{/VP_act_109} {NP_110}<Bpf>complex</Bpf> modulation{/NP_110} of {NP_111}<p>insulin receptor</p> functions{/NP_111} in {NP_112}response{/NP_112} to {VP_act_113}multiple signalling{/VP_act_113} {NP_114}pathways{/NP_114} .

NORM=insulin receptor
SYNONYM=insulin receptor


{NP_1}PMID{/NP_1} - {CP_2}19819166{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_9};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_9}<pp>phosphopeptides</pp>{/NP_PP_9})

{NP_4}AB{/NP_4} - {NP_5}Time-resolved observation{/NP_5} of {NP_6}<Bpf>product</Bpf> ions{/NP_6} {VP_pass_7}generated{/VP_pass_7} by {NP_8}157 nm photodissociation{/NP_8} of {NP_PP_9}singly protonated <pp>phosphopeptides</pp>{/NP_PP_9} .

OUTPUT 1
PTM = ({NP_PP_11};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_11}<pp>phosphopeptides</pp>{/NP_PP_11})

{NP_10}Vacuum UV photodissociation tandem mass spectra{/NP_10} of {NP_PP_11}singly charged arginine-terminated <pp>phosphopeptides</pp>{/NP_PP_11} {VP_pass_12}were recorded{/VP_pass_12} at {NP_13}times{/NP_13} {VP_act_14}ranging{/VP_act_14} from {NP_15}300 ns{/NP_15} to {NP_16}ms{/NP_16} after {NP_17}photoexcitation{/NP_17} , {VP_act_18}to investigate{/VP_act_18} when {NP_G_19}the <c>phosphate group</c>{/NP_G_19} {VP_act_20}falls{/VP_act_20} off from {NP_21}the <Bpf>precursor</Bpf> and <Bpf>product</Bpf> ions{/NP_21} and whether {NP_22}loss{/NP_22} of {NP_G_23}<c>phosphate</c>{/NP_G_23} {VP_pass_24}can be eliminated{/VP_pass_24} in {NP_25}tandem mass spectra{/NP_25} .

For {NP_26}<Bppp>peptide</Bppp> ions{/NP_26} {VP_act_27}containing{/VP_act_27} {NP_PP_28}<pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_28} , {NP_29}little loss{/NP_29} of {NP_B_30}98 <B>Da</B>{/NP_B_30} from {NP_31}the <Bpf>product</Bpf> ions{/NP_31} {VP_pass_32}was observed{/VP_pass_32} up to {NP_33}1 micros{/NP_33} after {NP_34}photoexcitation{/NP_34} .

{AV_35}However{/AV_35} , {NP_36}neutral losses{/NP_36} from {NP_37}the <Bpf>precursor</Bpf> ions{/NP_37} {VP_pass_38}were{/VP_pass_38} {NP_39}considerable just 300 ns{/NP_39} after {NP_40}photoactivation{/NP_40} .

{NP_41}Loss{/NP_41} of {NP_B_42}98 <B>Da</B>{/NP_B_42} from {NP_43}<Bpf>product</Bpf> ions first appears{/NP_43} about {NP_44}1 micros{/NP_44} after {NP_45}laser irradiation{/NP_45} and {VP_act_46}becomes{/VP_act_46} {NP_47}more common 13 micros{/NP_47} after {NP_48}photoexcitation{/NP_48} .

{JP_49}Consistent{/JP_49} with {NP_50}previous reports{/NP_50} , {NP_PP_51}<pp>phosphotyrosine</pp>{/NP_PP_51} {VP_pass_52}was more stable{/VP_pass_52} than {NP_PP_53}either <pp>phosphoserine</pp> or <pp>phosphothreonine</pp>{/NP_PP_53} .


{NP_1}PMID{/NP_1} - {CP_2}11006587{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_10};phosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_10}<Bppp>peptides</Bppp>{/NP_PP_10})

{NP_4}AB{/NP_4} - {NP_5}Electron{/NP_5} {VP_act_6}capture{/VP_act_6} {NP_7}dissociation{/NP_7} of {AV_8}singly{/AV_8} and {VP_act_9}multiply{/VP_act_9} {NP_PP_10}phosphorylated <Bppp>peptides</Bppp>{/NP_PP_10} .

OUTPUT 2
PTM = ({NP_PP_19};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_19}<pp>phosphopeptide</pp>{/NP_PP_19})

{NP_11}Analysis{/NP_11} of {NP_PP_12}<pp>phosphotyrosine</pp> and <pp>phosphoserine</pp>{/NP_PP_12} {VP_act_13}containing{/VP_act_13} {NP_PP_14}<Bppp>peptides</Bppp>{/NP_PP_14} by {NP_15}nano-electrospray <c>Fourier transform ion cyclotron resonance ( FTICR )</c> mass spectrometry{/NP_15} {VP_act_16}established{/VP_act_16} {NP_B_17}<B>electron capture dissociation ( ECD )</B>{/NP_B_17} as {NP_18}a viable method{/NP_18} for {NP_PP_19}<pp>phosphopeptide</pp>{/NP_PP_19} {VP_act_20}sequencing{/VP_act_20} .

OUTPUT 3
PTM = ({NP_PP_23};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_23}<pp>phosphopeptides</pp>{/NP_PP_23})

In {JP_21}general{/JP_21} , {NP_22}<c>ECD</c> spectra{/NP_22} of {NP_PP_23}synthetic and native <pp>phosphopeptides</pp>{/NP_PP_23} {VP_act_24}appeared{/VP_act_24} {NP_25}less <Bpf>complex</Bpf>{/NP_25} than {NP_26}conventional <B>collision activated dissociation ( CAD )</B> mass spectra{/NP_26} of {NP_27}these species{/NP_27} .

{NP_C_28}<c>ECD</c>{/NP_C_28} of {VP_act_29}multiply{/VP_act_29} {NP_30}protonated <pp>phosphopeptide</pp> ions{/NP_30} {VP_act_31}generated{/VP_act_31} {JP_32}mainly c-{/JP_32} and {VP_act_33}z{/VP_act_33} ( . ) {NP_34}<Bppp>-type peptide fragment</Bppp> ion series{/NP_34} .

{NP_35}No loss{/NP_35} of {NP_P_36}water , <c>phosphate groups</c> or <p>phosphoric acid</p>{/NP_P_36} from {NP_37}intact <pp>phosphopeptide</pp> ions{/NP_37} nor from {NP_38}the c{/NP_38} and {VP_act_39}z{/VP_act_39} ( . ) {NP_B_40}<B>fragment ion products</B>{/NP_B_40} {VP_pass_41}was observed{/VP_pass_41} in {NP_42}the <c>ECD</c> spectra{/NP_42} .

OUTPUT 4
PTM = ({NP_PP_47};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_47}<pp>phosphopeptides</pp>{/NP_PP_47})

OUTPUT 5
PTM = ({NP_PP_49};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_49}<Bppp>phosphorylation sites</Bppp>{/NP_PP_49})
(-;-;{NP_PP_50}<Bppp>peptides</Bppp>{/NP_PP_50})

{NP_C_43}<c>ECD</c>{/NP_C_43} {VP_act_44}enabled{/VP_act_44} {NP_PP_45}complete or near-complete <Bppp>amino acid</Bppp>{/NP_PP_45} {VP_act_46}sequencing{/VP_act_46} of {NP_PP_47}<pp>phosphopeptides</pp>{/NP_PP_47} for {NP_48}the assignment{/NP_48} of up to {NP_PP_49}four <Bppp>phosphorylation sites</Bppp>{/NP_PP_49} in {NP_PP_50}<Bppp>peptides</Bppp>{/NP_PP_50} in {NP_B_51}the mass range 1400 to 3500 <B>Da</B>{/NP_B_51} .

OUTPUT 6
PTM = ({NP_PP_56};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_56}<pp>amino acid</pp>{/NP_PP_56})
(-;-;{NP_PP_56}<pp>phosphopeptide</pp>{/NP_PP_56})

{NP_52}Nano-scale <B>Fe (III)</B>- affinity chromatography{/NP_52} {VP_pass_53}combined{/VP_pass_53} with {NP_P_54}nano-electrospray <p>FTMS/ECD</p>{/NP_P_54} {VP_act_55}facilitated{/VP_act_55} {NP_PP_56}<pp>phosphopeptide</pp> analysis and <pp>amino acid</pp>{/NP_PP_56} {VP_act_57}sequencing{/VP_act_57} from {NP_58}crude proteolytic <Bppp>peptide</Bppp> mixtures{/NP_58} .


{NP_1}PMID{/NP_1} - {CP_2}2431747{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Resolution and identification{/NP_5} of {NP_P_6}<pp>O-phosphoserine</pp> , <pp>O-phosphothreonine</pp> , <pp>O-phosphotyrosine</pp> , and <p>gamma-carboxyglutamic acid</p>{/NP_P_6} as {NP_B_7}their fluorescent <B>o-phthalaldehyde derivatives</B>{/NP_B_7} by {NP_8}high performance liquid chromatography{/NP_8} .

{NP_9}High performance liquid chromatography{/NP_9} {VP_pass_10}was used{/VP_pass_10} {VP_act_11}to resolve{/VP_act_11} {NP_PP_12}<pp>O-phosphoserine</pp> , <pp>O-phosphothreonine</pp> , and <pp>O-phosphotyrosine</pp>{/NP_PP_12} as {NP_B_13}their fluorescent <B>o-phthalaldehyde derivatives</B>{/NP_B_13} .

By {VP_act_14}adjusting{/VP_act_14} {NP_15}the buffer system{/NP_15} , {NP_16}very small amounts{/NP_16} of {NP_PP_17}<pp>O-phosphothreonine</pp>{/NP_PP_17} {VP_pass_18}could be detected and quantitated{/VP_pass_18} in {NP_19}the presence{/NP_19} of {NP_20}very large amounts{/NP_20} of {NP_PP_21}<pp>O-phosphoserine</pp>{/NP_PP_21} .

In {NP_22}addition{/NP_22} , {NP_PP_23}<p>gamma-carboxyglutamic acid</p> and <pp>glutamic acid</pp>{/NP_PP_23} {VP_pass_24}were also separated and quantitated{/VP_pass_24} .

{VP_act_25}Depending{/VP_act_25} on {NP_26}the buffer{/NP_26} {VP_act_27}used{/VP_act_27} , {NP_28}various combinations{/NP_28} of {NP_PP_29}these <Bppp>amino acids</Bppp>{/NP_PP_29} {VP_pass_30}could be resolved{/VP_pass_30} in {NP_31}a single run{/NP_31} .


{NP_1}PMID{/NP_1} - {CP_2}1719344{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Separation{/NP_5} of {NP_PP_6}<pp>phosphotyrosine</pp> , <pp>phosphoserine</pp> , and <pp>phosphothreonine</pp>{/NP_PP_6} by {NP_7}high-performance liquid chromatography{/NP_7} .


{NP_1}PMID{/NP_1} - {CP_2}6187758{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Dansylation{/NP_5} and {NP_6}high-performance liquid chromatographic separation{/NP_6} of {NP_PP_7}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> and <pp>phosphotyrosine</pp>{/NP_PP_7} from {NP_8}<p>32P-labeled protein</p> hydrolyzates{/NP_8} .


{NP_1}PMID{/NP_1} - {CP_2}6162272{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Distribution{/NP_5} of {NP_PP_6}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> and <pp>phosphotyrosine</pp>{/NP_PP_6} in {NP_P_7}<Bppf>proteins</Bppf>{/NP_P_7} of {NP_8}<s>vesicular stomatitis virus</s>{/NP_8} .


{NP_1}PMID{/NP_1} - {CP_2}24723360{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_C_5}<c>Tissue phosphoproteomics</c>{/NP_C_5} with {NP_B_6}<B>PolyMAC</B>{/NP_B_6} {VP_act_7}identifies{/VP_act_7} {NP_8}potential therapeutic targets{/NP_8} in {NP_9}a transgenic <s>mouse</s> model{/NP_9} of {NP_10}<p>HER2</p> positive breast cancer{/NP_10} .

{NP_11}Altered <Bppf>protein</Bppf> phosphorylation{/NP_11} {VP_act_12}is{/VP_act_12} {NP_13}a feature{/NP_13} of {NP_14}many <s>human</s> cancers{/NP_14} {NP_15}that{/NP_15} {VP_pass_16}can be targeted{/VP_pass_16} {AV_17}therapeutically{/AV_17} .

{NP_18}<pp>Phosphopeptide</pp> enrichment{/NP_18} {VP_act_19}is{/VP_act_19} {NP_20}a critical step{/NP_20} for {VP_act_21}maximizing{/VP_act_21} {NP_22}the depth{/NP_22} of {NP_23}<c>phosphoproteome</c> coverage{/NP_23} by {NP_B_24}<B>MS</B>{/NP_B_24} , but {VP_act_25}remains{/VP_act_25} {VP_act_26}challenging{/VP_act_26} for {NP_27}<Bpcl>tissue</Bpcl> specimens{/NP_27} because of {NP_28}their high complexity{/NP_28} .

{NP_29}We{/NP_29} {VP_act_30}describe{/VP_act_30} {NP_31}the first analysis{/NP_31} of {NP_C_32}a <c>tissue phosphoproteome</c>{/NP_C_32} {VP_act_33}using{/VP_act_33} {NP_B_34}<B>polymer-based metal ion affinity capture ( PolyMAC )</B>{/NP_B_34} , {NP_35}a nanopolymer{/NP_35} {NP_36}that{/NP_36} {VP_act_37}has{/VP_act_37} {NP_38}excellent yield{/NP_38} and {NP_39}specificity{/NP_39} for {NP_40}<pp>phosphopeptide</pp> enrichment{/NP_40} , on {NP_41}a transgenic <s>mouse</s> model{/NP_41} of {NP_42}<B>HER2-driven</B> breast cancer{/NP_42} .

By {VP_act_43}combining{/VP_act_43} {NP_44}<pp>phosphotyrosine</pp> immunoprecipitation{/NP_44} with {NP_B_45}<B>PolyMAC</B>{/NP_B_45} , {NP_PP_46}411 unique <Bppp>peptides</Bppp>{/NP_PP_46} with {NP_PP_47}139 <pp>phosphotyrosine</pp>{/NP_PP_47} , {NP_PP_48}45 <pp>phosphoserine</pp>{/NP_PP_48} , and {NP_PP_49}29 <pp><B>phosphothreonine</B> sites</pp>{/NP_PP_49} {VP_pass_50}were identified{/VP_pass_50} from {NP_B_51}five <B>LC-MS/MS</B>{/NP_B_51} {VP_act_52}runs{/VP_act_52} .

{VP_act_53}Combining{/VP_act_53} {VP_act_54}reverse{/VP_act_54} {NP_55}phase liquid chromatography fractionation{/NP_55} at {NP_56}pH 8.0{/NP_56} with {NP_B_57}<B>PolyMAC</B>{/NP_B_57} {VP_act_58}identified{/VP_act_58} {NP_PP_59}1571 unique <Bppp>peptides</Bppp>{/NP_PP_59} with {NP_PP_60}1279 <pp>phosphoserine</pp>{/NP_PP_60} , {NP_PP_61}213 <pp>phosphothreonine</pp>{/NP_PP_61} , and {NP_PP_62}21 <pp><B>phosphotyrosine</B> sites</pp>{/NP_PP_62} from {NP_B_63}eight <B>LC-MS/MS</B>{/NP_B_63} {VP_act_64}runs{/VP_act_64} .

OUTPUT 8
PTM = ({NP_PP_70};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_70}<Bppp>phosphorylation motifs</Bppp>{/NP_PP_70})

{NP_65}Linear <Bppp>motif</Bppp> analysis{/NP_65} {VP_act_66}indicated{/VP_act_66} that {NP_67}many{/NP_67} of {NP_C_68}the <c>phosphosites</c>{/NP_C_68} {VP_act_69}correspond{/VP_act_69} to {NP_PP_70}well-known <Bppp>phosphorylation motifs</Bppp>{/NP_PP_70} .

{NP_71}Analysis{/NP_71} of {NP_C_72}the <c>tyrosine phosphoproteome</c>{/NP_C_72} with {NP_73}the <B>Drug Gene Interaction</B> database{/NP_73} {VP_act_74}uncovered{/VP_act_74} {NP_75}a network{/NP_75} of {NP_76}potential therapeutic targets{/NP_76} {VP_pass_77}centered{/VP_pass_77} on {NP_P_78}<p>Src family kinases</p>{/NP_P_78} with {NP_P_79}<Bppf>inhibitors</Bppf>{/NP_P_79} {NP_80}that{/NP_80} {VP_pass_81}are{/VP_pass_81} {NP_B_82}either <B>FDA-approved</B>{/NP_B_82} or in {NP_83}clinical development{/NP_83} .

{NP_84}These results{/NP_84} {VP_act_85}demonstrate{/VP_act_85} that {NP_B_86}<B>PolyMAC</B>{/NP_B_86} {VP_pass_87}is well suited{/VP_pass_87} for {NP_88}<c>phosphoproteomic</c> analysis{/NP_88} of {NP_89}<Bpcl>tissue</Bpcl> specimens{/NP_89} .


{NP_1}PMID{/NP_1} - {CP_2}14576432{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_B_5}<B>BRCT</B>{/NP_B_5} {VP_act_6}repeats{/VP_act_6} as {NP_7}<Bppp>phosphopeptide</Bppp> -binding modules{/NP_7} {VP_pass_8}involved{/VP_pass_8} in {NP_P_9}<Bppf>protein</Bppf>{/NP_P_9} {VP_act_10}targeting{/VP_act_10} .

{NP_11}We{/NP_11} {VP_act_12}used{/VP_act_12} {NP_13}a proteomic approach{/NP_13} {VP_act_14}to identify{/VP_act_14} {NP_15}<Bppp>phosphopeptide</Bppp> -binding modules{/NP_15} {VP_act_16}mediating{/VP_act_16} {NP_17}signal transduction events{/NP_17} in {NP_18}the DNA damage response pathway{/NP_18} .

OUTPUT 0
PTM = ({NP_PP_21};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_21}<pp>degenerate phosphopeptides</pp>{/NP_PP_21})

OUTPUT 3
PTM = ({VP_pass_32};phosphorylated)
Kinase = ({NP_P_33}<p>ATM ( ataxia telangiectasia-mutated )</p>{/NP_P_33};-)
({NP_P_33}<p>ATR ( ataxia telangiectasia - and RAD3-related )</p>{/NP_P_33};-)
Substrate = (-;-)
Site = (-;-;UNK)

{VP_act_19}Using{/VP_act_19} {NP_20}a library{/NP_20} of partially {NP_PP_21}<pp>degenerate phosphopeptides</pp>{/NP_PP_21} , {NP_22}we{/NP_22} {VP_act_23}identified{/VP_act_23} {NP_PP_24}tandem <pp>BRCT ( <p>BRCA1</p> carboxyl-terminal ) domains</pp>{/NP_PP_24} in {NP_P_25}<p>PTIP ( Pax transactivation domain-interacting protein )</p>{/NP_P_25} and in {NP_P_26}<p>BRCA1</p>{/NP_P_26} as {NP_PP_27}<pp>phosphoserine</pp>{/NP_PP_27} - or {NP_28}<c>phosphothreonine-specific</c> binding modules{/NP_28} {NP_29}that{/NP_29} {VP_act_30}recognize{/VP_act_30} {NP_P_31}<Bppf>substrates</Bppf>{/NP_P_31} {VP_pass_32}phosphorylated{/VP_pass_32} by {NP_P_33}the <Bppf>kinases</Bppf> <p>ATM ( ataxia telangiectasia-mutated )</p> and <p>ATR ( ataxia telangiectasia - and RAD3-related )</p>{/NP_P_33} in {NP_34}response{/NP_34} {VP_act_35}to gamma-irradiation{/VP_act_35} .

OUTPUT 5
PTM = ({NP_P_40};phospho-<p>H2AX</p>)
Kinase = (-;-)
Substrate = ({NP_P_40}<p>H2AX</p>{/NP_P_40};-)
Site = (-;-;{NP_PP_36}<pp><B>PTIP tandem BRCT</B> domains</pp>{/NP_PP_36})

{NP_PP_36}<pp><B>PTIP tandem BRCT</B> domains</pp>{/NP_PP_36} {VP_pass_37}are responsible{/VP_pass_37} for {NP_38}<Bppf>phosphorylation -dependent protein</Bppf> localization{/NP_38} into {NP_P_39}<p>53BP1</p>{/NP_P_39} - and {NP_P_40}phospho-<p>H2AX</p> (gamma-H2AX){/NP_P_40} {VP_act_41}-containing{/VP_act_41} {NP_42}nuclear foci{/NP_42} , {NP_43}a marker{/NP_43} of {NP_44}DNA damage{/NP_44} .

OUTPUT 6
PTM = ({NP_PP_56};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_56}<pp>phosphopeptides</pp>{/NP_PP_56})

{NP_45}These findings{/NP_45} {VP_act_46}provide{/VP_act_46} {NP_47}a molecular basis{/NP_47} for {NP_48}<pp>BRCT domain</pp> function{/NP_48} in {NP_49}the DNA damage response{/NP_49} and {VP_act_50}may help{/VP_act_50} {VP_act_51}to explain{/VP_act_51} why {NP_PP_52}the <pp><p>BRCA1</p> <pp>BRCT domain mutation Met1775</pp> --> Arg</pp>{/NP_PP_52} , {NP_53}which{/NP_53} {VP_act_54}fails{/VP_act_54} {VP_act_55}to bind{/VP_act_55} {NP_PP_56}<pp>phosphopeptides</pp>{/NP_PP_56} , {VP_act_57}predisposes{/VP_act_57} {NP_58}<s>women</s>{/NP_58} to {NP_59}breast and ovarian cancer{/NP_59} .


{NP_1}PMID{/NP_1} - {CP_2}29406695{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_8};Phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_8}<pp>Phosphopeptide</pp>{/NP_PP_8})

{NP_4}AB{/NP_4} - {VP_act_5}Neutralizing{/VP_act_5} {NP_B_6}the Detrimental <B>Effect</B>{/NP_B_6} of {NP_B_7}an <B>N-Hydroxysuccinimide Quenching Reagent</B>{/NP_B_7} on {NP_PP_8}<pp>Phosphopeptide</pp>{/NP_PP_8} in {NP_B_9}<B>Quantitative Proteomics</B>{/NP_B_9} .

{CP_10}One{/CP_10} of {NP_11}the most common chemistries{/NP_11} {VP_act_12}used{/VP_act_12} {VP_act_13}to label{/VP_act_13} {NP_14}primary amines{/NP_14} {VP_act_15}utilizes{/VP_act_15} {NP_C_16}<c>N-hydroxysuccinimide ( NHS )</c>{/NP_C_16} , {NP_17}which{/NP_17} {VP_pass_18}is also structurally incorporated{/VP_pass_18} in {NP_19}various quantitative proteomic reagents{/NP_19} {JP_20}such{/JP_20} as {NP_21}isobaric tags{/NP_21} for {NP_B_22}relative and absolute quantification ( iTRAQ ) and <p>tandem mass tags ( TMT )</p>{/NP_B_22} .

OUTPUT 1
PTM = ({NP_PP_30};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_30}<pp>phosphopeptides</pp>{/NP_PP_30})

In {NP_23}this paper{/NP_23} {NP_24}we{/NP_24} {VP_act_25}report{/VP_act_25} {NP_26}detrimental effect{/NP_26} of {NP_C_27}<c>hydroxylamine</c>{/NP_C_27} , {NP_B_28}a widely used quenching <B>reagent</B>{/NP_B_28} for {NP_P_29}<p>excess NHS</p>{/NP_P_29} , on {NP_PP_30}<pp>phosphopeptides</pp>{/NP_PP_30} .

{NP_31}We{/NP_31} {VP_act_32}found{/VP_act_32} {NP_33}an impairment{/NP_33} in {NP_34}the degree{/NP_34} of {NP_35}<pp>phosphopeptide</pp> identification{/NP_35} when {NP_36}<c>hydroxylamine-quenched TMT-labeled</c> samples{/NP_36} {VP_pass_37}were vacuum-dried and desalted{/VP_pass_37} {VP_act_38}compared{/VP_act_38} to the {JP_39}nondried{/JP_39} ( {VP_act_40}just diluted{/VP_act_40} ) and {VP_act_41}desalted{/VP_act_41} {NP_42}ones{/NP_42} {AV_43}prior{/AV_43} to {NP_C_44}<c>phosphoenrichment</c>{/NP_C_44} .

{NP_45}We{/NP_45} {VP_act_46}have also demonstrated{/VP_act_46} that {JP_47}vacuum-drying{/JP_47} in {NP_48}the presence{/NP_48} of {NP_C_49}<c>hydroxylamine</c>{/NP_C_49} {VP_act_50}promotes{/VP_act_50} {NP_51}b-elimination{/NP_51} of {NP_G_52}<c>phosphate groups</c>{/NP_G_52} from {NP_PP_53}<pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_53} while {VP_act_54}having{/VP_act_54} {NP_55}a minimalistic effect{/NP_55} on {NP_PP_56}<pp>phosphotyrosine</pp>{/NP_PP_56} .

{AV_57}Additionally{/AV_57} , {NP_58}we{/NP_58} {VP_act_59}herein report{/VP_act_59} that {NP_60}this negative impact{/NP_60} of {NP_C_61}<c>hydroxylamine</c>{/NP_C_61} {VP_pass_62}could be minimized{/VP_pass_62} by {NP_63}direct desalting{/NP_63} after {NP_64}appropriate dilution{/NP_64} of {NP_65}quenched samples{/NP_65} .

{NP_66}We{/NP_66} {VP_act_67}also found{/VP_act_67} {NP_68}a 1.6-fold{/NP_68} {VP_pass_69}increase{/VP_pass_69} in {NP_70}the number{/NP_70} of {NP_71}<pp>phosphopeptide</pp> identifications{/NP_71} after {VP_act_72}employing{/VP_act_72} our {VP_act_73}optimized{/VP_act_73} {NP_74}method{/NP_74} .

OUTPUT 4
PTM = ({NP_PP_79};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_79}<pp>phosphopeptides</pp>{/NP_PP_79})

{NP_75}The above method{/NP_75} {VP_pass_76}was also successfully applied{/VP_pass_76} to {NP_77}<s>human</s> tumor <Bpcl>tissues</Bpcl>{/NP_77} {VP_act_78}to quantify{/VP_act_78} over {NP_PP_79}15000 <pp>phosphopeptides</pp>{/NP_PP_79} from {NP_80}3 mg <B>TMT 6-plex</B> labeled{/NP_80} - {NP_PP_81}<Bppp>peptides</Bppp>{/NP_PP_81} .


{NP_1}PMID{/NP_1} - {CP_2}23994561{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Determination{/NP_5} of {NP_PP_6}<pp>phosphoserine/threonine</pp>{/NP_PP_6} by {NP_7}nano ultra-performance liquid chromatography-tandem mass spectrometry{/NP_7} {VP_act_8}coupled{/VP_act_8} with {NP_9}microscale{/NP_9} {VP_act_10}labeling{/VP_act_10} .

{NP_11}<Bppf>Protein</Bppf> phosphorylation{/NP_11} {VP_act_12}is{/VP_act_12} {NP_13}an important regulatory post-translational modification{/NP_13} in {NP_14}many <Bpcf>biochemical</Bpcf> processes{/NP_14} .

{NP_15}The <pp>phosphopeptide</pp> analysis strategies{/NP_15} {VP_pass_16}developed{/VP_pass_16} in {NP_17}this study{/NP_17} {VP_pass_18}were{/VP_pass_18} all at {NP_19}microscale{/NP_19} .

After {VP_act_20}using{/VP_act_20} {NP_21}a standard microwave oven{/NP_21} {VP_act_22}to assist{/VP_act_22} {NP_PP_23}<Bppf>protein</Bppf> digestion , <pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_23} {VP_pass_24}were tagged{/VP_pass_24} with {NP_25}<Bpf>chemical analogues</Bpf>{/NP_25} , {JP_26}such{/JP_26} as {NP_C_27}<c>2-mercaptoethanol</c> and <c>3-mercapto-1-propanol</c>{/NP_C_27} , {VP_act_28}to enable{/VP_act_28} {NP_29}simultaneously relative quantitation and identification{/NP_29} .

OUTPUT 3
PTM = ({NP_PP_35};phosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_35}<Bppp>sites</Bppp>{/NP_PP_35})

OUTPUT 4
PTM = ({NP_PP_38};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_38}<pp>phosphopeptides</pp>{/NP_PP_38})

{NP_30}This method{/NP_30} {VP_act_31}enabled{/VP_act_31} {NP_32}the use{/NP_32} of {NP_C_33}<c>thio alcohols</c>{/NP_C_33} for {NP_34}direct labeling{/NP_34} of {NP_PP_35}phosphorylated <Bppp>sites</Bppp>{/NP_PP_35} ( {VP_pass_neg_36}not labeled{/VP_pass_neg_36} at {NP_C_37}the <c>mercapto</c> , <c>amino</c> , <c>hydroxyl</c> , or <c>carboxyl groups</c>{/NP_C_37} ) of {NP_PP_38}<pp>phosphopeptides</pp>{/NP_PP_38} .

{NP_39}Various digestion parameters{/NP_39} ( {NP_40}e.g.{/NP_40} , {NP_41}microwave power{/NP_41} , {NP_42}reaction time{/NP_42} , {NP_43}<B>NH4HCO3</B> concentration{/NP_43} ) and {NP_44}derivatization efficiency parameters{/NP_44} ( {NP_45}e.g.{/NP_45} , {NP_46}reaction time{/NP_46} , {VP_act_47}labeling{/VP_act_47} {NP_48}tag concentration{/NP_48} ) {VP_pass_49}were studied and optimized{/VP_pass_49} .

In {NP_50}both control and experimental samples{/NP_50} , {NP_51}microwave-assisted digestion{/NP_51} {VP_act_52}coupled{/VP_act_52} with {NP_53}relative quantitation{/NP_53} {VP_act_54}using{/VP_act_54} {NP_55}<Bpf>analogue</Bpf> tags{/NP_55} {VP_act_56}enabled{/VP_act_56} {NP_57}calculation{/NP_57} of {NP_58}<pp>phosphopeptide</pp> ratios{/NP_58} in {NP_PP_59}the same <Bppp>sequence</Bppp>{/NP_PP_59} .

OUTPUT 5
PTM = ({NP_PP_62};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_62}<pp>quantifying phosphopeptides</pp>{/NP_PP_62})

OUTPUT 6
PTM = ({NP_PP_69};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_69}<pp>phosphopeptides</pp>{/NP_PP_69})

{NP_60}A non-labeling method{/NP_60} {VP_pass_61}was also established{/VP_pass_61} for {NP_PP_62}<pp>quantifying phosphopeptides</pp>{/NP_PP_62} in {NP_63}<s>human</s> plasma{/NP_63} by {VP_act_64}using{/VP_act_64} {NP_P_65}the abundant protein <p>albumin</p>{/NP_P_65} as {NP_66}an internal control{/NP_66} for {VP_act_67}normalizing{/VP_act_67} {NP_68}relative quantities{/NP_68} of {NP_PP_69}<pp>phosphopeptides</pp>{/NP_PP_69} .

{NP_C_70}<c>Nano ultra-performance liquid chromatography ( nanoUPLC )</c>{/NP_C_70} {VP_pass_71}was combined{/VP_pass_71} with {NP_B_72}<B>LTQ Orbitrap</B>{/NP_B_72} {VP_act_73}to enable{/VP_act_73} {NP_74}simultaneous <Bppf>protein</Bppf> relative quantitation and identification{/NP_74} .

OUTPUT 7
PTM = ({NP_PP_78};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_78}<pp>quantifying phosphopeptides</pp>{/NP_PP_78})

{NP_75}These strategies{/NP_75} {VP_act_76}proved{/VP_act_76} {VP_pass_77}to be effective{/VP_pass_77} for {NP_PP_78}<pp>quantifying phosphopeptides</pp>{/NP_PP_78} in {NP_79}biological samples{/NP_79} .


{NP_1}PMID{/NP_1} - {CP_2}14578343{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Phosphopeptide binding specificities{/NP_5} of {NP_PP_6}<pp><p>BRCA1</p> COOH-terminal ( BRCT ) domains</pp>{/NP_PP_6} .

OUTPUT 0
PTM = ({NP_7};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_10}<Bppp>sites</Bppp>{/NP_PP_10})

{NP_7}<Bppf>Protein</Bppf> phosphorylation{/NP_7} by {NP_P_8}<Bppf>protein kinases</Bppf>{/NP_P_8} {VP_act_9}may generate{/VP_act_9} {NP_PP_10}docking <Bppp>sites</Bppp>{/NP_PP_10} for {NP_P_11}other <Bppf>proteins</Bppf>{/NP_P_11} .

{NP_12}It{/NP_12} {VP_act_13}thus allows{/VP_act_13} {NP_14}the assembly{/NP_14} of {NP_15}signaling <Bpf>complexes</Bpf>{/NP_15} in {NP_16}response{/NP_16} to {NP_17}<Bppf>kinase</Bppf> activation{/NP_17} .

{NP_PP_18}Several <Bppp>protein domains</Bppp>{/NP_PP_18} {NP_19}that{/NP_19} {VP_act_20}bind{/VP_act_20} {NP_PP_21}<pp>phosphoserine</pp> or <pp>phosphothreonine residues</pp>{/NP_PP_21} {VP_pass_22}have been identified{/VP_pass_22} , {VP_act_23}including{/VP_act_23} {NP_P_24}the <p>14-3-3</p>{/NP_P_24} , {NP_P_25}<p>PIN1</p>{/NP_P_25} , {NP_P_26}<p>FHA</p>{/NP_P_26} , {NP_B_27}<B>KIX</B>{/NP_B_27} , {NP_PP_28}<pp>WD-40 domain</pp>{/NP_PP_28} , and {NP_PP_29}polo <Bppp>box</Bppp>{/NP_PP_29} ( {NP_B_30}<B>Yaffe</B> , <B>M. B.</B> , and <B>Elia</B>{/NP_B_30} , {NP_B_31}<B>A. E. ( 2001 )</B> Curr. <B>Opin</B>{/NP_B_31} .

{NP_32}<Bpcl>Cell Biol. 13</Bpcl>{/NP_32} , {NP_33}131-138{/NP_33} ; {NP_B_34}<B>Elia</B> , <B>A. E.</B> , <B>Cantley</B> , <B>L. C.</B> , and <B>Yaffe</B>{/NP_B_34} , {NP_B_35}<B>M. B. ( 2003 ) Science 299</B>{/NP_B_35} , {NP_36}1228-1231{/NP_36} ) .

{NP_PP_37}The <pp><p>BRCA1</p> COOH-terminal ( BRCT ) domains</pp>{/NP_PP_37} {VP_pass_38}are{/VP_pass_38} {NP_39}<Bppf>protein</Bppf> modules{/NP_39} {VP_pass_40}found{/VP_pass_40} in {NP_P_41}many <Bppf>proteins</Bppf>{/NP_P_41} {NP_42}that{/NP_42} {VP_act_43}regulate{/VP_act_43} {NP_44}DNA damage responses{/NP_44} ( {NP_B_45}<B>Koonin</B> , <B>E. V.</B> , <B>Altschul</B> , <B>S. F.</B> , and <B>Bork</B>{/NP_B_45} , {NP_46}<B>P. ( 1996 )</B> Nat. Genet. 13{/NP_46} , {NP_47}266-268{/NP_47} ) .

Whether {NP_PP_48}<pp>BRCT domains</pp>{/NP_PP_48} {VP_act_49}can mediate{/VP_act_49} {NP_50}phosphorylation -dependent interactions{/NP_50} {VP_pass_neg_51}has not been systematically investigated{/VP_pass_neg_51} .

OUTPUT 3
PTM = ({NP_PP_57};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_57}<pp>phosphopeptides</pp>{/NP_PP_57})

{NP_52}We{/NP_52} {VP_act_53}report{/VP_act_53} {AV_54}here{/AV_54} that {NP_PP_55}the <pp>BRCT domains</pp>{/NP_PP_55} {VP_act_56}also recognize{/VP_act_56} {NP_PP_57}<pp>phosphopeptides</pp>{/NP_PP_57} .

{NP_58}Oriented <Bppp>peptide</Bppp> library analysis{/NP_58} {VP_act_59}indicated{/VP_act_59} that {NP_PP_60}the <pp>BRCT domains</pp>{/NP_PP_60} from {NP_PP_61}<p>BRCA1</p> , <p>MDC1</p> , <p>BARD1</p> , and <pp><p>DNA Ligase IV</p> preferred distinct phosphoserine-containing peptides</pp>{/NP_PP_61} .

In {NP_62}addition{/NP_62} , {NP_63}the interaction{/NP_63} between {NP_P_64}<p>BRCA1</p>{/NP_P_64} and {NP_PP_65}the <pp><pp>BRCT</pp> binding motif</pp>{/NP_PP_65} of {NP_P_66}<p>BACH1</p>{/NP_P_66} {VP_pass_67}was required{/VP_pass_67} for {NP_68}<p>BACH1</p> checkpoint activity{/NP_68} .

OUTPUT 5
PTM = ({NP_PP_73};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_73}<pp>phosphopeptides</pp>{/NP_PP_73})

{AV_69}Furthermore{/AV_69} , {NP_PP_70}<pp>BRCT domains</pp>{/NP_PP_70} of {NP_B_71}the <s>yeast</s> <B>DNA repair protein Rad9</B>{/NP_B_71} {VP_act_72}could bind{/VP_act_72} {NP_PP_73}<pp>phosphopeptides</pp>{/NP_PP_73} , {VP_act_74}suggesting{/VP_act_74} that {NP_PP_75}the <pp>BRCT domains</pp>{/NP_PP_75} {VP_act_76}represent{/VP_act_76} {NP_77}a class{/NP_77} of {NP_78}ancient <Bppp>phosphopeptide</Bppp> -binding modules{/NP_78} .

{NP_79}Potential targets{/NP_79} of {NP_PP_80}<pp>BRCT domains</pp>{/NP_PP_80} {VP_pass_81}were identified{/VP_pass_81} through {NP_82}data{/NP_82} {VP_act_83}base{/VP_act_83} {NP_84}search{/NP_84} .

{NP_85}Structural analysis{/NP_85} of {NP_PP_86}<p>BRCA1</p> <pp>BRCT</pp>{/NP_PP_86} {VP_act_87}repeats{/VP_act_87} {VP_act_88}also predicted{/VP_act_88} {NP_PP_89}conserved <Bppp>residues</Bppp>{/NP_PP_89} {NP_90}that{/NP_90} {VP_act_91}may form{/VP_act_91} {NP_92}the <Bppp>phosphopeptide</Bppp> -binding pocket{/NP_92} .

OUTPUT 6
PTM = ({NP_PP_97};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_94}the <pp>BRCT repeats</pp>{/NP_PP_94})
(-;-;{NP_PP_97}<Bppp><Bppp>phosphopeptide</Bppp> -binding domains</Bppp>{/NP_PP_97})

{AV_93}Thus{/AV_93} , {NP_PP_94}the <pp>BRCT repeats</pp>{/NP_PP_94} {VP_pass_95}are{/VP_pass_95} {NP_96}a new <Bpf>family</Bpf>{/NP_96} of {NP_PP_97}<Bppp><Bppp>phosphopeptide</Bppp> -binding domains</Bppp>{/NP_PP_97} in {NP_98}DNA damage responses{/NP_98} .


{NP_1}PMID{/NP_1} - {CP_2}8394059{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_5};Phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_5}<pp>Phosphopeptides</pp>{/NP_PP_5})

{NP_4}AB{/NP_4} - {NP_PP_5}<pp>Phosphopeptides</pp>{/NP_PP_5} as {NP_P_6}<Bppf>substrates</Bppf>{/NP_P_6} for {NP_7}thylakoid protein <p>phosphatase</p> activity{/NP_7} .

{NP_8}Lack{/NP_8} of {NP_P_9}a suitable <Bppf>substrate</Bppf>{/NP_P_9} {VP_pass_10}has been{/VP_pass_10} {NP_11}a major obstacle{/NP_11} in {VP_act_12}studying{/VP_act_12} {NP_13}the <c>chloroplastic</c> thylakoid <p>membrane protein phosphatase</p> activity{/NP_13} .

OUTPUT 1
PTM = ({NP_PP_16};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_16}<pp>phosphopeptides</pp>{/NP_PP_16})

In {NP_14}this study{/NP_14} , {NP_15}the suitability{/NP_15} of {NP_PP_16}synthetic <pp>phosphopeptides</pp>{/NP_PP_16} for {NP_17}this purpose{/NP_17} {VP_pass_18}was investigated{/VP_pass_18} .

OUTPUT 2
PTM = ({NP_PP_20};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_20}<pp>phosphopeptides</pp>{/NP_PP_20})

OUTPUT 3
PTM = ({NP_PP_22};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_22}<pp><pp>N-terminal</pp> phosphorylation site</pp>{/NP_PP_22})
(-;-;{NP_PP_22}<pp>N-terminal</pp>{/NP_PP_22})

OUTPUT 4
PTM = ({NP_P_23};phosphoprotein)
Kinase = (-;-)
Substrate = ({NP_P_24}<p>light-harvesting chlorophyll a/b-binding protein ( LHCP-II )</p>{/NP_P_24};-)
Site = (-;-;{NP_PP_22}<pp>N-terminal</pp> phosphorylation site</pp>{/NP_PP_22})

{VP_act_19}Phosphothreonine-containing{/VP_act_19} {NP_PP_20}<pp>phosphopeptides</pp>{/NP_PP_20} {VP_act_21}mimicking{/VP_act_21} {NP_PP_22}the <pp><pp>N-terminal</pp> phosphorylation site</pp>{/NP_PP_22} of {NP_P_23}the major thylakoid <p>phosphoprotein</p>{/NP_P_23} , {NP_P_24}the <p>light-harvesting chlorophyll a/b-binding protein ( LHCP-II )</p>{/NP_P_24} , {VP_pass_25}were dephosphorylated{/VP_pass_25} by {NP_26}isolated peak thylakoid membranes{/NP_26} .

OUTPUT 5
PTM = ({NP_PP_27};Phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_27}<pp>Phosphopeptides</pp>{/NP_PP_27})

{NP_PP_27}<pp>Phosphopeptides</pp>{/NP_PP_27} {VP_act_28}representing{/VP_act_28} {NP_PP_29}unrelated <Bppp>sequences</Bppp>{/NP_PP_29} or in {NP_30}which{/NP_30} {NP_PP_31}the target <pp>phosphothreonine</pp>{/NP_PP_31} {VP_pass_32}had been changed{/VP_pass_32} to {NP_PP_33}a <pp>phosphoserine</pp>{/NP_PP_33} {VP_pass_neg_34}were not dephosphorylated{/VP_pass_neg_34} .

OUTPUT 8
PTM = ({NP_PP_36};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_36}<pp>phosphopeptides</pp>{/NP_PP_36})

{NP_35}The dephosphorylation{/NP_35} of {NP_PP_36}<pp>phosphopeptides</pp>{/NP_PP_36} by {NP_37}thylakoid membranes{/NP_37} {VP_pass_38}was similar{/VP_pass_38} to {NP_39}the dephosphorylation{/NP_39} of {NP_B_40}endogenous <B>LHCP-II</B>{/NP_B_40} in {NP_41}its <B>pH-dependence</B> profile{/NP_41} , {NP_42}sensitivity{/NP_42} to {NP_P_43}<Bppf>inhibitors</Bppf>{/NP_P_43} , and {NP_44}bivalent cation requirement{/NP_44} .

OUTPUT 9
PTM = ({NP_PP_46};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_46}<pp><B>LHCP-II</B> phosphorylation site</pp>{/NP_PP_46})

OUTPUT 10
PTM = ({NP_PP_52};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_52}<pp>phosphopeptides</pp>{/NP_PP_52})

{NP_B_45}The same <B>phosphopeptide analogs</B>{/NP_B_45} of {NP_PP_46}the <pp><B>LHCP-II</B> phosphorylation site</pp>{/NP_PP_46} {VP_act_47}inhibited{/VP_act_47} {NP_48}endogenous <B>LHCP-II</B> dephosphorylation{/NP_48} in {NP_49}isolated thylakoids{/NP_49} , whereas {NP_C_50}the <c>dephospho-analogs</c>{/NP_C_50} and {VP_act_51}nonsubstrate{/VP_act_51} {NP_PP_52}<pp>phosphopeptides</pp>{/NP_PP_52} {VP_act_53}had{/VP_act_53} {NP_54}no effect{/NP_54} .

OUTPUT 11
PTM = ({NP_PP_58};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_58}<pp>phosphopeptides</pp>{/NP_PP_58})

{AV_55}Collectively{/AV_55} , {NP_56}these results{/NP_56} {VP_act_57}suggest{/VP_act_57} that {NP_PP_58}<pp>phosphopeptides</pp>{/NP_PP_58} {VP_act_59}mimicking{/VP_act_59} {NP_PP_60}a thylakoid <pp><p>phosphoprotein</p> dephosphorylation site</pp>{/NP_PP_60} {VP_pass_61}can be exploited{/VP_pass_61} for {NP_62}further study{/NP_62} of {NP_63}the thylakoid protein <p>phosphatase</p> activity{/NP_63} .


{NP_1}PMID{/NP_1} - {CP_2}2506143{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_6};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6})

{NP_4}AB{/NP_4} - {NP_5}Synthesis{/NP_5} of {NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6} {VP_act_7}containing{/VP_act_7} {NP_PP_8}<pp>O-phosphoserine</pp> or <pp>O-phosphothreonine</pp>{/NP_PP_8} .

{NP_PP_9}<Bppp>Peptides</Bppp>{/NP_PP_9} {VP_act_10}containing{/VP_act_10} {NP_PP_11}<pp>phosphoserine</pp> or <pp>phosphothreonine</pp>{/NP_PP_11} {VP_pass_12}were synthesized{/VP_pass_12} by {NP_13}solid phase methods{/NP_13} .

{NP_PP_14}<pp>Phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_14} {VP_pass_15}were incorporated{/VP_pass_15} into {NP_PP_16}<Bppp>peptides</Bppp>{/NP_PP_16} {VP_act_17}using{/VP_act_17} {NP_C_18}<c>Boc-diphenylphosphono esters</c>{/NP_C_18} of {NP_PP_19}<pp>serine</pp> and <pp>threonine</pp>{/NP_PP_19} and {NP_P_20}standard <p>DCC/HOBt</p>{/NP_P_20} {VP_act_21}coupling{/VP_act_21} .

{NP_C_22}The <c>phenylphosphoesters</c>{/NP_C_22} {VP_pass_neg_23}were not removed{/VP_pass_neg_23} when {NP_PP_24}the <Bppp>peptides</Bppp>{/NP_PP_24} {VP_pass_25}were cleaved{/VP_pass_25} from {NP_B_26}the <B>resin</B>{/NP_B_26} by {NP_B_27}<B>HF</B>{/NP_B_27} or by {NP_P_28}<p>trifluoromethane sulfonic acid</p>{/NP_P_28} , but {VP_pass_29}were subsequently removed{/VP_pass_29} by {NP_30}catalytic hydrogenation{/NP_30} .

OUTPUT 4
PTM = ({NP_PP_31};Phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_31}<pp>Phosphopeptides</pp>{/NP_PP_31})

{NP_PP_31}<pp>Phosphopeptides</pp>{/NP_PP_31} {VP_pass_32}were purified{/VP_pass_32} by {NP_33}HPLC{/NP_33} and by {NP_34}<B>Fe+3-Chelex</B> chromatography{/NP_34} and {NP_35}their identity{/NP_35} {VP_pass_36}verified{/VP_pass_36} by {NP_37}mass spectrometry{/NP_37} .

{NP_PP_38}Two <pp>peptides</pp>{/NP_PP_38} , {NP_PP_39}<pp>Leu-Arg-Arg-Ala-Ser(P) -Leu-Gly</pp> and <pp>Leu-Arg-Arg-Ala-Thr(P) -Leu-Gly</pp>{/NP_PP_39} , {VP_pass_40}were prepared{/VP_pass_40} by {NP_41}both enzymatic and <Bpcf>chemical</Bpcf> methods{/NP_41} and {VP_act_42}had{/VP_act_42} {NP_43}identical properties{/NP_43} .


{NP_1}PMID{/NP_1} - {CP_2}24646179{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {VP_act_5}Expanded{/VP_act_5} {NP_6}cellular <Bppp>amino acid</Bppp> pools{/NP_6} {VP_act_7}containing{/VP_act_7} {NP_PP_8}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp>phosphotyrosine</pp>{/NP_PP_8} .

{VP_act_9}Adding{/VP_act_9} {NP_PP_10}nonstandard <Bppp>amino acids</Bppp>{/NP_PP_10} to {NP_11}the genetic code{/NP_11} of {NP_B_12}<s><B>E.coli</B></s>{/NP_B_12} {VP_act_13}expands{/VP_act_13} {NP_14}the <Bpcf>chemical</Bpcf> and biological functional space{/NP_14} for {NP_P_15}<Bppf>proteins</Bppf>{/NP_P_15} .

{NP_16}This{/NP_16} {VP_pass_17}is accomplished{/VP_pass_17} with {JP_18}engineered{/JP_18} , {NP_19}orthogonal <p>aminoacyl-tRNA synthetase</p> and tRNA pairs{/NP_19} {NP_20}that{/NP_20} {VP_act_21}require{/VP_act_21} {NP_PP_22}a nonstandard <Bppp>amino acid</Bppp>{/NP_PP_22} in {NP_23}sufficient intracellular quantities{/NP_23} {VP_act_24}to support{/VP_act_24} {NP_25}<Bppf>protein</Bppf> synthesis{/NP_25} .

While {NP_26}cotranslational insertion{/NP_26} of {NP_PP_27}<pp>phosphoserine</pp>{/NP_PP_27} into {NP_P_28}<Bppf>proteins</Bppf>{/NP_P_28} {VP_pass_29}has been accomplished{/VP_pass_29} , {NP_30}conditions{/NP_30} {NP_31}that{/NP_31} {VP_act_32}modulate{/VP_act_32} {NP_33}intracellular <c>phosphoamino acid</c> concentrations{/NP_33} {VP_pass_34}are still poorly understood{/VP_pass_34} .

{AV_35}Here{/AV_35} {NP_36}we{/NP_36} {VP_act_37}used{/VP_act_37} {NP_38}genetic and metabolic engineering{/NP_38} {VP_act_39}to increase{/VP_act_39} {NP_40}the free intracellular levels{/NP_40} of {NP_PP_41}<pp>phosphoserine</pp>{/NP_PP_41} in {NP_B_42}<s><B>E.coli</B></s>{/NP_B_42} .

{NP_43}We{/NP_43} {VP_act_44}show{/VP_act_44} that {NP_45}deletion{/NP_45} of {NP_P_46}the <p>phosphoserine phosphatase serB</p>{/NP_P_46} {VP_act_47}elevates{/VP_act_47} {NP_48}the intracellular levels{/NP_48} of {NP_PP_49}<pp>phosphoserine</pp>{/NP_PP_49} within {NP_50}ranges{/NP_50} {JP_51}comparable{/JP_51} to those of {NP_PP_52}standard <Bppp>amino acids</Bppp>{/NP_PP_52} .

{NP_53}These new conditions{/NP_53} {VP_act_54}improved{/VP_act_54} {NP_55}insertion{/NP_55} of {NP_PP_56}<pp>phosphoserine</pp>{/NP_PP_56} into {NP_P_57}recombinant <Bppf>proteins</Bppf>{/NP_P_57} .

{AV_58}Surprisingly{/AV_58} , {NP_59}we{/NP_59} {VP_act_60}also observed{/VP_act_60} {JP_61}dramatic{/JP_61} {VP_pass_62}increases{/VP_pass_62} in {NP_63}intracellular levels{/NP_63} of {NP_PP_64}<pp>phosphothreonine</pp> and <pp>phosphotyrosine</pp>{/NP_PP_64} when {NP_S_65}<S>WT cells</S>{/NP_S_65} {VP_pass_66}were grown{/VP_pass_66} in {NP_B_67}<B>LB</B>{/NP_B_67} with {NP_S_68}supplemented <pp>phosphothreonine</pp> and <S>serB deficient cells</S>{/NP_S_68} {VP_pass_69}were grown{/VP_pass_69} in {NP_70}low <c>phosphate</c> media{/NP_70} with {NP_PP_71}supplemented <pp>phosphotyrosine</pp>{/NP_PP_71} , {AV_72}respectively{/AV_72} .

OUTPUT 9
PTM = ({NP_PP_78};phosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_78}<Bppp>amino acids</Bppp>{/NP_PP_78})

{NP_73}These findings{/NP_73} {VP_act_74}remove{/VP_act_74} {NP_75}a major barrier{/NP_75} for {NP_76}further expansion{/NP_76} of {NP_77}the genetic code{/NP_77} with {NP_PP_78}additional phosphorylated <Bppp>amino acids</Bppp>{/NP_PP_78} .


{NP_1}PMID{/NP_1} - {CP_2}24768166{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_10};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_10}<pp>phosphopeptide</pp>{/NP_PP_10})

OUTPUT 1
PTM = ({NP_PP_12};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_12}<Bppp>phosphopeptide</Bppp>{/NP_PP_12})

{NP_4}AB{/NP_4} - {NP_5}Development{/NP_5} of {NP_C_6}caged non-hydrolyzable <c>phosphoamino acids</c>{/NP_C_6} and {NP_7}application{/NP_7} {VP_act_8}to photo-control{/VP_act_8} of {NP_9}binding affinity{/NP_9} of {NP_PP_10}<pp>phosphopeptide</pp>{/NP_PP_10} {JP_11}mimetic{/JP_11} to {NP_PP_12}<Bppp>phosphopeptide</Bppp>{/NP_PP_12} {VP_act_13}-recognizing{/VP_act_13} {NP_P_14}<Bppf>protein</Bppf>{/NP_P_14} .

{NP_15}The design and synthesis{/NP_15} of {NP_PP_16}caged non-hydrolyzable phospho-<pp>serine</pp> , <pp>-threonine</pp> , and <pp>-tyrosine derivatives</pp>{/NP_PP_16} {NP_17}that{/NP_17} {VP_act_18}generate{/VP_act_18} {NP_C_19}parent non-hydrolyzable <c>phosphoamino acids</c>{/NP_C_19} , {VP_act_20}containing{/VP_act_20} {NP_C_21}a <c>difluoromethylene unit</c>{/NP_C_21} {AV_22}instead{/AV_22} of {NP_C_23}the <c>oxygen</c>{/NP_C_23} of {NP_C_24}a <c>phosphoester</c>{/NP_C_24} , after {NP_25}UV-irradiation{/NP_25} {VP_pass_26}are described{/VP_pass_26} .

OUTPUT 3
PTM = ({NP_PP_33};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_33}<pp>phosphopeptides</pp>{/NP_PP_33})

{NP_PP_27}The caged non-hydrolyzable <Bppp>amino acids</Bppp>{/NP_PP_27} {VP_pass_28}were incorporated{/VP_pass_28} into {NP_PP_29}<Bppp>peptides</Bppp>{/NP_PP_29} by {NP_30}standard <pp><B>Fmoc</B> solid-phase peptide</pp> synthesis{/NP_30} , and {NP_PP_31}the obtained <Bppp>peptides</Bppp>{/NP_PP_31} {VP_pass_32}were successfully converted{/VP_pass_32} to {NP_PP_33}the parent non-hydrolyzable <pp>phosphopeptides</pp>{/NP_PP_33} by {NP_34}UV-irradiation{/NP_34} .

{NP_35}Application{/NP_35} of {NP_PP_36}the caged non-hydrolyzable <Bppp>phosphoserine-containing peptide</Bppp>{/NP_PP_36} {VP_act_37}to photo-control{/VP_act_37} {NP_38}the binding affinity{/NP_38} of {NP_PP_39}the <Bppp>peptide</Bppp>{/NP_PP_39} to {NP_P_40}<p>14-3-3b protein</p>{/NP_P_40} {VP_pass_41}is also reported{/VP_pass_41} .


{NP_1}PMID{/NP_1} - {CP_2}1705399{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Synthesis{/NP_5} of {NP_PP_6}<pp>phosphotyrosyl-containing phosphopeptides</pp>{/NP_PP_6} by {NP_7}<Bppp>solid-phase peptide</Bppp> synthesis{/NP_7} .

{NP_8}The synthesis{/NP_8} of {NP_PP_9}<pp>phosphotyrosine-containing phosphopeptides</pp>{/NP_PP_9} {VP_act_10}using{/VP_act_10} {NP_11}<pp>solid-phase peptide synthesis ( SPPS )</pp> techniques{/NP_11} {VP_pass_12}is described{/VP_pass_12} .

{NP_13}We{/NP_13} {VP_act_14}present{/VP_act_14} {NP_15}the synthesis{/NP_15} of {NP_B_16}a <B>Boc-phosphotyrosine derivative</B>{/NP_B_16} , which when {VP_act_17}used{/VP_act_17} with {NP_18}modifications{/NP_18} of {NP_19}the conventional <pp>SPPS</pp> protocol{/NP_19} {VP_act_20}permits{/VP_act_20} {NP_21}the incorporation{/NP_21} of {NP_PP_22}<pp>phosphotyrosine</pp>{/NP_PP_22} into {NP_PP_23}synthetic <Bppp>peptides</Bppp>{/NP_PP_23} .

OUTPUT 4
PTM = ({NP_PP_24};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_24}<pp>phosphopeptides</pp>{/NP_PP_24})

{NP_PP_24}The resulting <pp>phosphopeptides</pp>{/NP_PP_24} {VP_pass_25}were authenticated{/VP_pass_25} by {NP_26}fast atom bombardment mass spectrometry , <pp>amino acid</pp> analysis , and <c>phosphate</c> assay{/NP_26} .

OUTPUT 5
PTM = ({NP_PP_30};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_30}<pp>phosphopeptides</pp>{/NP_PP_30})

OUTPUT 6
PTM = ({NP_P_36};phosphoprotein)
Kinase = (-;-)
Substrate = ({NP_P_36}<p>phosphoprotein phosphatases</p>{/NP_P_36};-)
Site = (-;-;UNK)

{NP_P_27}Alkaline <p>phosphatase</p>{/NP_P_27} {VP_pass_28}was found{/VP_pass_28} {VP_act_29}to dephosphorylate{/VP_act_29} {NP_PP_30}synthetic <pp>phosphopeptides</pp>{/NP_PP_30} at {NP_31}different rates{/NP_31} , {VP_act_32}supporting{/VP_act_32} {NP_33}the potential use{/NP_33} of {NP_P_34}these synthetic <Bppf>substrates</Bppf>{/NP_P_34} for {NP_35}studies{/NP_35} of {NP_P_36}<p>phosphoprotein phosphatases</p>{/NP_P_36} .

OUTPUT 7
PTM = ({NP_PP_38};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_38}a <pp>phosphopeptide</pp>{/NP_PP_38})

OUTPUT 8
PTM = ({NP_PP_44};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_44}<pp>phosphopeptides</pp>{/NP_PP_44})

OUTPUT 9
PTM = ({NP_45};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_44}<pp>phosphopeptides</pp>{/NP_PP_44})

{NP_37}Synthesis{/NP_37} of {NP_PP_38}a <pp>phosphopeptide</pp>{/NP_PP_38} {VP_act_39}using{/VP_act_39} {NP_40}the described protocol{/NP_40} {VP_act_41}has{/VP_act_41} {NP_42}several advantages{/NP_42} over {NP_43}the preparation{/NP_43} of {NP_PP_44}<pp>phosphopeptides</pp>{/NP_PP_44} via {NP_45}enzymatic phosphorylation{/NP_45} .


{NP_1}PMID{/NP_1} - {CP_2}1782219{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_5};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = ({NP_P_6}8{/NP_P_6};{NP_P_6}Ser{/NP_P_6};UNK)

{NP_4}AB{/NP_4} - {NP_5}Monovalent cation -dependent reversible phosphorylation{/NP_5} of {NP_P_6}ribosomal <p>protein</p> <pp>S8</pp>{/NP_P_6} in {NP_7}growth{/NP_7} {VP_act_8}arrested{/VP_act_8} {NP_9}Tetrahymena{/NP_9} :

OUTPUT 1
PTM = ({NP_PP_13};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_13}<pp>phosphopeptides</pp>{/NP_PP_13})

OUTPUT 2
PTM = ({VP_act_15};diphosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = ({NP_P_17}8{/NP_P_17};{NP_P_17}Ser{/NP_P_17};UNK)

{NP_10}kinetics{/NP_10} of {NP_11}formation{/NP_11} , {NP_C_12}<c>phosphoamino acids</c>{/NP_C_12} , and {NP_PP_13}<pp>phosphopeptides</pp>{/NP_PP_13} of {JP_14}mono-{/JP_14} , and {VP_act_15}diphosphorylated{/VP_act_15} {NP_16}<Bpf>derivatives</Bpf>{/NP_16} of {NP_P_17}<p>protein</p> <pp>S8</pp>{/NP_P_17} .

OUTPUT 3
PTM = ({VP_act_21};diphosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = ({NP_P_23}8{/NP_P_23};{NP_P_23}Ser{/NP_P_23};UNK)

{NP_18}The kinetics{/NP_18} of {NP_19}formation{/NP_19} of {JP_20}mono-{/JP_20} , and {VP_act_21}diphosphorylated{/VP_act_21} {NP_22}<Bpf>derivatives</Bpf>{/NP_22} of {NP_P_23}ribosomal <p>protein</p> <pp>S8</pp>{/NP_P_23} in {NP_24}Tetrahymena{/NP_24} {VP_act_25}starving{/VP_act_25} in {NP_26}the presence{/NP_26} of {NP_B_27}<B>Na+</B>{/NP_B_27} {VP_pass_28}have been determined{/VP_pass_28} , and {NP_C_29}the <c>phosphoamino acids</c>{/NP_C_29} {JP_30}present{/JP_30} in {NP_31}these <Bpf>derivatives</Bpf>{/NP_31} {VP_pass_32}have been identified{/VP_pass_32} .

{NP_33}The mono-phosphorylated <Bpf>product</Bpf>{/NP_33} , {NP_B_34}<B>S8'</B>{/NP_B_34} , {VP_act_35}contains{/VP_act_35} {NP_PP_36}only <pp>phosphoserine</pp>{/NP_PP_36} , and {VP_act_37}behaves{/VP_act_37} {AV_38}kinetically{/AV_38} as {NP_39}the <Bpf>precursor</Bpf>{/NP_39} of {NP_40}the diphosphorylated <Bpf>product S8"</Bpf>{/NP_40} {NP_41}which{/NP_41} {VP_act_42}contains{/VP_act_42} {NP_PP_43}<pp>phosphoserine</pp>{/NP_PP_43} , and {NP_PP_44}<pp>phosphothreonine</pp>{/NP_PP_44} .

{NP_45}Tryptic digestion release{/NP_45} {NP_PP_46}a single major <pp>phosphoserine</pp>{/NP_PP_46} {VP_act_47}containing{/VP_act_47} {NP_PP_48}<Bppp>peptide</Bppp>{/NP_PP_48} from {NP_49}both <B>S8'</B> and S8"{/NP_49} , and {NP_PP_50}a single <pp>phosphothreonine</pp>{/NP_PP_50} {VP_act_51}containing{/VP_act_51} {NP_PP_52}<Bppp>peptide</Bppp>{/NP_PP_52} from {NP_53}S8"{/NP_53} .


{NP_1}PMID{/NP_1} - {CP_2}18228327{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}<c>Phosphoamino acid</c> analysis{/NP_5} .

{NP_P_6}<Bppf>Proteins</Bppf>{/NP_P_6} {VP_pass_7}involved{/VP_pass_7} in {NP_8}signal transduction{/NP_8} {VP_pass_9}are often phosphorylated{/VP_pass_9} .

{NP_10}Determination{/NP_10} of {NP_11}the specific <Bppp>amino acid</Bppp> residue(s){/NP_11} {VP_act_12}involved{/VP_act_12} {VP_pass_13}is used{/VP_pass_13} in {VP_act_14}characterizing{/VP_act_14} {NP_15}the particular pathway{/NP_15} .

{NP_16}Partial acid hydrolysis{/NP_16} of {NP_P_17}phosphorylated <Bppf>proteins</Bppf>{/NP_P_17} {VP_pass_18}followed{/VP_pass_18} by {NP_19}two-dimensional <B>thin</B> layer chromatography{/NP_19} {VP_pass_20}is used{/VP_pass_20} {VP_act_21}to identify{/VP_act_21} {NP_PP_22}the phosphorylated <Bppp>residues</Bppp>{/NP_PP_22} of {NP_P_23}the <Bppf>protein</Bppf>{/NP_P_23} as {NP_PP_24}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , or <pp>phosphotyrosine</pp>{/NP_PP_24} .

{NP_25}Mild alkaline hydrolysis{/NP_25} {VP_pass_26}is used{/VP_pass_26} {VP_act_27}to enhance{/VP_act_27} {NP_28}detection{/NP_28} of {NP_PP_29}<pp>phosphothreonine</pp> and <pp>phosphotyrosine</pp>{/NP_PP_29} .


{NP_1}PMID{/NP_1} - {CP_2}18429115{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}<c>Phosphoamino acid</c> analysis{/NP_5} .

OUTPUT 0
PTM = ({NP_PP_9};phosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_9}<Bppp>residue</Bppp>{/NP_PP_9})

{NP_6}It{/NP_6} {VP_pass_7}is often valuable{/VP_pass_7} {VP_act_8}to identify{/VP_act_8} {NP_PP_9}the phosphorylated <Bppp>residue</Bppp>{/NP_PP_9} in {NP_P_10}a <Bppf>protein</Bppf>{/NP_P_10} .

{NP_11}This <Bpcf>unit</Bpcf>{/NP_11} {VP_act_12}presents{/VP_act_12} {NP_13}a protocol{/NP_13} for {NP_14}partial acid hydrolysis{/NP_14} of {NP_P_15}<Bppf>proteins</Bppf>{/NP_P_15} {VP_pass_16}phosphorylated{/VP_pass_16} at {NP_PP_17}<pp>serine</pp> , <pp>threonine</pp> , or <pp>tyrosine</pp>{/NP_PP_17} , {VP_pass_18}followed{/VP_pass_18} by {NP_19}two-dimensional thin-layer electrophoresis{/NP_19} of {NP_C_20}the labeled <c>phosphoamino acid</c>{/NP_C_20} .

{NP_PP_21}<pp>Phosphothreonine</pp> and <pp>phosphotyrosine</pp>{/NP_PP_21} {VP_pass_22}are more stable{/VP_pass_22} to {NP_23}hydrolysis{/NP_23} in {NP_24}alkali{/NP_24} than {VP_pass_25}are{/VP_pass_25} {NP_PP_26}RNA and <pp>phosphoserine</pp>{/NP_PP_26} .

{AV_27}Therefore{/AV_27} , {NP_28}an alternate procedure{/NP_28} {VP_act_29}using{/VP_act_29} {NP_30}mild alkaline hydrolysis{/NP_30} of {NP_31}<Bppf>protein</Bppf> samples{/NP_31} {VP_act_32}to enhance{/VP_act_32} {NP_33}the detection{/NP_33} of {NP_PP_34}<pp>phosphothreonine</pp> and <pp>phosphotyrosine</pp>{/NP_PP_34} {VP_pass_35}is also provided{/VP_pass_35} .


{NP_1}PMID{/NP_1} - {CP_2}10037602{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Function{/NP_5} of {NP_PP_6}<pp>WW domains</pp>{/NP_PP_6} as {NP_7}<pp>phosphoserine</pp> - or phosphothreonine-binding modules{/NP_7} .

{NP_P_8}<Bppf>Protein</Bppf>{/NP_P_8} {VP_act_9}-interacting{/VP_act_9} {NP_10}modules{/NP_10} {VP_act_11}help{/VP_act_11} {VP_act_12}determine{/VP_act_12} {NP_13}the specificity{/NP_13} of {NP_14}signal transduction events , and <Bppf>protein</Bppf> phosphorylation{/NP_14} {VP_act_15}can modulate{/VP_act_15} {NP_16}the assembly{/NP_16} of {NP_17}such modules{/NP_17} into {NP_18}specific <Bpf>signaling complexes</Bpf>{/NP_18} .

Although {NP_19}phosphotyrosine-binding modules{/NP_19} {VP_pass_20}have been{/VP_pass_20} {JP_21}well-characterized{/JP_21} , {NP_22}<pp>phosphoserine</pp> - or phosphothreonine-binding modules{/NP_22} {VP_pass_neg_23}have not been described{/VP_pass_neg_23} .

{NP_PP_24}<pp>WW domains</pp>{/NP_PP_24} {VP_pass_25}are{/VP_pass_25} {NP_26}small <Bppf>protein</Bppf> modules{/NP_26} {VP_pass_27}found{/VP_pass_27} in {NP_P_28}various <Bppf>proteins</Bppf>{/NP_P_28} {NP_29}that{/NP_29} {VP_pass_30}participate{/VP_pass_30} in {NP_31}<Bpcl>cell</Bpcl> signaling{/NP_31} or {NP_32}regulation{/NP_32} .

OUTPUT 4
PTM = ({NP_P_37};phosphoproteins)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_33}<pp>WW domains</pp>{/NP_PP_33})

{NP_PP_33}<pp>WW domains</pp>{/NP_PP_33} of {NP_P_34}the essential mitotic <p>prolyl isomerase Pin1</p>{/NP_P_34} and {NP_P_35}the <p>ubiquitin ligase Nedd4</p>{/NP_P_35} {VP_act_36}bound{/VP_act_36} to {NP_P_37}<p>phosphoproteins</p>{/NP_P_37} , {VP_act_38}including{/VP_act_38} {NP_P_39}physiological <Bppf>substrates</Bppf>{/NP_P_39} of {NP_P_40}<Bppf>enzymes</Bppf>{/NP_P_40} , in {NP_41}a phosphorylation -dependent manner{/NP_41} .

{NP_PP_42}The <pp><B><p>Pin1</p> WW</B> domain</pp>{/NP_PP_42} {VP_act_43}functioned{/VP_act_43} as {NP_PP_44}a <pp>phosphoserine</pp>{/NP_PP_44} - or {NP_45}phosphothreonine-binding module{/NP_45} , with {NP_46}properties{/NP_46} {JP_47}similar{/JP_47} to those of {NP_PP_48}<p>SRC</p> homology 2 <Bppp>domains</Bppp>{/NP_PP_48} .

{NP_49}<pp>Phosphoserine</pp> - or phosphothreonine-binding activity{/NP_49} {VP_pass_50}was required{/VP_pass_50} for {NP_P_51}<p>Pin1</p>{/NP_P_51} {VP_act_52}to interact{/VP_act_52} with {NP_P_53}its <Bppf>substrates</Bppf>{/NP_P_53} in {NP_54}vitro{/NP_54} and {VP_act_55}to perform{/VP_act_55} {NP_56}its essential function{/NP_56} in {NP_57}vivo{/NP_57} .


{NP_1}PMID{/NP_1} - {CP_2}16478119{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}<c>Phosphate group</c> -driven fragmentation{/NP_5} of {VP_act_6}multiply{/VP_act_6} {NP_7}charged <pp>phosphopeptide</pp> anions{/NP_7} .

{NP_8}Improved recognition{/NP_8} of {NP_PP_9}<Bppp>peptides</Bppp>{/NP_PP_9} {VP_pass_10}phosphorylated{/VP_pass_10} at {NP_PP_11}<pp>serine</pp> , <pp>threonine</pp> , or <pp>tyrosine</pp>{/NP_PP_11} by {NP_12}negative ion electrospray tandem mass spectrometry{/NP_12} .

{NP_13}The nanoelectrospray <Bpf>product</Bpf> ion spectra{/NP_13} of {VP_act_14}multiply{/VP_act_14} {NP_15}charged <pp>phosphopeptide</pp> anions{/NP_15} {VP_act_16}reveal{/VP_act_16} {NP_17}the occurrence{/NP_17} of {NP_18}<pp><c>phosphate-specific</c> high-mass fragment</pp> ions{/NP_18} of {NP_B_19}the <B>type [M</B>{/NP_B_19} - {NP_20}nH{/NP_20} - {JP_21}79] ( n-1 ){/JP_21} - .

{NP_PP_22}These so far unrecognized <Bppp>fragments</Bppp>{/NP_PP_22} , {NP_23}which{/NP_23} {VP_pass_24}are observed{/VP_pass_24} for {NP_PP_25}<c>phosphoserine-</c> , <c>phosphothreonine-</c> , and <pp>phosphotyrosine-containing peptides</pp>{/NP_PP_25} , {VP_pass_26}are{/VP_pass_26} {NP_27}the counterparts{/NP_27} of {NP_28}the established inorganic <pp>phosphopeptide</pp> marker ion{/NP_28} {VP_pass_29}found{/VP_pass_29} at {NP_30}m/z 79{/NP_30} = {NP_B_31}<B>[PO3]-</B>{/NP_B_31} .

{NP_32}The high-mass marker ions{/NP_32} {VP_pass_33}are formed{/VP_pass_33} with {NP_34}high efficiency{/NP_34} at {NP_35}moderate collision{/NP_35} {VP_act_36}offset{/VP_act_36} {NP_37}values{/NP_37} and {VP_pass_38}are particularly useful{/VP_pass_38} for {NP_39}sensitive recognition{/NP_39} of {NP_PP_40}<B>pSer-</B> , <B>pThr-</B> , and <pp>pTyr-peptides</pp>{/NP_PP_40} {JP_41}due{/JP_41} to {NP_42}the low background level{/NP_42} in {NP_43}MS/MS spectra{/NP_43} at {NP_44}m/z values{/NP_44} above those of {NP_45}the <Bpf>precursor</Bpf> ions{/NP_45} .

By {NP_46}virtue{/NP_46} of {NP_47}this feature{/NP_47} , {NP_48}the detection{/NP_48} of {NP_49}the new phosphorylation-specific <Bppp>fragment</Bppp> ions{/NP_49} {VP_act_50}appears{/VP_act_50} {VP_pass_51}to be more sensitive{/VP_pass_51} than {NP_52}the detection{/NP_52} of {NP_53}the low-mass <c>phosphate</c> marker ion{/NP_53} at {NP_54}m/z 79{/NP_54} , {NP_55}where{/NP_55} {NP_56}a higher interference{/NP_56} by {NP_57}nonspecific background signals{/NP_57} {VP_pass_58}is generally observed{/VP_pass_58} .

OUTPUT 3
PTM = ({NP_PP_61};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_61}a <pp>phosphopeptide</pp>{/NP_PP_61})

{NP_59}The number{/NP_59} of {NP_G_60}<c>phosphate groups</c>{/NP_G_60} within {NP_PP_61}a <pp>phosphopeptide</pp>{/NP_PP_61} {VP_pass_62}can also be estimated{/VP_pass_62} on {NP_63}the basis{/NP_63} of {NP_B_64}the <B>[M</B>{/NP_B_64} - {NP_65}nH{/NP_65} - {JP_66}79] ( n-1 ){/JP_66} - {NP_67}ions{/NP_67} , since {NP_68}these exhibit{/NP_68} {NP_69}an effective{/NP_69} , {NP_70}sequential neutral loss{/NP_70} of {NP_B_71}<B>H3PO4</B>{/NP_B_71} of {NP_G_72}the residing <c>phosphate groups</c>{/NP_G_72} .

OUTPUT 4
PTM = ({NP_PP_80};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_80}<pp>phosphopeptides</pp>{/NP_PP_80})

{NP_73}A mechanistic explanation{/NP_73} for {NP_74}the formation{/NP_74} of {NP_B_75}the <B>[M</B>{/NP_B_75} - {NP_76}nH{/NP_76} - {JP_77}79] ( n-1 ){/JP_77} - {NP_78}ions{/NP_78} from {VP_act_79}multiply{/VP_act_79} {NP_PP_80}charged <pp>phosphopeptides</pp>{/NP_PP_80} {VP_pass_81}is given{/VP_pass_81} .

{NP_82}The high-mass marker ions{/NP_82} {VP_pass_83}are proposed{/VP_pass_83} {VP_act_84}to originate{/VP_act_84} from {NP_85}<pp>phosphopeptide</pp> anions{/NP_85} , {NP_86}which{/NP_86} {VP_act_87}carry{/VP_act_87} {NP_88}two negative charges{/NP_88} {VP_pass_89}located{/VP_pass_89} at {NP_G_90}the <c>phosphate group</c>{/NP_G_90} .

OUTPUT 5
PTM = ({NP_PP_98};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_98}<pp>phosphopeptides</pp>{/NP_PP_98})

{NP_91}A new search tool{/NP_91} {VP_act_92}denominated{/VP_act_92} {NP_93}"variable m/z gain analysis"{/NP_93} , {NP_94}which{/NP_94} {VP_act_95}utilizes{/VP_act_95} {NP_PP_96}these newly recognized high-mass <Bppp>fragments</Bppp>{/NP_PP_96} for {VP_act_97}spotting{/VP_act_97} of {NP_PP_98}<pp>phosphopeptides</pp>{/NP_PP_98} in {NP_99}a negative ion parent scan{/NP_99} , {VP_pass_100}is proposed{/VP_pass_100} .

{NP_101}The findings{/NP_101} {VP_act_102}strengthen{/VP_act_102} {NP_103}the value{/NP_103} of {NP_B_104}negative ion <B>ESI-MS/MS</B>{/NP_B_104} for {NP_105}analysis{/NP_105} of {NP_106}<Bppf>protein</Bppf> phosphorylation{/NP_106} .


{NP_1}PMID{/NP_1} - {CP_2}9794085{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_6};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6})

{NP_4}AB{/NP_4} - {NP_5}Fragmentation{/NP_5} of {NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6} in {NP_7}an ion trap mass spectrometer{/NP_7} .

OUTPUT 1
PTM = ({NP_PP_10};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_10}<pp>phosphopeptides</pp>{/NP_PP_10})

{NP_8}A systematic study{/NP_8} of {NP_9}the fragmentation pattern{/NP_9} of {NP_PP_10}<pp>phosphopeptides</pp>{/NP_PP_10} in {NP_11}an <c>electrospray ( ESI )</c> ion trap mass spectrometer{/NP_11} {VP_pass_12}is presented{/VP_pass_12} .

{NP_13}We{/NP_13} {VP_act_14}show{/VP_act_14} that {NP_PP_15}<pp>phosphotyrosine</pp>{/NP_PP_15} - and {NP_PP_16}<Bppp>phosphothreonine-containing peptides</Bppp>{/NP_PP_16} {VP_act_17}show{/VP_act_17} {NP_18}complicated fragmentation patterns{/NP_18} .

OUTPUT 4
PTM = ({NP_PP_19};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_10}<pp>phosphopeptides</pp>{/NP_PP_10})
(-;-;{NP_PP_19}<pp>phosphopeptides</pp>{/NP_PP_19})

{NP_PP_19}These <pp>phosphopeptides</pp>{/NP_PP_19} {VP_pass_20}were observed{/VP_pass_20} {VP_act_21}to lose{/VP_act_21} {NP_C_22}the <c>phosphate moiety</c>{/NP_C_22} in {NP_23}the form{/NP_23} of {NP_P_24}<p>H3PO4 and/or HPO3</p>{/NP_P_24} , but {VP_pass_25}were also detected{/VP_pass_25} with {NP_26}no loss{/NP_26} of {NP_G_27}the <c>phosphate group</c>{/NP_G_27} .

{NP_28}The tendency{/NP_28} {VP_act_29}to lose{/VP_act_29} {NP_C_30}the <c>phosphate moiety</c>{/NP_C_30} {VP_act_31}depends{/VP_act_31} {AV_32}strongly{/AV_32} on {NP_33}the charge state{/NP_33} .

{AV_34}Thus{/AV_34} , {NP_35}the highest observed charge state{/NP_35} {VP_act_36}tends{/VP_act_36} {VP_act_37}to retain{/VP_act_37} {NP_C_38}the <c>phosphate moiety</c>{/NP_C_38} with {NP_39}extensive fragmentation{/NP_39} along {NP_40}the <Bppp>peptide</Bppp> backbone{/NP_40} .

{NP_41}We{/NP_41} {VP_act_42}also show{/VP_act_42} that {NP_PP_43}<Bppp>phosphoserine-containing peptides</Bppp>{/NP_PP_43} {VP_act_44}have{/VP_act_44} {NP_45}relatively simple fragmentation patterns{/NP_45} of {VP_act_46}losing{/VP_act_46} {NP_B_47}<B>H3PO4</B>{/NP_B_47} .

{NP_48}This loss{/NP_48} {VP_act_49}is{/VP_act_49} {NP_50}independent{/NP_50} of {NP_51}the charge state{/NP_51} .

OUTPUT 6
PTM = ({NP_PP_56};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_56}<Bppp>phosphorylation sites</Bppp>{/NP_PP_56})

{NP_52}We{/NP_52} {VP_act_53}suggest{/VP_act_53} {NP_54}strategies{/NP_54} for {NP_55}the accurate identification{/NP_55} of {NP_PP_56}<Bppp>phosphorylation sites</Bppp>{/NP_PP_56} {VP_act_57}using{/VP_act_57} {NP_58}the ion trap mass spectrometer{/NP_58} .


{NP_1}PMID{/NP_1} - {CP_2}1111592{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}<pp>Phosphopeptide</pp> and <p>phosphoprotein</p> metabolism{/NP_5} in {NP_6}brain{/NP_6} .

{NP_7}<pp>Phosphopeptide</pp> and <p>phosphoprotein</p> phosphorylation{/NP_7} {VP_pass_8}was studied{/VP_pass_8} in {NP_9}<s>rat</s> brain microsomes{/NP_9} and {NP_10}<s>rat</s> brain slices{/NP_10} {NP_11}which{/NP_11} {VP_pass_12}were incubated{/VP_pass_12} in {NP_13}the presence{/NP_13} of {NP_P_14}<p>[gamma-32 P] ATP</p>{/NP_P_14} under {NP_15}various experimental conditions{/NP_15} .

OUTPUT 2
PTM = ({NP_P_18};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_P_18}<pp>phosphopeptides</pp>{/NP_P_18})

{NP_PP_16}Radioactive <pp>phosphoserine</pp>{/NP_PP_16} {VP_pass_17}was isolated{/VP_pass_17} from {NP_P_18}<pp>phosphopeptides</pp> and <p>phosphoproteins</p>{/NP_P_18} .

OUTPUT 3
PTM = ({NP_PP_24};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_24}<pp>phosphopeptides</pp>{/NP_PP_24})

{NP_19}Naplus{/NP_19} , {NP_P_20}<B>K+</B> , <B>Mg2+</B> and <p>cyclic AMP</p>{/NP_P_20} {VP_act_21}had{/VP_act_21} {NP_22}a stimulating effect{/NP_22} on {NP_23}the labelling{/NP_23} of {NP_PP_24}<pp>phosphopeptides</pp>{/NP_PP_24} .

OUTPUT 4
PTM = ({NP_PP_30};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_30}<pp>phosphopeptides</pp>{/NP_PP_30})

{NP_25}Ouabain{/NP_25} and {NP_B_26}<B>Ca2+</B>{/NP_B_26} {VP_act_27}lowered{/VP_act_27} {NP_28}the level{/NP_28} of {NP_29}<c>32P</c> incorporation{/NP_29} into {NP_PP_30}the <pp>phosphopeptides</pp>{/NP_PP_30} .

OUTPUT 6
PTM = ({NP_PP_34};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_34}<pp>phosphopeptides</pp>{/NP_PP_34})

{NP_P_31}The <p>phosphoproteins</p>{/NP_P_31} {VP_pass_32}behaved{/VP_pass_32} {AV_33}similarly{/AV_33} to {NP_PP_34}the <pp>phosphopeptides</pp>{/NP_PP_34} except for {NP_35}the <p>potassium</p> effect{/NP_35} .

OUTPUT 7
PTM = ({NP_PP_40};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_40}<pp>phosphopeptides</pp>{/NP_PP_40})

{NP_36}Chase experiments{/NP_36} {VP_act_37}showed{/VP_act_37} a {VP_pass_38}faster decrease{/VP_pass_38} in {NP_39}the labelling{/NP_39} of {NP_PP_40}<pp>phosphopeptides</pp>{/NP_PP_40} than in {NP_P_41}<p>phosphoproteins</p>{/NP_P_41} .

{NP_42}We{/NP_42} {VP_act_43}suggest{/VP_act_43} that {NP_44}both <Bpcf>compounds</Bpcf>{/NP_44} {VP_pass_45}may be involved{/VP_pass_45} in {NP_46}active transport phenomena{/NP_46} .


{NP_1}PMID{/NP_1} - {CP_2}6208480{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Effects{/NP_5} of {NP_C_6}<p>epidermal growth factor</p> and <c>12-O-tetradecanoylphorbol-13-acetate</c>{/NP_C_6} on {NP_7}metabolism{/NP_7} of {NP_P_8}the <p>epidermal growth factor receptor</p>{/NP_P_8} in {NP_S_9}normal <s>human</s> <S>fibroblasts</S>{/NP_S_9} .

OUTPUT 0
PTM = ({NP_10};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_P_11}<p>epidermal growth factor ( EGF ) receptor</p>{/NP_P_11};-)
Site = (-;-;UNK)

{NP_10}The biosynthesis , phosphorylation , and degradation{/NP_10} of {NP_P_11}the <p>epidermal growth factor ( EGF ) receptor</p>{/NP_P_11} {VP_pass_12}were examined{/VP_pass_12} in {NP_S_13}normal <s>human</s> <S>fibroblasts</S>{/NP_S_13} .

{NP_P_14}The <Bppf>receptor</Bppf>{/NP_P_14} {VP_pass_15}was initially synthesized{/VP_pass_15} as {NP_B_16}an <B>Mr</B>{/NP_B_16} = {NP_17}160,000 immature form{/NP_17} {NP_18}which{/NP_18} {VP_act_19}matured{/VP_act_19} to {NP_B_20}an <B>Mr</B>{/NP_B_20} = {NP_21}170,000 form{/NP_21} in {NP_22}a monensin-sensitive manner{/NP_22} .

{NP_23}<c>Tunicamycin</c> treatment{/NP_23} {VP_act_24}led{/VP_act_24} to {NP_25}the accumulation{/NP_25} of {NP_B_26}an <B>Mr</B>{/NP_B_26} = {NP_P_27}130,000 <Bppf>protein</Bppf>{/NP_P_27} .

OUTPUT 1
PTM = ({VP_pass_29};phosphorylated)
Kinase = (-;-)
Substrate = ({NP_P_11}<p>epidermal growth factor ( EGF ) receptor</p>{/NP_P_11};-)
Site = (-;{NP_PP_30}Ser{/NP_PP_30};UNK)
(-;{NP_PP_30}Thr{/NP_PP_30};UNK)

{NP_P_28}The <Bppf>receptor</Bppf>{/NP_P_28} {VP_pass_29}was phosphorylated{/VP_pass_29} on {NP_PP_30}<pp>serine</pp> and <pp>threonine residues</pp>{/NP_PP_30} in {VP_act_31}normally growing{/VP_act_31} and {NP_32}<Bpcl>quiescent cells</Bpcl>{/NP_32} , and {NP_33}treatment{/NP_33} with {NP_P_34}<p>EGF</p>{/NP_P_34} or {NP_C_35}the tumor <pp>promoter</pp> <c>12-O-tetradecanoylphorbol-13-acetate ( TPA )</c>{/NP_C_35} {VP_pass_36}resulted{/VP_pass_36} in a {CP_37}two{/CP_37} - {VP_pass_38}to threefold increase{/VP_pass_38} in {NP_G_39}<c>receptor -bound phosphate</c>{/NP_G_39} .

{NP_P_40}<p>EGF</p>{/NP_P_40} {VP_act_41}increased{/VP_act_41} {NP_42}the amount{/NP_42} of {NP_PP_43}<pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_43} and {VP_act_44}caused{/VP_act_44} {NP_45}the appearance{/NP_45} of {NP_46}a minor amount{/NP_46} of {NP_PP_47}<pp>phosphotyrosine</pp>{/NP_PP_47} .

{NP_C_48}<c>TPA</c>{/NP_C_48} {VP_act_49}increased{/VP_act_49} {NP_50}the levels{/NP_50} of {NP_PP_51}<pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_51} {AV_52}exclusively{/AV_52} .

OUTPUT 5
PTM = ({NP_PP_57};phosphotyrosine)
Kinase = (-;-)
Substrate = ({NP_P_11}<p>epidermal growth factor ( EGF ) receptor</p>{/NP_P_11};-)
Site = (-;{NP_PP_57}Tyr{/NP_PP_57};UNK)

{NP_53}Prior treatment{/NP_53} with {NP_C_54}<c>TPA</c>{/NP_C_54} {VP_act_55}inhibited{/VP_act_55} {NP_56}the <p>EGF</p> -dependent appearance{/NP_56} of {NP_PP_57}<pp>phosphotyrosine</pp>{/NP_PP_57} in {NP_P_58}the <Bppf>receptor</Bppf>{/NP_P_58} .

OUTPUT 6
PTM = ({NP_PP_60};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_60}<pp>phosphopeptides</pp>{/NP_PP_60})

{NP_59}Analysis{/NP_59} of {NP_PP_60}tryptic <pp>phosphopeptides</pp>{/NP_PP_60} {VP_act_61}revealed{/VP_act_61} that {CP_62}six{/CP_62} of {NP_PP_63}the seven major <Bppp>peptides</Bppp>{/NP_PP_63} {VP_pass_64}were common{/VP_pass_64} to {NP_P_65}the <Bppf>receptor</Bppf>{/NP_P_65} from {NP_66}<Bpcl>cells</Bpcl>{/NP_66} {VP_act_67}treated{/VP_act_67} with {NP_C_68}<p>EGF</p> or <c>TPA</c>{/NP_C_68} .

{NP_P_69}<p>EGF</p>{/NP_P_69} {VP_act_70}strongly stimulated{/VP_act_70} {NP_71}<c>[3H]thymidine</c> incorporation{/NP_71} in {NP_72}confluent <Bpcl>cells</Bpcl>{/NP_72} , {VP_act_73}increased{/VP_act_73} {NP_74}final saturation density three{/NP_74} to {AV_75}fourfold{/AV_75} , and {VP_act_76}increased{/VP_act_76} {NP_77}whole{/NP_77} - {NP_78}<Bpcl>cell</Bpcl> levels{/NP_78} of {NP_PP_79}<pp>phosphotyrosine</pp>{/NP_PP_79} about {JP_80}threefold{/JP_80} .

{NP_81}Treatment{/NP_81} of {NP_82}<Bpcl>cells</Bpcl>{/NP_82} with {NP_C_83}<c>TPA</c>{/NP_C_83} before {NP_84}addition{/NP_84} of {NP_P_85}<p>EGF</p>{/NP_P_85} {VP_act_86}inhibited{/VP_act_86} all {CP_87}three{/CP_87} of {NP_88}these <p>EGF</p> -dependent responses{/NP_88} .

{NP_P_89}<p>EGF</p>{/NP_P_89} {VP_act_90}also decreased{/VP_act_90} {NP_91}the <Bppf>receptor</Bppf> half-life{/NP_91} from {NP_92}15 h{/NP_92} to {NP_93}1 h{/NP_93} , but {NP_94}this{/NP_94} {VP_pass_neg_95}was not inhibited{/VP_pass_neg_95} by {NP_C_96}<c>TPA</c>{/NP_C_96} .

{NP_C_97}<c>TPA</c>{/NP_C_97} {AV_98}alone{/AV_98} {VP_act_99}had{/VP_act_99} {NP_100}no detectable effect{/NP_100} on {NP_101}the <Bppf>receptor</Bppf> half-life{/NP_101} .


{NP_1}PMID{/NP_1} - {CP_2}19426863{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_6};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6})

{NP_4}AB{/NP_4} - {NP_5}Selective enrichment{/NP_5} in {NP_PP_6}<pp>phosphopeptides</pp>{/NP_PP_6} for {NP_7}the identification{/NP_7} of {NP_P_8}phosphorylated mitochondrial <Bppf>proteins</Bppf>{/NP_P_8} .

{NP_9}In vivo <Bppf>protein</Bppf> phosphorylation{/NP_9} {VP_act_10}is{/VP_act_10} {NP_11}a reversible and dynamic process{/NP_11} {VP_pass_12}controlled{/VP_pass_12} by {NP_P_13}<p>protein kinases</p> and <p>phosphatases</p>{/NP_P_13} for {NP_14}the addition and removal{/NP_14} of {NP_G_15}the <c>phosphate group</c>{/NP_G_15} to {NP_PP_16}<pp>serine</pp> , <pp>threonine</pp> , and <pp>tyrosine residues</pp>{/NP_PP_16} .

In {NP_17}addition{/NP_17} to {NP_18}other regulation events{/NP_18} , {VP_act_19}increasing{/VP_act_19} {NP_20}evidence{/NP_20} {VP_act_21}indicates{/VP_act_21} that {NP_22}reversible <Bppf>protein</Bppf> phosphorylation{/NP_22} {VP_act_23}plays{/VP_act_23} {NP_24}an important role{/NP_24} in {VP_act_25}regulating{/VP_act_25} {NP_26}mitochondrial function{/NP_26} .

{VP_act_27}Detecting{/VP_act_27} {NP_28}changes{/NP_28} in {NP_29}the state{/NP_29} of {NP_30}<Bppf>protein</Bppf> phosphorylation{/NP_30} {VP_act_31}is{/VP_act_31} {NP_32}a difficult task{/NP_32} since {NP_33}phosphorylation{/NP_33} on {NP_P_34}a specific <Bppf>protein</Bppf>{/NP_P_34} {VP_pass_35}is typically transient{/VP_pass_35} and {VP_act_36}usually presents{/VP_act_36} in {NP_37}substoichiometric concentration{/NP_37} .

OUTPUT 7
PTM = ({NP_PP_44};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_44}<pp>phosphopeptides</pp>{/NP_PP_44})

{AV_38}Moreover{/AV_38} , what {VP_act_39}makes{/VP_act_39} {NP_40}<pp><B>mass spectrometry ( MS )</B>- based phosphopeptide</pp> analysis{/NP_40} {JP_41}difficult{/JP_41} {VP_act_42}is{/VP_act_42} {NP_43}that ionization efficiency{/NP_43} of {NP_PP_44}<pp>phosphopeptides</pp>{/NP_PP_44} {VP_pass_45}is lower{/VP_pass_45} than {NP_46}their nonphosphorylated <Bpf>analogues</Bpf>{/NP_46} .

OUTPUT 8
PTM = ({NP_PP_50};phosphoproteins)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_50}<pp>phosphopeptides</pp>{/NP_PP_50})

{NP_47}Different strategies{/NP_47} {VP_pass_48}have been proposed{/VP_pass_48} for {NP_49}the selective enrichment{/NP_49} of {NP_PP_50}low abundance <p>phosphoproteins</p> and <pp>phosphopeptides</pp>{/NP_PP_50} {JP_51}present{/JP_51} in {NP_52}biological samples{/NP_52} .

As {NP_53}a result{/NP_53} of {NP_54}recent advances{/NP_54} , {NP_C_55}<c>phosphoproteomics</c>{/NP_C_55} {VP_pass_56}has become{/VP_pass_56} {CP_57}one{/CP_57} of {NP_58}the most rapidly developing areas{/NP_58} of {NP_59}proteomics{/NP_59} .

In {NP_60}the last few years{/NP_60} , {NP_61}a number{/NP_61} of {NP_62}studies{/NP_62} {VP_pass_63}have focused{/VP_pass_63} on {NP_64}the analysis{/NP_64} of {NP_C_65}<c>phosphoproteome</c>{/NP_C_65} {VP_act_66}purified{/VP_act_66} from {NP_67}<s>yeast</s> , liver and heart mitochondria{/NP_67} , as well as on {NP_68}the identification{/NP_68} of {NP_P_69}endogenously phosphorylated <Bppf>subunits</Bppf>{/NP_P_69} of {NP_70}mitochondrial oxidative phosphorylation system <Bpf>complexes</Bpf>{/NP_70} .

{NP_71}This chapter{/NP_71} {VP_act_72}describes{/VP_act_72} {NP_73}methods{/NP_73} for {NP_74}the selective enrichment{/NP_74} of {NP_PP_75}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp>phosphotyrosine</pp>{/NP_PP_75} {VP_act_76}containing{/VP_act_76} {NP_P_77}<Bppp>peptides</Bppp> and <Bppf>proteins</Bppf>{/NP_P_77} and {NP_78}<B>phosphate-specific MS</B> strategy{/NP_78} {JP_79}generally applicable{/JP_79} to {NP_80}<p>phosphoprotein</p> analysis{/NP_80} but {VP_act_81}focusing{/VP_act_81} {AV_82}specifically{/AV_82} on {NP_83}mitochondrial samples{/NP_83} .


{NP_1}PMID{/NP_1} - {CP_2}6189415{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}A rapid microdetermination{/NP_5} of {NP_PP_6}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp>phosphotyrosine</pp>{/NP_PP_6} in {NP_P_7}<Bppf>proteins</Bppf>{/NP_P_7} by {NP_8}automatic cation exchange{/NP_8} on {NP_9}a conventional <Bppp>amino acid</Bppp> analyzer{/NP_9} .

{NP_10}A cation-exchange chromatographic method{/NP_10} for {NP_11}the separation and determination{/NP_11} of {NP_PP_12}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp>phosphotyrosine</pp>{/NP_PP_12} in {NP_P_13}<Bppf>proteins</Bppf>{/NP_P_13} after {NP_14}partial acid hydrolysis{/NP_14} {VP_pass_15}is described{/VP_pass_15} .

{NP_16}The short column ( 0.6 <B>X 8</B> cm ){/NP_16} of {NP_17}an automatic <Bppp>amino acid</Bppp> analyzer{/NP_17} {VP_pass_18}was used{/VP_pass_18} and {NP_19}elution{/NP_19} {VP_pass_20}was carried{/VP_pass_20} out {AV_21}isocratically{/AV_21} with {NP_22}10 mM trifluoroacetic acid{/NP_22} .

{NP_23}The method{/NP_23} {VP_pass_24}is highly sensitive{/VP_pass_24} and each of {NP_25}the <c>three O-phosphoamino</c> acids{/NP_25} {VP_pass_26}can be accurately determined{/VP_pass_26} {AV_27}down{/AV_27} to {NP_28}the <B>50-pmol</B> level{/NP_28} .

{NP_29}Higher sensitivity{/NP_29} {VP_pass_30}may be obtained{/VP_pass_30} by {NP_31}the use{/NP_31} of {NP_P_32}<p>[32P]phosphate-labeled proteins</p>{/NP_P_32} .

{NP_P_33}A <Bppf>correction factor</Bppf>{/NP_P_33} for {NP_34}the decomposition{/NP_34} of {NP_PP_35}<pp>phosphoserine</pp> or <pp>phosphothreonine</pp>{/NP_PP_35} during {NP_36}acid hydrolysis{/NP_36} {VP_pass_37}can be deduced{/VP_pass_37} from {NP_38}the amount{/NP_38} of {NP_G_39}inorganic <c>phosphate</c>{/NP_G_39} {VP_pass_40}recovered{/VP_pass_40} at {NP_41}the column void volume{/NP_41} .

{NP_42}The method{/NP_42} {VP_pass_43}is sensitive enough{/VP_pass_43} {VP_pass_44}to be used{/VP_pass_44} for {NP_P_45}<p>32P-labeled proteins</p>{/NP_P_45} {VP_pass_46}isolated{/VP_pass_46} by {NP_47}two-dimensional gel electrophoresis{/NP_47} .


{NP_1}PMID{/NP_1} - {CP_2}2307228{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_5};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_5}<pp>phosphopeptides</pp>{/NP_PP_5})

{NP_4}AB{/NP_4} - {NP_PP_5}Synthetic <pp>phosphopeptides</pp>{/NP_PP_5} {VP_pass_6}are{/VP_pass_6} {NP_P_7}<Bppf>substrates</Bppf>{/NP_P_7} for {NP_P_8}<p>casein kinase II</p>{/NP_P_8} .

{NP_P_9}<p>Casein kinase II</p>{/NP_P_9} {VP_act_10}is{/VP_act_10} {NP_P_11}a <Bppf>protein serine/threonine kinase</Bppf>{/NP_P_11} {NP_12}that{/NP_12} {VP_act_13}exhibits{/VP_act_13} {NP_14}a preference{/NP_14} for {NP_P_15}acidic <Bppf>substrates</Bppf>{/NP_P_15} .

{NP_16}Previous studies{/NP_16} {VP_act_17}have demonstrated{/VP_act_17} that {NP_PP_18}a <pp>glutamic acid 3 amino acids C-terminal (+3)</pp>{/NP_PP_18} to {NP_PP_19}a <pp>serine</pp> or <pp>threonine</pp>{/NP_PP_19} {VP_pass_20}is required{/VP_pass_20} for {NP_21}phosphorylation{/NP_21} .

OUTPUT 3
PTM = ({NP_PP_28};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_28}<pp>phosphopeptides</pp>{/NP_PP_28})

{VP_act_22}To examine{/VP_act_22} {NP_23}the ability{/NP_23} of {NP_PP_24}<pp>phosphoserine</pp> and <pp>phosphothreonine residues</pp>{/NP_PP_24} {VP_act_25}to serve{/VP_act_25} as {NP_26}specificity determinants{/NP_26} for {NP_P_27}<p>casein kinase II</p>{/NP_P_27} , {NP_PP_28}<pp>phosphopeptides</pp>{/NP_PP_28} {VP_act_29}containing{/VP_act_29} either of {NP_C_30}these <c>phosphoamino acids</c>{/NP_C_30} in {NP_31}the <B>+3</B> position{/NP_31} {VP_pass_32}were synthesized and tested{/VP_pass_32} as {NP_P_33}<Bppf>substrates</Bppf>{/NP_P_33} .

OUTPUT 4
PTM = ({NP_PP_34};Phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_34}<pp>Phosphopeptides</pp>{/NP_PP_34})

OUTPUT 6
PTM = ({VP_pass_38};phosphorylated)
Kinase = (-;-)
Substrate = ({NP_P_27}<p>casein kinase II</p>{/NP_P_27};-)
Site = (-;{NP_PP_36}Ser{/NP_PP_36};UNK)

{NP_PP_34}<pp>Phosphopeptides</pp>{/NP_PP_34} {VP_act_35}containing{/VP_act_35} {NP_PP_36}<pp>phosphoserine</pp>{/NP_PP_36} in {NP_37}the <B>+3</B> position{/NP_37} {VP_pass_38}were readily phosphorylated{/VP_pass_38} .

In {NP_39}contrast{/NP_39} , {NP_PP_40}<Bppp>corresponding phosphothreonine-containing peptides</Bppp>{/NP_PP_40} {VP_pass_41}were very poorly phosphorylated{/VP_pass_41} .

{NP_42}These results{/NP_42} {VP_act_43}imply{/VP_act_43} that {NP_44}prior phosphorylation{/NP_44} of {NP_P_45}<Bppf>substrate proteins</Bppf>{/NP_P_45} on {NP_PP_46}<pp>serine</pp>{/NP_PP_46} , but not {NP_PP_47}<pp>threonine residues</pp>{/NP_PP_47} , {VP_act_48}may{/VP_act_48} {NP_P_49}<p>II</p>{/NP_P_49} .


{NP_1}PMID{/NP_1} - {CP_2}8504096{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_5};autophosphorylation)
Kinase = ({NP_5}<p>Insulin receptor</p>{/NP_5};-)
Substrate = ({NP_5}<p>Insulin receptor</p>{/NP_5};-)
Site = (-;-;UNK)

{NP_4}AB{/NP_4} - {NP_5}<p>Insulin receptor</p> autophosphorylation{/NP_5} .

{NP_C_6}<c>II</c>{/NP_C_6} .

OUTPUT 1
PTM = ({NP_PP_8};autophosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_8}<Bppp>autophosphorylation sites</Bppp>{/NP_PP_8})

{NP_7}Determination{/NP_7} of {NP_PP_8}<Bppp>autophosphorylation sites</Bppp>{/NP_PP_8} by {NP_9}<Bppp>chemical sequence</Bppp> analysis and identification{/NP_9} of {NP_PP_10}the <Bppp>juxtamembrane sites</Bppp>{/NP_PP_10} .

OUTPUT 2
PTM = ({NP_PP_11};Autophosphorylation)
Kinase = ({NP_P_12}<p>insulin receptor</p>{/NP_P_12};-)
Substrate = ({NP_P_12}<p>insulin receptor</p>{/NP_P_12};-)
Site = (-;-;{NP_PP_11}<Bppp>Autophosphorylation sites</Bppp>{/NP_PP_11})

OUTPUT 3
PTM = ({NP_PP_15};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_15}<pp>[32P]phosphopeptides</pp>{/NP_PP_15})

OUTPUT 4
PTM = ({NP_PP_17};autophosphorylated)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_17}<pp>cytoplasmic kinase domain ( CKD )</pp>{/NP_PP_17})

{NP_PP_11}<Bppp>Autophosphorylation sites</Bppp>{/NP_PP_11} of {NP_P_12}the <s>human</s> <p>insulin receptor</p>{/NP_P_12} {VP_pass_13}were identified{/VP_pass_13} by {NP_14}<Bppp>microsequence</Bppp> analysis{/NP_14} of {NP_PP_15}19 discrete tryptic <pp>[32P]phosphopeptides</pp>{/NP_PP_15} , {VP_act_16}purified{/VP_act_16} from {NP_PP_17}the autophosphorylated <pp>cytoplasmic kinase domain ( CKD )</pp>{/NP_PP_17} .

OUTPUT 5
PTM = ({NP_PP_18};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_18}<pp>phosphopeptides</pp>{/NP_PP_18})

OUTPUT 6
PTM = ({NP_PP_22};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_22}<pp>phosphopeptides</pp>{/NP_PP_22})

{NP_PP_18}Seventeen <pp>phosphopeptides</pp>{/NP_PP_18} {VP_pass_19}were generated{/VP_pass_19} by {NP_20}cleavage{/NP_20} at {NP_PP_21}<pp><pp>Arg</pp> and/or Lys</pp>{/NP_PP_21} , but {NP_PP_22}two <pp>phosphopeptides</pp>{/NP_PP_22} {VP_pass_23}were generated{/VP_pass_23} {AV_24}reproducibly{/AV_24} by {NP_25}anomalous cleavages{/NP_25} .

{NP_PP_26}Two new <Bppp>sites</Bppp>{/NP_PP_26} {VP_pass_27}were identified{/VP_pass_27} in {NP_PP_28}the <Bppp>juxtamembrane region</Bppp>{/NP_PP_28} of {NP_P_29}the intact <p>insulin receptor beta- subunit</p>{/NP_P_29} ( {NP_PP_30}the <pp>amino terminus</pp>{/NP_PP_30} of {NP_PP_31}the <pp>CKD</pp>{/NP_PP_31} ) , {VP_act_32}including{/VP_act_32} {NP_PP_33}<pp>phosphotyrosines 965 and 972</pp>{/NP_PP_33} .

OUTPUT 8
PTM = ({NP_PP_39};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_39}<pp>phosphopeptides</pp>{/NP_PP_39})

{NP_PP_34}Three <Bppp>sites</Bppp>{/NP_PP_34} in {NP_PP_35}the central <Bppp>region</Bppp>{/NP_PP_35} , {VP_act_36}including{/VP_act_36} {NP_PP_37}<pp>phosphotyrosines 1158 , 1162 , and 1163</pp>{/NP_PP_37} , {VP_pass_38}were identified{/VP_pass_38} from {NP_PP_39}six <pp>phosphopeptides</pp>{/NP_PP_39} ; {NP_PP_40}<pp>tyrosine</pp>{/NP_PP_40} at {CP_41}1158{/CP_41} {VP_pass_42}was{/VP_pass_42} the {JP_43}least phosphorylated{/JP_43} .

OUTPUT 9
PTM = ({NP_PP_44};Monophosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_44}<pp>Monophosphopeptides</pp>{/NP_PP_44})

{NP_PP_44}<pp>Monophosphopeptides</pp>{/NP_PP_44} {VP_act_45}contained{/VP_act_45} {NP_PP_46}<pp>phosphotyrosine</pp>{/NP_PP_46} at {NP_PP_47}either <Bppp>residue 1158 or 1163</Bppp>{/NP_PP_47} , but {AV_48}not{/AV_48} at {CP_49}1162{/CP_49} .

{NP_50}Bisphosphorylation{/NP_50} {VP_act_51}included{/VP_act_51} {NP_PP_52}<pp>phosphotyrosines</pp>{/NP_PP_52} {AV_53}only{/AV_53} at {CP_54}1162 and 1163{/CP_54} .

OUTPUT 13
PTM = ({NP_PP_55};autophosphorylation)
Kinase = ({NP_P_12}<p>insulin receptor</p>{/NP_P_12};-)
Substrate = ({NP_P_12}<p>insulin receptor</p>{/NP_P_12};-)
Site = (-;-;{NP_PP_47}either <Bppp>residue 1158 or 1163</Bppp>{/NP_PP_47})
(-;-;{NP_PP_55}<Bppp>autophosphorylation sites</Bppp>{/NP_PP_55})
(-;{NP_PP_46}Tyr{/NP_PP_46};UNK)

OUTPUT 14
PTM = ({NP_PP_58};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_58}<pp>phosphopeptides</pp>{/NP_PP_58})

{NP_PP_55}The two <Bppp>autophosphorylation sites</Bppp>{/NP_PP_55} near {NP_PP_56}the <pp>carboxy terminus</pp>{/NP_PP_56} {VP_pass_57}were found{/VP_pass_57} in {NP_PP_58}seven <pp>phosphopeptides</pp>{/NP_PP_58} , {VP_act_59}including{/VP_act_59} {NP_PP_60}<pp>phosphotyrosines</pp>{/NP_PP_60} at {CP_61}1328 and 1334{/CP_61} .

When {VP_pass_62}mapped{/VP_pass_62} by {NP_63}reverse-phase high-performance liquid chromatography{/NP_63} , {NP_PP_64}these <pp>phosphopeptides</pp>{/NP_PP_64} {VP_pass_65}eluted{/VP_pass_65} in {NP_PP_66}the order central <Bppp>domain</Bppp>{/NP_PP_66} , {JP_67}first{/JP_67} ; {NP_PP_68}<Bppp>carboxy-terminal region</Bppp>{/NP_PP_68} , {JP_69}second{/JP_69} ; and {NP_70}juxtamembrane{/NP_70} ( {NP_71}amino{/NP_71} - {NP_PP_72}<Bppp>terminal</Bppp>{/NP_PP_72} ) {NP_PP_73}<Bppp>domain</Bppp>{/NP_PP_73} , {JP_74}last{/JP_74} .

NORM=insulin receptor
SYNONYM=Insulin receptor
SYNONYM=insulin receptor


{NP_1}PMID{/NP_1} - {CP_2}15273693{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_PP_5};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_5}<pp>phosphopeptides</pp>{/NP_PP_5})

{NP_4}AB{/NP_4} - {NP_PP_5}Caged <pp>phosphopeptides</pp>{/NP_PP_5} {VP_act_6}reveal{/VP_act_6} {NP_7}a temporal role{/NP_7} for {NP_P_8}<p>14-3-3</p>{/NP_P_8} in {NP_9}<B>G1</B> arrest and S-phase checkpoint function{/NP_9} .

OUTPUT 1
PTM = ({NP_PP_13};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_13}<Bppp><Bppp>phosphopeptide</Bppp> -binding domains</Bppp>{/NP_PP_13})

{VP_act_10}Using{/VP_act_10} {NP_11}classical genetics{/NP_11} {VP_act_12}to study{/VP_act_12} {NP_PP_13}modular <Bppp><Bppp>phosphopeptide</Bppp> -binding domains</Bppp>{/NP_PP_13} within {NP_14}a <Bpf>family</Bpf>{/NP_14} of {NP_P_15}<Bppf>proteins</Bppf>{/NP_P_15} {NP_16}that{/NP_16} {VP_pass_17}are functionally redundant is difficult{/VP_pass_17} when {NP_18}other <Bpf>members</Bpf>{/NP_18} of {NP_19}the <Bpf>domain family</Bpf>{/NP_19} {VP_act_20}compensate{/VP_act_20} for {NP_21}the <Bpf>product</Bpf>{/NP_21} of {NP_P_22}the knocked-out <Bppf>gene</Bppf>{/NP_P_22} .

OUTPUT 2
PTM = ({NP_PP_34};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_34}<pp>phosphopeptides</pp>{/NP_PP_34})

{AV_23}Here{/AV_23} {NP_24}we{/NP_24} {VP_act_25}describe{/VP_act_25} {NP_26}a <Bpcf>chemical</Bpcf> genetics{/NP_26} {VP_act_27}approach{/VP_act_27} {NP_28}that{/NP_28} {VP_act_29}overcomes{/VP_act_29} {NP_30}this limitation{/NP_30} by {VP_act_31}using{/VP_act_31} {NP_B_32}<B>UV-activatable</B>{/NP_B_32} {VP_act_33}caged{/VP_act_33} {NP_PP_34}<pp>phosphopeptides</pp>{/NP_PP_34} .

By {JP_35}incorporating{/JP_35} {NP_PP_36}a caged <pp>phosphoserine residue</pp>{/NP_PP_36} within {NP_PP_37}a consensus <Bppp>motif</Bppp>{/NP_PP_37} , {NP_38}these reagents{/NP_38} {VP_act_39}simultaneously and synchronously inactivate{/VP_act_39} {NP_B_40}all <B>phosphoserine/phosphothreonine -binding domain family members</B>{/NP_B_40} in a {JP_41}rapid{/JP_41} and {VP_act_42}temporally regulated{/VP_act_42} {NP_43}manner{/NP_43} .

{NP_44}We{/NP_44} {VP_act_45}applied{/VP_act_45} {NP_46}this approach{/NP_46} {VP_act_47}to study{/VP_act_47} {NP_48}the global function{/NP_48} of {NP_P_49}<p>14-3-3 proteins</p>{/NP_P_49} in {NP_50}<Bpcl>cell</Bpcl> cycle control{/NP_50} .

OUTPUT 5
PTM = ({NP_PP_52};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_52}<pp>phosphopeptides</pp>{/NP_PP_52})

{NP_51}Activation{/NP_51} of {NP_PP_52}the caged <pp>phosphopeptides</pp>{/NP_PP_52} by {NP_53}UV irradiation{/NP_53} {VP_act_54}displaced{/VP_act_54} {NP_P_55}endogenous <Bppf>proteins</Bppf>{/NP_P_55} from {VP_act_56}14-3-3-binding{/VP_act_56} , {VP_act_57}causing{/VP_act_57} {NP_58}premature <Bpcl>cell</Bpcl> cycle entry{/NP_58} , {NP_59}release{/NP_59} of {NP_S_60}<S>G1 cells</S>{/NP_S_60} from {NP_61}interphase arrest{/NP_61} and {NP_62}loss{/NP_62} of {NP_63}the S-phase checkpoint{/NP_63} after {NP_64}DNA damage{/NP_64} , {VP_pass_65}accompanied{/VP_pass_65} by {NP_66}high levels{/NP_66} of {NP_67}<Bpcl>cell</Bpcl> death{/NP_67} .

OUTPUT 6
PTM = ({NP_PP_74};phosphopeptide)
Kinase = (-;-)
Substrate = ({NP_P_76}<p>SH2</p>{/NP_P_76};-)
Site = (-;-;{NP_PP_74}<Bppp><Bppp>phosphopeptide</Bppp> -binding domains</Bppp>{/NP_PP_74})

{NP_68}This class{/NP_68} of {NP_69}reagents{/NP_69} {VP_act_70}will greatly facilitate{/VP_act_70} {NP_71}molecular dissection{/NP_71} of {NP_72}kinase -dependent signaling pathways{/NP_72} when {VP_act_73}applied{/VP_act_73} to {NP_PP_74}other <Bppp><Bppp>phosphopeptide</Bppp> -binding domains</Bppp>{/NP_PP_74} {VP_act_75}including{/VP_act_75} {NP_P_76}<p>SH2</p>{/NP_P_76} , {NP_PP_77}<pp>Polo-box</pp>{/NP_PP_77} and {NP_PP_78}tandem <pp>BRCT domains</pp>{/NP_PP_78} .


{NP_1}PMID{/NP_1} - {CP_2}17073441{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Development{/NP_5} of a <Bppf>substrate</Bppf> -based {NP_P_6}cyclic <Bppf>phosphopeptide inhibitor</Bppf>{/NP_P_6} of {NP_P_7}<p>protein phosphatase 2Cdelta</p>{/NP_P_7} , {NP_P_8}<p>Wip1</p>{/NP_P_8} .

{NP_P_9}The <p>wild-type p53</p> -induced <p>phosphatase</p>{/NP_P_9} , {NP_P_10}<p>Wip1</p> ( <p>PP2Cdelta</p> or <p>PPM1D</p> ){/NP_P_10} {VP_act_11}is{/VP_act_11} {NP_12}a <Bpf>member</Bpf>{/NP_12} of {NP_13}the <B><p>protein phosphatase 2C ( PP2C )</p> family</B> and functions{/NP_13} as {NP_14}a negative <Bpf>regulator</Bpf>{/NP_14} of {NP_15}the <p>p38</p> MAP kinase-p53 signaling pathway{/NP_15} .

{NP_P_16}<p>PPM1D</p>{/NP_P_16} {VP_pass_17}is amplified{/VP_pass_17} or {NP_P_18}<p>Wip1</p>{/NP_P_18} {VP_pass_19}is overexpressed{/VP_pass_19} in {NP_20}several <s>human</s> cancers{/NP_20} , and {NP_21}it{/NP_21} {VP_act_22}acts{/VP_act_22} as {NP_P_23}a weak <Bppf>oncogene</Bppf>{/NP_P_23} .

Although {NP_24}inhibition{/NP_24} of {NP_P_25}<p>Wip1</p>{/NP_P_25} {VP_act_26}may have{/VP_act_26} {NP_27}therapeutic value{/NP_27} , {NP_P_28}no specific <Bppf>inhibitors</Bppf>{/NP_P_28} {VP_pass_29}are available{/VP_pass_29} .

In {NP_30}this study{/NP_30} , {NP_31}we{/NP_31} {VP_act_32}designed{/VP_act_32} {NP_P_33}<Bppf>phosphopeptide inhibitors</Bppf>{/NP_P_33} for {NP_P_34}<p>Wip1</p>{/NP_P_34} on {NP_35}the basis{/NP_35} of {NP_PP_36}its optimal <Bppp>substrate sequence</Bppp>{/NP_PP_36} .

OUTPUT 2
PTM = ({NP_PP_39};phosphoserine)
Kinase = (-;-)
Substrate = ({NP_42}<p>Wip1 phosphatase</p>{/NP_42};-)
Site = (-;{NP_PP_39}Ser{/NP_PP_39};UNK)

{NP_37}We{/NP_37} {VP_act_38}found{/VP_act_38} that {NP_PP_39}phosphoserine-containing diphosphorylated <Bppp>peptides</Bppp>{/NP_PP_39} with {NP_PP_40}the <pp>sequence pSXpY</pp>{/NP_PP_40} {VP_act_41}inhibited{/VP_act_41} {NP_42}<p>Wip1 phosphatase</p> activity{/NP_42} , whereas {NP_PP_43}<Bppp>phosphothreonine-containing peptides</Bppp>{/NP_PP_43} with {NP_PP_44}the <pp>sequence pTXpY</pp>{/NP_PP_44} {VP_pass_45}were{/VP_pass_45} {NP_P_46}physiological <Bppf>substrates</Bppf>{/NP_P_46} .

OUTPUT 4
PTM = ({NP_PP_51};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_51}<pp>Ile</pp>{/NP_PP_51})
(-;-;{NP_PP_51}<pp>Val</pp>{/NP_PP_51})
(-;-;{NP_PP_51}<pp>phosphopeptides</pp>{/NP_PP_51})

{AV_47}Moreover{/AV_47} , {NP_B_48}the <B>X residue</B>{/NP_B_48} in {NP_PP_49}the <pp>pSXpY sequence</pp>{/NP_PP_49} {VP_act_50}modulated{/VP_act_50} {NP_PP_51}<B>inhibitor</B> activity , and <c>beta-branched amino</c> acid -substituted ( <pp>Ile</pp> or <pp>Val</pp> ) <pp>phosphopeptides</pp>{/NP_PP_51} {VP_act_52}showed{/VP_act_52} {NP_53}high inhibitory potencies{/NP_53} .

{NP_54}A <c>thioether</c> cyclic <pp>phosphopeptide</pp> c ( <B>MpSIpYVA</B> ){/NP_54} {VP_act_55}had{/VP_act_55} {NP_B_56}a <B>K(i) <1.0 microM</B>{/NP_B_56} .

OUTPUT 5
PTM = ({NP_PP_60};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_60}<pp>phosphopeptide</pp>{/NP_PP_60})

{NP_P_57}Two <p>serine/threonine phosphatases</p>{/NP_P_57} , {NP_P_58}<p>PP2Calpha</p> and <p>PP2A</p>{/NP_P_58} , {VP_pass_neg_59}were not significantly inhibited{/VP_pass_neg_59} by {NP_PP_60}the cyclic <pp>phosphopeptide</pp>{/NP_PP_60} with {NP_PP_61}a nonhydrolyzable <pp>phosphoserine</pp>{/NP_PP_61} {JP_62}mimetic{/JP_62} .

{NP_63}A homology model{/NP_63} of {NP_P_64}<p>Wip1</p>{/NP_P_64} {VP_act_65}bound{/VP_act_65} to {NP_66}a <pp>cyclic phosphopeptide</pp> and <pp>site</pp> -directed mutagenesis{/NP_66} {VP_act_67}helped{/VP_act_67} {VP_act_68}to identify{/VP_act_68} {NP_PP_69}<Bppp>residues</Bppp>{/NP_PP_69} {JP_70}important{/JP_70} for {NP_71}<Bppf><p>Wip1</p> inhibitor</Bppf> selectivity{/NP_71} among {NP_P_72}the <p>PP2C family</p>{/NP_P_72} .

{NP_73}These results{/NP_73} {VP_act_74}provide{/VP_act_74} {NP_75}the first proof{/NP_75} of {NP_76}concept{/NP_76} of {NP_P_77}a specific <Bppf>inhibitor</Bppf>{/NP_P_77} of {NP_PP_78}the catalytic <Bppp>site</Bppp>{/NP_PP_78} of {NP_P_79}<p>Wip1</p>{/NP_P_79} and {VP_act_80}should be useful{/VP_act_80} for {VP_act_81}developing{/VP_act_81} {NP_82}potential <Bpcf>anti-cancer drugs</Bpcf>{/NP_82} .


{NP_1}PMID{/NP_1} - {CP_2}12595692{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Proteomic screen{/NP_5} {VP_act_6}finds{/VP_act_6} {NP_PP_7}<pp><p>pSer/pThr</p> -binding domain</pp>{/NP_PP_7} {VP_act_8}localizing{/VP_act_8} {NP_P_9}<p>Plk1</p>{/NP_P_9} {VP_act_10}to mitotic{/VP_act_10} {NP_P_11}<Bppf>substrates</Bppf>{/NP_P_11} .

OUTPUT 0
PTM = ({NP_PP_16};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_16}<pp><pp>phosphopeptide</pp> binding domains</pp>{/NP_PP_16})

{NP_12}We{/NP_12} {VP_act_13}have developed{/VP_act_13} {NP_14}a proteomic approach{/NP_14} for {VP_act_15}identifying{/VP_act_15} {NP_PP_16}<pp><pp>phosphopeptide</pp> binding domains</pp>{/NP_PP_16} {NP_17}that{/NP_17} {VP_act_18}modulate{/VP_act_18} {NP_19}kinase -dependent signaling pathways{/NP_19} .

OUTPUT 1
PTM = ({NP_PP_21};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_21}<pp>degenerate phosphopeptides</pp>{/NP_PP_21})

OUTPUT 2
PTM = ({NP_PP_23};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_23}<pp><Bppf>protein kinase</Bppf> phosphorylation motif</pp>{/NP_PP_23})

{NP_20}An immobilized library{/NP_20} of partially {NP_PP_21}<pp>degenerate phosphopeptides</pp>{/NP_PP_21} {VP_act_22}biased{/VP_act_22} toward {NP_PP_23}a particular <pp><Bppf>protein kinase</Bppf> phosphorylation motif</pp>{/NP_PP_23} {VP_pass_24}is used{/VP_pass_24} {VP_pass_25}to isolate{/VP_pass_25} {NP_PP_26}phospho-<Bppp>binding domains</Bppp>{/NP_PP_26} {NP_27}that{/NP_27} {VP_act_28}bind{/VP_act_28} to {NP_P_29}<Bppf>proteins</Bppf>{/NP_P_29} {VP_pass_30}phosphorylated{/VP_pass_30} by {NP_P_31}that <Bppf>kinase</Bppf>{/NP_P_31} .

{VP_act_32}Applying{/VP_act_32} {NP_33}this approach{/NP_33} to {NP_P_34}<p>cyclin-dependent kinases ( Cdks )</p>{/NP_P_34} , {NP_35}we{/NP_35} {VP_act_36}identified{/VP_act_36} {NP_PP_37}the <pp>polo-box domain ( PBD )</pp>{/NP_PP_37} of {NP_P_38}the mitotic kinase <p>polo-like kinase 1 ( Plk1 )</p>{/NP_P_38} as {NP_PP_39}a specific <c>phosphoserine ( pSer )</c> or <pp><c>phosphothreonine ( pThr )</c> binding domain</pp>{/NP_PP_39} and {VP_act_40}determined{/VP_act_40} {NP_PP_41}its optimal <Bppp>binding motif</Bppp>{/NP_PP_41} .

OUTPUT 5
PTM = ({NP_PP_47};phosphopeptide)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_47}<pp>phosphopeptide</pp>{/NP_PP_47})

{NP_PP_42}This <Bppp>motif</Bppp>{/NP_PP_42} {VP_pass_43}is present{/VP_pass_43} in {NP_P_44}known <Bppf><p>Plk1</p> substrates</Bppf>{/NP_P_44} {JP_45}such{/JP_45} as {NP_P_46}<p>Cdc25</p>{/NP_P_46} , and {NP_PP_47}an optimal <pp>phosphopeptide</pp>{/NP_PP_47} {VP_act_48}containing{/VP_act_48} {NP_PP_49}the <Bppp>motif</Bppp>{/NP_PP_49} {VP_act_50}disrupted{/VP_act_50} {NP_51}<Bppf>PBD-substrate</Bppf> binding and localization{/NP_51} of {NP_PP_52}the <pp>PBD</pp>{/NP_PP_52} to {NP_53}centrosomes{/NP_53} .

OUTPUT 6
PTM = ({NP_61};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_61}<B>Cdk</B>{/NP_61};-)
Site = (-;-;{NP_PP_58}specific <Bppp>sites</Bppp>{/NP_PP_58})
(-;-;{NP_PP_62}<Bppp>sites</Bppp>{/NP_PP_62})

{NP_54}This{/NP_54} {VP_act_55}finding reveals{/VP_act_55} how {NP_P_56}<p>Plk1</p>{/NP_P_56} {VP_act_57}can localize{/VP_act_57} to {NP_PP_58}specific <Bppp>sites</Bppp>{/NP_PP_58} within {NP_59}<Bpcl>cells</Bpcl>{/NP_59} in {NP_60}response{/NP_60} to {NP_61}<B>Cdk</B> phosphorylation{/NP_61} at {NP_PP_62}those <Bppp>sites</Bppp>{/NP_PP_62} and {VP_act_63}provides{/VP_act_63} {NP_64}a structural mechanism{/NP_64} for {VP_act_65}targeting{/VP_act_65} {NP_PP_66}the <pp><p>Plk1 kinase</p> domain</pp>{/NP_PP_66} to {NP_P_67}its <Bppf>substrates</Bppf>{/NP_P_67} .


{NP_1}PMID{/NP_1} - {CP_2}12923550{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_7};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_6}<Bppp>mapping sites</Bppp>{/NP_PP_6})

{NP_4}AB{/NP_4} - {NP_5}<p>Phosphospecific</p> proteolysis{/NP_5} for {NP_PP_6}<Bppp>mapping sites</Bppp>{/NP_PP_6} of {NP_7}<Bppf>protein</Bppf> phosphorylation{/NP_7} .

OUTPUT 1
PTM = ({NP_8};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_19}<Bppp>sites</Bppp>{/NP_PP_19})

OUTPUT 2
PTM = ({NP_20};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_19}<Bppp>sites</Bppp>{/NP_PP_19})

{NP_8}<Bppf>Protein</Bppf> phosphorylation{/NP_8} {VP_act_9}is{/VP_act_9} {NP_10}a dominant mechanism{/NP_10} of {NP_11}information transfer{/NP_11} in {NP_12}<Bpcl>cells</Bpcl>{/NP_12} , and {NP_13}a major goal{/NP_13} of {NP_14}current proteomic efforts{/NP_14} {VP_act_15}is{/VP_act_15} {VP_act_16}to generate{/VP_act_16} {NP_17}a system-level{/NP_17} {VP_act_18}map{/VP_act_18} {NP_PP_19}describing all the <Bppp>sites</Bppp>{/NP_PP_19} of {NP_20}<Bppf>protein</Bppf> phosphorylation{/NP_20} .

OUTPUT 3
PTM = ({NP_PP_26};phosphopeptides)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_26}<pp>quantifying phosphopeptides</pp>{/NP_PP_26})

{NP_21}Recent efforts{/NP_21} {VP_pass_22}have focused{/VP_pass_22} on {VP_act_23}developing{/VP_act_23} {NP_24}technologies{/NP_24} for {VP_act_25}enriching{/VP_act_25} and {NP_PP_26}<pp>quantifying phosphopeptides</pp>{/NP_PP_26} .

OUTPUT 4
PTM = ({NP_29};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_28}<Bppp>sites</Bppp>{/NP_PP_28})

{NP_27}Identification{/NP_27} of {NP_PP_28}the <Bppp>sites</Bppp>{/NP_PP_28} of {NP_29}phosphorylation{/NP_29} {VP_act_30}typically relies{/VP_act_30} on {NP_31}tandem mass spectrometry{/NP_31} to {NP_PP_32}<Bppp><Bppp>sequence</Bppp> individual peptides</Bppp>{/NP_PP_32} .

OUTPUT 5
PTM = ({NP_49};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_48}<Bppp>sites</Bppp>{/NP_PP_48})

{AV_33}Here{/AV_33} {NP_34}we{/NP_34} {VP_act_35}describe{/VP_act_35} {NP_36}an approach{/NP_36} for {NP_37}<pp>phosphopeptide</pp> mapping{/NP_37} {NP_38}that{/NP_38} {VP_act_39}makes{/VP_act_39} {NP_40}it{/NP_40} {JP_41}possible{/JP_41} {VP_act_42}to interrogate{/VP_act_42} {NP_PP_43}a <Bppp>protein sequence</Bppp>{/NP_PP_43} {AV_44}directly{/AV_44} with {NP_P_45}a <Bppf>protease</Bppf>{/NP_P_45} {NP_46}that{/NP_46} {VP_act_47}recognizes{/VP_act_47} {NP_PP_48}<Bppp>sites</Bppp>{/NP_PP_48} of {NP_49}phosphorylation{/NP_49} .

The {JP_50}key{/JP_50} to {NP_51}this approach{/NP_51} {VP_act_52}is{/VP_act_52} {NP_53}the selective <Bpcf>chemical</Bpcf> transformation{/NP_53} of {NP_PP_54}<pp>phosphoserine</pp> and <pp>phosphothreonine residues</pp>{/NP_PP_54} into {NP_B_55}<B>lysine analogs</B>{/NP_B_55} ( {NP_PP_56}<pp>aminoethylcysteine</pp> and <pp>beta-methylaminoethylcysteine</pp>{/NP_PP_56} , {AV_57}respectively{/AV_57} ) .

OUTPUT 7
PTM = ({NP_63};phosphorylation)
Kinase = (-;-)
Substrate = (-;-)
Site = (-;-;{NP_PP_62}<Bppp>sites</Bppp>{/NP_PP_62})

{NP_PP_58}<c>Aminoethylcysteine</c> -modified <Bppp>peptides</Bppp>{/NP_PP_58} {VP_pass_59}are then cleaved{/VP_pass_59} with {NP_P_60}a lysine-specific <Bppf>protease</Bppf>{/NP_P_60} {VP_act_61}to map{/VP_act_61} {NP_PP_62}<Bppp>sites</Bppp>{/NP_PP_62} of {NP_63}phosphorylation{/NP_63} .

{NP_64}A blocking step{/NP_64} {VP_act_65}enables{/VP_act_65} {NP_66}single{/NP_66} - {NP_PP_67}<Bppp>site cleavage</Bppp>{/NP_PP_67} , and {NP_68}adaptation{/NP_68} of {NP_69}this reaction{/NP_69} to {NP_70}the solid phase{/NP_70} {VP_act_71}facilitates{/VP_act_71} {NP_72}<pp>phosphopeptide</pp> enrichment and modification{/NP_72} in {NP_73}one step{/NP_73} .


{NP_1}PMID{/NP_1} - {CP_2}17288512{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Quantitative proteomic approaches{/NP_5} for {VP_act_6}studying{/VP_act_6} {NP_7}<pp>phosphotyrosine</pp> signaling{/NP_7} .

{NP_8}<Bppf>Protein</Bppf> <pp>tyrosine</pp> phosphorylation{/NP_8} {VP_act_9}is{/VP_act_9} {NP_10}a fundamental mechanism{/NP_10} for {VP_act_11}controlling{/VP_act_11} {NP_12}many aspects{/NP_12} of {NP_13}cellular processes{/NP_13} , as well as {NP_14}aspects{/NP_14} of {NP_15}<s>human</s> health{/NP_15} and {NP_16}diseases{/NP_16} .

{JP_17}Compared{/JP_17} with {NP_PP_18}<pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_18} , {NP_19}<pp>phosphotyrosine</pp> signaling{/NP_19} {VP_pass_20}is more tightly regulated{/VP_pass_20} , but {VP_act_21}often more challenging{/VP_act_21} {VP_act_22}to characterize{/VP_act_22} , {JP_23}due{/JP_23} to {NP_24}significantly lower levels{/NP_24} of {NP_25}<pp>tyrosine</pp> phosphorylation{/NP_25} ( {NP_26}i.e.{/NP_26} , {NP_27}a relative abundance{/NP_27} of {CP_28}1800{/CP_28} : {CP_29}200{/CP_29} : {CP_30}1{/CP_30} {VP_pass_31}was estimated{/VP_pass_31} for {NP_PP_32}<pp>phosphoserine/phosphothreonine/phosphotyrosine</pp>{/NP_PP_32} in {NP_33}<Bpcl>vertebrate cells</Bpcl>{/NP_33} ) .

In {NP_34}this review{/NP_34} , {NP_35}we{/NP_35} {VP_act_36}outline{/VP_act_36} {NP_37}recent advances{/NP_37} in {NP_38}analytical methodologies{/NP_38} for {NP_39}enrichment , identification and accurate quantitation{/NP_39} of {NP_PP_40}<pp>tyrosine</pp>-phosphorylated <Bppf>proteins</Bppf> and <Bppp>peptides</Bppp>{/NP_PP_40} .

{NP_41}Advances{/NP_41} in {NP_42}<Bppf>antibody</Bppf> -based technologies{/NP_42} , {NP_43}capillary liquid chromatography{/NP_43} {VP_act_44}coupled{/VP_act_44} with {NP_45}mass spectrometry{/NP_45} , and {NP_46}various stable isotope{/NP_46} {VP_act_47}labeling{/VP_act_47} {NP_48}strategies{/NP_48} {VP_pass_49}are discussed{/VP_pass_49} , as well as {VP_act_50}non-mass{/VP_act_50} {NP_51}spectrometry-based methods{/NP_51} , {JP_52}such{/JP_52} as {NP_53}those using <Bppp>protein/peptide</Bppp> arrays{/NP_53} .

As {NP_54}a result{/NP_54} of {NP_55}these advances{/NP_55} , {NP_56}powerful tools{/NP_56} {AV_57}now{/AV_57} {VP_act_58}have{/VP_act_58} {NP_59}the power{/NP_59} {VP_act_60}to crack{/VP_act_60} {NP_61}signal transduction codes{/NP_61} at {NP_62}the system level{/NP_62} , and {VP_act_63}provide{/VP_act_63} {NP_64}a basis{/NP_64} for {VP_act_65}discovering{/VP_act_65} {NP_66}novel <Bpcf>drug</Bpcf> targets{/NP_66} for {NP_67}<s>human</s> diseases{/NP_67} .


{NP_1}PMID{/NP_1} - {CP_2}1692212{/CP_2}

{NP_3}TI{/NP_3} -

OUTPUT 0
PTM = ({NP_5};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_P_6}a <p>38 kDa protein</p>{/NP_P_6};-)
Site = (-;{NP_5}Tyr{/NP_5};UNK)

{NP_4}AB{/NP_4} - {NP_5}<pp>Vasopressin dependent tyrosine</pp> phosphorylation{/NP_5} of {NP_P_6}a <p>38 kDa protein</p>{/NP_P_6} in {NP_7}<s>human</s> platelets{/NP_7} .

{NP_8}<p>Arginine vasopressin</p> administration{/NP_8} ( {NP_B_9}10 ( -10 ) -10 ( -6 ) <B>M</B>{/NP_B_9} ) to {NP_10}isolated <s>human</s> platelets{/NP_10} {VP_act_11}induces{/VP_act_11} an {VP_pass_12}increase{/VP_pass_12} in {NP_13}the specific immunoblotting{/NP_13} of {NP_P_14}a <p>38 kDa protein</p>{/NP_P_14} {VP_pass_15}revealed{/VP_pass_15} by {NP_P_16}a <p>phosphotyrosine antibody</p>{/NP_P_16} .

{NP_17}This signal{/NP_17} {VP_pass_18}is biphasic{/VP_pass_18} with {NP_19}maximal stimulation{/NP_19} within {NP_20}one minute{/NP_20} .

Neither {NP_B_21}<B>forskolin</B>{/NP_B_21} ( {NP_B_22}10 ( -5 ) <B>M</B>{/NP_B_22} ) nor {NP_C_23}<c>phorbol ester</c>{/NP_C_23} ( {NP_B_24}10 ( -6 ) <B>M</B>{/NP_B_24} ) {VP_act_25}produces{/VP_act_25} {NP_26}a similar 38 <p>kDa</p> signal{/NP_26} .

{NP_27}The specific immunoblotted signals{/NP_27} {VP_pass_28}are competitively abolished{/VP_pass_28} by {CP_29}1{/CP_29} mM <pp>phosphotyrosine</pp> but not {NP_PP_30}<pp>phosphoserine</pp> or <pp>phosphothreonine</pp>{/NP_PP_30} .

{NP_31}Electrophoretic separation{/NP_31} at {NP_32}pH 3.5{/NP_32} of {NP_33}the acid hydrolysates{/NP_33} of {NP_P_34}the <p>38 kDa proteins</p>{/NP_P_34} {VP_act_35}reveals{/VP_act_35} {NP_36}a <p>vasopressin</p> dependent{/NP_36} {VP_pass_37}increase{/VP_pass_37} in {NP_38}levels{/NP_38} of {NP_PP_39}<pp>phosphotyrosine</pp>{/NP_PP_39} as well as {NP_PP_40}<pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_40} .

OUTPUT 4
PTM = ({NP_41};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_41}<p>kDa</p>{/NP_41};-)
Site = (-;-;UNK)

{NP_41}The 38 <p>kDa</p> phosphorylation{/NP_41} {VP_pass_42}is also induced{/VP_pass_42} by {NP_C_43}the specific <c><p>arginine vasopressin</p> V1 receptor agonist</c> (Phe2Orn8Vastocina){/NP_C_43} and {VP_pass_44}blocked{/VP_pass_44} by {NP_B_45}the <B>V1 receptor antagonist [desGly (NH2)</B> d ( <p>CH2</p> ) <B>5Tyr</B>{/NP_B_45} ( {NP_46}Me{/NP_46} ) {NP_B_47}<B>AVPb]</B>{/NP_B_47} .

OUTPUT 5
PTM = ({NP_52};phosphorylation)
Kinase = (-;-)
Substrate = ({NP_P_53}a <p>38 kDa protein</p>{/NP_P_53};-)
Site = (-;{NP_52}Tyr{/NP_52};UNK)

{NP_48}These observations{/NP_48} {VP_act_49}suggest{/VP_act_49} that {NP_50}<p>arginine vasopressin</p> signal transduction{/NP_50} {VP_pass_51}may be associated{/VP_pass_51} with {NP_52}the <pp>tyrosine</pp> phosphorylation{/NP_52} of {NP_P_53}a <p>38 kDa protein</p>{/NP_P_53} .


{NP_1}PMID{/NP_1} - {CP_2}2109702{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_5}Expression{/NP_5} of {NP_P_6}<p>c-myc gene</p>{/NP_P_6} in {NP_7}<s>human</s> ovary carcinoma <Bpcl>cells</Bpcl>{/NP_7} {VP_act_8}treated{/VP_act_8} with {NP_C_9}<c>vanadate</c>{/NP_C_9} .

{NP_10}The widely accepted hypothesis{/NP_10} of {NP_11}<c>vanadate</c> action{/NP_11} on {NP_12}<Bpcl>cells</Bpcl> postulates{/NP_12} that {NP_13}this ion{/NP_13} {VP_act_14}inhibits{/VP_act_14} {NP_C_15}<Bppf>protein</Bppf> <c>phosphatase(s)</c>{/NP_C_15} {NP_16}that{/NP_16} {VP_act_17}dephosphorylates{/VP_act_17} {NP_PP_18}<Bppf>protein</Bppf> <pp>phosphotyrosine residues</pp>{/NP_PP_18} .

{NP_19}This inhibition causes <pp>tyrosine</pp> hyperphosphorylation{/NP_19} of {NP_P_20}<Bppf>cell proteins</Bppf>{/NP_P_20} {VP_pass_21}followed{/VP_pass_21} by {NP_22}changes{/NP_22} in {NP_23}physiological action{/NP_23} of {NP_P_24}<p>phosphoproteins</p>{/NP_P_24} {VP_act_25}resulting{/VP_act_25} in {NP_26}stimulation{/NP_26} of {NP_27}<Bpcl>cell</Bpcl> proliferation{/NP_27} , {NP_28}expression{/NP_28} of {NP_29}<Bppf>protooncogenes</Bppf> , and <Bpcl>transient cell</Bpcl> transformation{/NP_29} .

{NP_30}We{/NP_30} {VP_act_31}have found{/VP_act_31} that {NP_32}treatment{/NP_32} of {NP_S_33}<s>human</s> <S>ovary carcinoma ( CaOv ) cells</S>{/NP_S_33} with {NP_C_34}<c>vanadate</c>{/NP_C_34} {VP_act_35}causes{/VP_act_35} the {VP_pass_36}increase{/VP_pass_36} in {NP_37}total <Bppf>protein</Bppf> phosphorylation{/NP_37} from {NP_38}1.5{/NP_38} - to {NP_39}2.0-fold{/NP_39} whereas {NP_40}the ratio{/NP_40} between {NP_41}<pp>phosphoserine</pp> , <pp>phosphothreonine</pp> , and <pp>phosphotyrosine</pp> content{/NP_41} {VP_act_42}remains{/VP_act_42} {JP_43}unchanged{/JP_43} .

At {NP_44}the same time{/NP_44} , {NP_45}enhancement{/NP_45} of {NP_46}<p>c-myc gene</p> expression ( not c-fos ){/NP_46} {VP_pass_47}was observed{/VP_pass_47} .

{AV_48}Hence{/AV_48} , the {VP_pass_49}increase{/VP_pass_49} in {NP_50}the ratio{/NP_50} of {NP_PP_51}<pp>phosphotyrosine</pp>{/NP_PP_51} to {NP_PP_52}<pp>phosphoserine</pp> and <pp>phosphothreonine</pp>{/NP_PP_52} {VP_pass_neg_53}is not{/VP_pass_neg_53} {NP_54}an obligatory intermediate stage{/NP_54} before {NP_55}vanadate -dependent activation{/NP_55} of {NP_56}<p>c-myc</p> expression{/NP_56} .


{NP_1}PMID{/NP_1} - {CP_2}2989019{/CP_2}

{NP_3}TI{/NP_3} -

{NP_4}AB{/NP_4} - {NP_P_5}Acid <p>phosphatase</p> and <p>phosphoamino acid phosphatases</p>{/NP_P_5} in {VP_act_6}<s>murine</s>{/VP_act_6} {NP_7}erythroleukaemic <Bpcl>cells</Bpcl>{/NP_7} .

OUTPUT 1
PTM = ({NP_PP_10};phosphotyrosine)
Kinase = (-;-)
Substrate = ({NP_P_11}<p>phosphothreonine phosphatases</p>{/NP_P_11};-)
Site = (-;{NP_PP_10}Tyr{/NP_PP_10};UNK)
(-;{NP_P_11}Ser{/NP_P_11};UNK)
(-;{NP_P_11}Thr{/NP_P_11};UNK)

OUTPUT 2
PTM = ({NP_P_11};phosphoserine)
Kinase = (-;-)
Substrate = ({NP_P_11}<p>phosphothreonine phosphatases</p>{/NP_P_11};-)
Site = (-;{NP_P_11}Ser{/NP_P_11};UNK)

{NP_8}The activities{/NP_8} of {NP_9}acid{/NP_9} and {NP_PP_10}<p>alkaline phosphatases</p> and <pp>phosphotyrosine</pp>{/NP_PP_10} , {NP_P_11}<pp>phosphoserine</pp> and <p>phosphothreonine phosphatases</p>{/NP_P_11} {VP_pass_12}were measured{/VP_pass_12} in {NP_S_13}<S>Friend <s>murine</s> erythroleukaemic ( MEL ) cells</S>{/NP_S_13} .

{NP_14}The effects{/NP_14} of {VP_act_15}treating{/VP_act_15} {NP_16}the <Bpcl>cells</Bpcl>{/NP_16} with {NP_C_17}<c>dimethyl sulphoxide ( DMSO )</c>{/NP_C_17} , {NP_18}an inducer{/NP_18} of {NP_19}differentiation{/NP_19} , {VP_pass_20}were examined{/VP_pass_20} .

In {NP_21}untreated <Bpcl>cells</Bpcl> alkaline <p>phosphatase</p> activity{/NP_21} {VP_pass_22}was undetectable{/VP_pass_22} , though there {VP_pass_23}were{/VP_pass_23} {NP_24}significant amounts{/NP_24} of {NP_P_25}acid <p>phosphatase</p>{/NP_P_25} ( {NP_P_26}76 +/- 15 <p>mU/mg protein</p>{/NP_P_26} ) and {NP_P_27}<p>phosphotyrosine phosphatase</p>{/NP_P_27} ( {NP_P_28}16 +/- 0.9mU/mg <Bppf>protein</Bppf>{/NP_P_28} ) ; {NP_29}<pp>phosphoserine</pp> and <p>phosphothreonine phosphatase</p> activities{/NP_29} ( {NP_30}9 +/- 0.4{/NP_30} and {NP_P_31}7 +/- 0.6mU/mg <Bppf>protein</Bppf>{/NP_P_31} , {AV_32}respectively{/AV_32} ) {VP_pass_33}were lower{/VP_pass_33} than for {NP_P_34}<p>phosphotyrosine phosphatase</p>{/NP_P_34} .

{NP_35}Addition{/NP_35} of {CP_36}1{/CP_36} or {NP_C_37}2% <c>DMSO</c>{/NP_C_37} to {NP_38}the <Bpcl>culture</Bpcl> medium{/NP_38} {VP_pass_39}resulted{/VP_pass_39} in {NP_40}the expected <Bpcl>cell</Bpcl> death{/NP_40} within {NP_41}2 weeks{/NP_41} .

With {NP_C_42}0.5% <c>DMSO</c>{/NP_C_42} , {NP_43}<Bpcl>cells</Bpcl>{/NP_43} {VP_act_44}remained{/VP_act_44} {JP_45}viable{/JP_45} for {NP_46}atleast 8 weeks{/NP_46} , but while some {VP_act_47}appeared{/VP_act_47} {VP_act_48}to have{/VP_act_48} {NP_49}smaller nuclei{/NP_49} and {VP_act_50}retained{/VP_act_50} {NP_51}their rounded appearance{/NP_51} , {NP_52}others{/NP_52} {VP_pass_53}became fibroblastic{/VP_pass_53} within {NP_54}several days{/NP_54} and {VP_act_55}adhered{/VP_act_55} to {NP_56}the <Bpcl>culture</Bpcl> vessel{/NP_56} .

{NP_57}The treated <Bpcl>cells</Bpcl>{/NP_57} {NP_58}which{/NP_58} {VP_act_59}had kept{/VP_act_59} {NP_60}their morphology{/NP_60} {VP_act_61}showed{/VP_act_61} {NP_62}no difference{/NP_62} in {NP_63}acid <p>phosphatase</p> activities{/NP_63} as {JP_64}compared{/JP_64} with {NP_65}untreated controls{/NP_65} ; {NP_P_66}<p>phosphotyrosine phosphatase</p>{/NP_P_66} {VP_pass_67}was{/VP_pass_67} {NP_P_68}lower ( 9 +/- 0.8mU/mg <Bppf>protein</Bppf> ){/NP_P_68} and {NP_P_69}<pp>phosphoserine</pp> and <p>phosphothreonine phophatases</p>{/NP_P_69} {JP_70}higher{/JP_70} ( {NP_71}11 +/- 0.5{/NP_71} and {NP_P_72}10 +/- 0.4mU/mg <Bppf>protein</Bppf>{/NP_P_72} , {AV_73}respectively{/AV_73} ) than in {NP_74}the controls{/NP_74} .

{NP_75}The <B>Km</B> values{/NP_75} for {NP_G_76}<c>p-nitrophenyl phosphate</c>{/NP_G_76} {VP_pass_77}were similar{/VP_pass_77} in {JP_78}untreated{/JP_78} and {VP_act_79}treated{/VP_act_79} {NP_80}<Bpcl>cells</Bpcl>{/NP_80} ( {CP_81}0.069{/CP_81} and {NP_82}0.068mM{/NP_82} , {AV_83}respectively{/AV_83} ) ; for {NP_PP_84}<pp>phosphotyrosine</pp>{/NP_PP_84} {NP_85}the <B>Km</B> value{/NP_85} {VP_pass_86}was lower{/VP_pass_86} in {NP_B_87}the treated <Bpcl>cells</Bpcl> ( 0.97mM ){/NP_B_87} than in {NP_88}the controls ( 1.9mM ){/NP_88} .


